













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 
















2 Literature Review 7
2.1 Genetic factors & missing heritability . . . . . . . . . . . . . . . . 7
2.2 Core pathways . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
2.2.1 NOD2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
2.2.2 Autophagy . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
2.3 Environmental risk factors . . . . . . . . . . . . . . . . . . . . . . 17
2.4 Epigenetic mechanisms . . . . . . . . . . . . . . . . . . . . . . . . 22
2.4.1 DNA methylation . . . . . . . . . . . . . . . . . . . . . . . 22
2.4.2 Histone modifications . . . . . . . . . . . . . . . . . . . . . 27
2.4.3 MicroRNA . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.5 Epigenetics in Crohn’s disease . . . . . . . . . . . . . . . . . . . . 31
2.5.1 Findings in IBD . . . . . . . . . . . . . . . . . . . . . . . . 31
2.5.2 The potential of epigenetics as a diagnostic tool in IBD . . 36
2.5.3 New potential treatments from epigenetics . . . . . . . . . 38
2.6 Paediatric IBD . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
2.7 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
3 Defining the Methylome of Crohn’s Disease in Children 49
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
3.2 Materials & methods . . . . . . . . . . . . . . . . . . . . . . . . . 51
3.2.1 Patient recruitment and selection . . . . . . . . . . . . . . 51
3.2.2 Experimental techniques . . . . . . . . . . . . . . . . . . . 54
3.2.3 Data analysis . . . . . . . . . . . . . . . . . . . . . . . . . 56
i
CONTENTS
3.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
3.3.1 Combining the two paediatric cohorts . . . . . . . . . . . . 59
3.3.2 Methylation profile . . . . . . . . . . . . . . . . . . . . . . 63
3.3.3 Individual CpGs . . . . . . . . . . . . . . . . . . . . . . . 70
3.3.4 Differentially methylated regions . . . . . . . . . . . . . . 75
3.3.5 Correlation with GWAS . . . . . . . . . . . . . . . . . . . 96
3.3.6 GO term analysis . . . . . . . . . . . . . . . . . . . . . . . 107
3.3.7 Enrichment of DNA motifs . . . . . . . . . . . . . . . . . . 111
3.3.8 Replication by pyrosequencing . . . . . . . . . . . . . . . . 116
3.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
3.4.1 Implications for future study design . . . . . . . . . . . . . 119
3.4.2 β values & M values . . . . . . . . . . . . . . . . . . . . . 137
3.4.3 GWAS correlation . . . . . . . . . . . . . . . . . . . . . . 144
3.4.4 Transcription factors . . . . . . . . . . . . . . . . . . . . . 148
3.4.5 Genes of interest . . . . . . . . . . . . . . . . . . . . . . . 153
3.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167
3.6 Supplemental . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 170
3.6.1 Pyrosequencing . . . . . . . . . . . . . . . . . . . . . . . . 170
3.6.2 DNA motifs . . . . . . . . . . . . . . . . . . . . . . . . . . 173
4 VMP1/MIR21 177
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 177
4.1.1 Context of VMP1 Illumina 450k results . . . . . . . . . . . 177
4.1.2 VMP1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 181
4.1.3 MIR21 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183
4.2 Materials & methods . . . . . . . . . . . . . . . . . . . . . . . . . 189
4.2.1 Pyrosequencing . . . . . . . . . . . . . . . . . . . . . . . . 189
4.2.2 qPCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193
4.2.3 Microarray expression data from Noble et al. . . . . . . . . 193
4.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 194
4.3.1 Replication of methylation findings . . . . . . . . . . . . . 194
4.3.2 Expression . . . . . . . . . . . . . . . . . . . . . . . . . . . 198
4.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 201
5 RPS6KA2 205
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 205
5.2 Materials & methods . . . . . . . . . . . . . . . . . . . . . . . . . 211
5.2.1 Sample collection . . . . . . . . . . . . . . . . . . . . . . . 211
5.2.2 qPCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 213
5.2.3 Western blot . . . . . . . . . . . . . . . . . . . . . . . . . 213
5.2.4 Microarray expression data from Noble et al. . . . . . . . . 214
5.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215
5.3.1 Pyrosequencing . . . . . . . . . . . . . . . . . . . . . . . . 215
5.3.2 Illumina 450k replication . . . . . . . . . . . . . . . . . . . 218
5.3.3 Biopsy microarray expression data . . . . . . . . . . . . . 218
5.3.4 qPCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221
ii
CONTENTS
5.3.5 Western blot . . . . . . . . . . . . . . . . . . . . . . . . . 223
5.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 225
6 Biomarkers 229
6.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229
6.2 Materials & methods . . . . . . . . . . . . . . . . . . . . . . . . . 231
6.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 232
6.3.1 Model generation & testing in children . . . . . . . . . . . 232
6.3.2 Testing of paediatric models in adults . . . . . . . . . . . . 240
6.3.3 Further paediatric modelling . . . . . . . . . . . . . . . . . 245
6.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 250
A IBD Character 253
A.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 253
A.2 Materials & methods . . . . . . . . . . . . . . . . . . . . . . . . . 254
A.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 256
A.3.1 QC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 256
A.3.2 Replication between Edinburgh and non-Edinburgh samples 257
A.3.3 Individual CpGs . . . . . . . . . . . . . . . . . . . . . . . 258
A.3.4 Comparison with paediatric results . . . . . . . . . . . . . 261
A.3.5 Differentially methylated regions . . . . . . . . . . . . . . 262
A.3.6 Methylation quantitative trait loci . . . . . . . . . . . . . . 268
A.4 Supplemental . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 271
B Abstracts 289
B.1 BSG abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 289
B.2 ECCO abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . 291




2.1 Chemical modifications of cytosine . . . . . . . . . . . . . . . . . 24
2.2 Bisulfite conversion of cytosine . . . . . . . . . . . . . . . . . . . . 25
2.3 An illustration of epigenetic mechanisms . . . . . . . . . . . . . . 26
2.4 MicroRNA action and processing pathways . . . . . . . . . . . . . 30
3.1 Replication between paediatric cohorts . . . . . . . . . . . . . . . 60
3.2 Manhattan plot of the combined analysis . . . . . . . . . . . . . . 61
3.3 QQ plot of the combined analysis . . . . . . . . . . . . . . . . . . 62
3.4 Mean methylation results . . . . . . . . . . . . . . . . . . . . . . . 64
3.5 Volcano plot . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
3.6 Methylation patterns at all Bonferroni significant probes . . . . . 66
3.7 Hypomethylation and increased variability in CD . . . . . . . . . 67
3.8 Power calculations based on all 650 significant probes . . . . . . . 69
3.9 CpG Islands near significant probes . . . . . . . . . . . . . . . . . 74
3.10 Mean methylation results for DMRs . . . . . . . . . . . . . . . . . 76
3.11 CpG Islands near DMR probes . . . . . . . . . . . . . . . . . . . 77
3.12 Methylation results for the VMP1 region . . . . . . . . . . . . . . 78
3.13 Methylation results for the ZBTB16 region . . . . . . . . . . . . . 79
3.14 Methylation results for the SLC15A4 region . . . . . . . . . . . . 80
3.15 Methylation results for the TNF region . . . . . . . . . . . . . . . 81
3.16 Methylation results for the DIABLO region . . . . . . . . . . . . . 82
3.17 Methylation results for the ZFYVE28 region . . . . . . . . . . . . 83
3.18 Methylation results for the RUNX3 region . . . . . . . . . . . . . 84
3.19 Methylation results for the HGF region . . . . . . . . . . . . . . . 85
3.20 Methylation results for the GPR56 region . . . . . . . . . . . . . . 86
3.21 Methylation results for the TOLLIP region . . . . . . . . . . . . . 87
3.22 Methylation results for the ITGB2 region . . . . . . . . . . . . . . 88
3.23 Methylation results for the PIEZO1 region . . . . . . . . . . . . . 89
3.24 Methylation results for the PRF1 region . . . . . . . . . . . . . . 90
3.25 Methylation results for the ZBTB12 region . . . . . . . . . . . . . 91
3.26 Methylation results for the CD247 region . . . . . . . . . . . . . . 92
3.27 Methylation results for the CETP region . . . . . . . . . . . . . . 93
3.28 Methylation results for the UBASH3A region . . . . . . . . . . . . 94
3.29 Methylation results for the WRAP73 region . . . . . . . . . . . . 95
3.30 Probe Density in proximity to IBD GWAS SNPs . . . . . . . . . . 97
3.31 Results of Probe Density Matching . . . . . . . . . . . . . . . . . 97
v
LIST OF FIGURES
3.32 Enrichment of methylation changes within 50kb of GWAS SNPs . 98
3.33 Methylation-GWAS correlation vs non-IBD GWAS SNPs . . . . . 101
3.34 Random probes are an inadequate control . . . . . . . . . . . . . 102
3.35 Correlations with GWAS SNPs for other conditions I . . . . . . . 104
3.36 Correlations with GWAS SNPs for other conditions II . . . . . . . 105
3.37 Bias due to probe number variation . . . . . . . . . . . . . . . . . 107
3.38 Lack of bias in Bonferroni significant genes . . . . . . . . . . . . . 108
3.39 Position of enriched motifs relative to methylation probes . . . . . 114
3.40 Technical replication of VMP1 result with pyrosequencing . . . . 116
3.41 Adult replication of 7 probes by pyrosequencing . . . . . . . . . . 118
3.42 Calculation of methylation odds ratio (’methOR’) . . . . . . . . . 120
3.43 Predicted methylation profiles in Rakyan et al. . . . . . . . . . . . 121
3.44 Methylation profiles in the 6 significant probes with greatest power 126
3.45 Methylation profiles in the 6 significant probes with lowest power 127
3.46 General patterns of methylation change at significant probes . . . 130
3.47 The false discovery rate in the combined paediatric results . . . . 135
3.48 Comparison of paediatric results from analysis with βvalues and M
values . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
3.49 Comparison of adult results from analysis with βvalues and M values140
3.50 Enrichment of methylation findings near GWAS SNPs . . . . . . . 145
3.51 Enrichment of all methylation changes within 50kb of GWAS SNPs 145
3.52 RUNX3 expression is increased in inflamed CD biopsies . . . . . . 152
3.53 Methylation results for the SOCS3 region . . . . . . . . . . . . . . 156
3.54 Microarray data for SOCS3 in biopsies . . . . . . . . . . . . . . . 157
3.55 Microarray data for SBNO2 expression in biopsies . . . . . . . . . 160
3.56 Methylation results for the SBNO2 region . . . . . . . . . . . . . 161
3.57 Microarray expression data for NLRC5 in biopsies . . . . . . . . . 163
3.58 Methylation results for the NLRC5 region . . . . . . . . . . . . . 164
3.59 Pyrosequencing reaction . . . . . . . . . . . . . . . . . . . . . . . 171
3.60 Example pyrogram . . . . . . . . . . . . . . . . . . . . . . . . . . 172
4.1 Complete VMP1/MIR21 Illumina 450k methylation results . . . . 178
4.2 Context of the VMP1 methylation results . . . . . . . . . . . . . . 180
4.3 DNA sequence surrounding the VMP1 probes . . . . . . . . . . . 184
4.4 VMP1/MIR21 pyrosequencing replication in adults . . . . . . . . 196
4.5 Pyrosequencing VMP1/MIR21 in rheumatological conditions . . . 197
4.6 Microarray data of VMP1 and MIR21 expression in biopsies . . . 199
4.7 qPCR showing increased blood pri-mir21 expression in CD . . . . 200
5.1 Experimentally validated and predicted isoforms of RPS6KA2 . . 209
5.2 Context of RPS6KA2 Illumina 450k results . . . . . . . . . . . . . 210
5.3 RPS6KA2 pyrosequencing replication in three adult cohorts . . . 216
5.4 Combined analysis of RPS6KA2 pyrosequencing replication . . . . 217
5.5 IBD Character results for RPS6KA2 probe cg17501210 . . . . . . 219
5.6 Microarray expression data for RPS6KA2 in biopsies . . . . . . . 220
5.7 RPS6KA2 qPCRs in various cell types and of different transcripts 222
vi
LIST OF FIGURES
5.8 RPS6KA2 Expression with siRNA incubation . . . . . . . . . . . 223
5.9 Autophagy with varying RPS6KA2 expression . . . . . . . . . . . 223
5.10 RPS6KA2 Expression during starvation . . . . . . . . . . . . . . . 224
5.11 SNPs in the vicinity of RPS6KA2 probe cg17501210 . . . . . . . . 227
6.1 Paediatric two-probe biomarkers: discovery cohort . . . . . . . . . 234
6.2 Paediatric two-probe biomarkers: replication cohort . . . . . . . . 235
6.3 Performance of paediatric biomarkers . . . . . . . . . . . . . . . . 236
6.4 Performance of paediatric biomarkers including age and sex . . . . 237
6.5 Paediatric biomarker probe results in adults . . . . . . . . . . . . 241
6.6 Comparison of methylation results in adults and children . . . . . 242
6.7 Performance of paediatric biomarkers in adults . . . . . . . . . . . 243
6.8 Median methylation in adults vs children . . . . . . . . . . . . . . 247
6.9 Adult replication of further biomarkers . . . . . . . . . . . . . . . 249
6.10 Paediatric two-probe biomarkers: both cohorts . . . . . . . . . . . 251
6.11 Paediatric two-probe biomarkers: both cohorts, combined . . . . . 252
A.1 Sex mismatch identification . . . . . . . . . . . . . . . . . . . . . 256
A.2 Log fold-change in Edinburgh vs other centres . . . . . . . . . . . 257
A.3 Log fold-change in paediatric and adult cohorts . . . . . . . . . . 261
A.4 Illumina 450k probe density by region . . . . . . . . . . . . . . . . 262
A.5 DMR lasso radius by region type . . . . . . . . . . . . . . . . . . 263




1.1 Comparison of Crohn’s disease and ulcerative colitis . . . . . . . . 3
1.2 Extraintestinal manifestations of inflammatory bowel disease . . . 6
2.1 Published IBD GWAS studies . . . . . . . . . . . . . . . . . . . . 10
2.2 Autophagy related genes in Crohn’s disease . . . . . . . . . . . . . 16
2.3 Environmental risk factors for Crohn’s disease . . . . . . . . . . . 21
2.4 Published IBD EWAS studies . . . . . . . . . . . . . . . . . . . . 33
2.5 The Montreal and Paris classifications of Crohn’s disease . . . . . 45
3.1 Summary paediatric cohort demographics . . . . . . . . . . . . . . 52
3.2 Summary initial adult replication cohort demographics . . . . . . 52
3.3 Montreal classification of the initial adult replication cohort . . . 53
3.4 Pyrosequencing primers . . . . . . . . . . . . . . . . . . . . . . . 55
3.5 Individually significant CpGs from the discovery cohort . . . . . . 59
3.6 Number of significant probes by significance threshold . . . . . . . 60
3.7 Group sizes for power to detect similar findings . . . . . . . . . . 68
3.8 Hypomethylation correlates with not being in a CGI . . . . . . . 70
3.9 Bonferroni significant probes in the combined analysis . . . . . . . 73
3.10 Differentially methylated regions . . . . . . . . . . . . . . . . . . . 75
3.11 Significant probes closest to GWAS SNPs . . . . . . . . . . . . . . 99
3.12 Methylation-GWAS significance correlation . . . . . . . . . . . . . 103
3.13 GO term enrichment in FDR significant probes . . . . . . . . . . 109
3.14 GO term enrichment in Bonferroni significant probes . . . . . . . 110
3.15 Prevalence of potentially enriched DNA motifs . . . . . . . . . . . 111
3.16 Enriched DNA motifs and transcription factor binding sites . . . . 112
3.17 Enriched DNA motifs and transcription factor binding sites . . . . 113
3.18 Context of the CTDGNGGT motif near Bonferroni significant probes 115
3.19 EWAS power simulations in Rakyan et al. . . . . . . . . . . . . . 120
3.20 MethORs and power to detect Bonferroni significant probes . . . 125
3.21 Patterns of methylation change . . . . . . . . . . . . . . . . . . . 128
3.22 Distribution of methylation patterns . . . . . . . . . . . . . . . . 128
3.23 Context of the CCACGNVA motif near Bonferroni significant probes 173
3.24 Other shared motifs near Bonferroni significant probes . . . . . . 174
3.25 Shared motifs near FDR significant probes . . . . . . . . . . . . . 175
3.26 Shared motifs near probes within DMRs . . . . . . . . . . . . . . 176
ix
LIST OF TABLES
4.1 Complete VMP1/MIR21 Illumina 450k methylation results . . . . 179
4.2 Experimentally validated or predicted mir21 binding sites . . . . . 188
4.3 Demographics for the adult pyrosequencing cohorts . . . . . . . . 189
4.4 Montreal classification for the first pyrosequencing cohort . . . . . 190
4.5 Demographics for the second adult replication cohort . . . . . . . 190
4.6 Rheumatology cohort demographics . . . . . . . . . . . . . . . . . 190
4.7 VMP1 5′ UTR CGI pyrosequencing primers . . . . . . . . . . . . 192
4.8 pri-mir21 qPCR primers . . . . . . . . . . . . . . . . . . . . . . . 193
5.1 RSKs and related enzymes . . . . . . . . . . . . . . . . . . . . . . 208
5.2 RPS6KA2 Pyrosequencing primers . . . . . . . . . . . . . . . . . 212
5.3 RPS6KA2 qPCR primers . . . . . . . . . . . . . . . . . . . . . . . 213
5.4 RPS6KA2 pyrosequencing cohorts and probes . . . . . . . . . . . 215
5.5 IBD Character results for RPS6KA2 probe cg17501210 . . . . . . 218
5.6 RPS6KA2 SNPs . . . . . . . . . . . . . . . . . . . . . . . . . . . . 228
6.1 A two probe model performs as well as nine probes . . . . . . . . 232
6.2 Probes selected for use in biomarkers . . . . . . . . . . . . . . . . 233
6.3 Paediatric two-probe biomarkers . . . . . . . . . . . . . . . . . . . 238
6.4 Summary results for paediatric biomarkers . . . . . . . . . . . . . 239
6.5 Adult results for biomarker probes . . . . . . . . . . . . . . . . . 240
6.6 Adult results with paediatric models . . . . . . . . . . . . . . . . 244
6.7 Top performing models from all 65 significant probes . . . . . . . 246
6.8 Biomarker testing in adults . . . . . . . . . . . . . . . . . . . . . 248
A.1 IBD Character samples by centre and diagnosis . . . . . . . . . . 255
A.2 Bonferroni significant results for each performed analysis . . . . . 258
A.3 IBD Character: IBD vs control - top 20 . . . . . . . . . . . . . . . 259
A.4 IBD Character: CD vs control - top 20 . . . . . . . . . . . . . . . 259
A.5 IBD Character: UC vs control - top 20 . . . . . . . . . . . . . . . 260
A.6 Top 100 IBD vs control DMRs in the IBD Character cohort . . . 267
A.7 The 100 most significant MeQTLs in the IBD Character cohort . 270
A.8 IBD Character: IBD vs control . . . . . . . . . . . . . . . . . . . 276
A.9 IBD Character: CD vs control . . . . . . . . . . . . . . . . . . . . 279
A.10 IBD Character: UC vs control . . . . . . . . . . . . . . . . . . . . 287
A.11 IBD Character: CD vs UC . . . . . . . . . . . . . . . . . . . . . . 287
x
Declaration
I declare that this thesis has been composed solely by myself and that it has
not been submitted, in whole or in part, for another degree or qualification.
Some sections of chapters 3, 4, 5, & 6 have been published in the follow-
ing article, of which I was the joint first author, drafted the manuscript,
prepared the figures, performed the majority of the experimental work and
performed the analysis, except initial processing and cell type correction of
the Illumina 450k data which was performed in collaboration with Dr Nick
Kennedy.
Adams AT, et al. Two-stage Genome-wide Methylation Profiling
in Childhood-onset Crohn’s Disease Implicates Epigenetic Alter-
ations at the VMP1/MIR21 and HLA Loci. Inflammatory Bowel
Diseases. 20(10): 1784–93. 2014.
Some sections of chapter 2, in particular sections 2.4 & 2.5 are planned to
be published in a review article, of which I am the first author and drafted
the manuscript.
Some sections of chapters 3 and 6 have appeared in patent applications
[3, 5].
Where work was performed in collaboration with colleagues, or datasets
which were generated by others in our group have been used, this is clearly






All genomic coordinates are for the GRCh37/Hg19 assembly unless stated
otherwise.
P values are uncorrected unless stated otherwise and are not normally cal-
culated beyond 2.2×10−308.
This document is available digitally, with all internal references and cita-
tions functioning as hyperlinks.
With the exception of proprietary software necessary for running the py-
rosequencing and qPCR machines this work was entirely produced using
free and open source software.
The publication detailed in the declaration (page xi) [4] is published under
a Creative Commons Attribution 3.0 Unported License, and is available as
an open access article from the publisher’s website. Where material appears
unchanged it is cited in the text, other sections may demonstrate varying
degrees of overlap.
This work is licensed under a Creative Commons Attribution-ShareAlike
4.0 International License.




This work was primarily funded by CICRA1, with additional funding from
the CSO2 and IBD Character3.
I would like to thank Prof. Jack Satsangi and Dr Elaine Nimmo for their
guidance and supervision, Dr Nick Kennedy for extensive technical advice,
and Dr Nidhi D. Sharma & Ms Kate O’Leary for everything.
Additionally I would like to thank the entire gastrointestinal research group
in the Western General Hospital, our collaborators in the BISCUIT, PICTS,
and IBD Character studies, and all the patients and volunteers whose gave
the blood samples and biopsies this work is based on.
I received extremely generous support from the RMBF4 for which I am very
be grateful.
Finally, I would not have been able to undertake this work without the
support of my family and thank them for everything they have done.
1Crohn’s in Childhood Research Association, registered charity 278212
2Chief Scientist Office, Scottish Government
3www.ibdcharacter.eu























AIEC Adherent Invasive Escherichia coli
ATP Adenosine triphosphate
AUC Area Under the Curve
AZA Azathioprine
BISCUIT Bacteria in IBD in Scottish Children Under-going
Investigation before Treatment study [244]
CARD Caspase (Activation and) Recruitment Domain
CD Crohn’s Disease
CGI CpG Island
CHD Coronary Heart Disease







DHS DNase I Hypersensitivity Site
DMEM Dulbecco’s Modified Eagle Medium
DMR Differentially Methylated Region
DNMT DNA Methyltransferase
dNTP Deoxynucleoside triphosphate
DSS Dextran Sulfate Sodium
EDTA Ethylenediaminetetraacetic acid
ER Endoplasmic Reticulum
EWAS Epigenome-Wide Association Study
FCS Foetal Calf Serum
FDR False Discovery Rate (Benjamini-Hochberg)
FWER Familywise Error Rate
GCC Glucocorticoid
GO Gene Ontology
GWAS Genome-Wide Association Study
H#K# Histone# Lysine#
HAT Histone Acetylase
HBSS Hank’s Balanced Salt Solution
HC Healthy Control
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TLR Toll-Like Receptor
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Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ul-
cerative colitis (UC), is a complex disease with multiple aetiological factors
including genetics, environmental exposures and microbiota. Epigenetic al-
terations such as DNA methylation, histone modification, and microRNA
activity may indicate or facilitate the interactions between genetic and non-
genetic processes.
This thesis describes a study of genome-wide changes in DNA methylation
between children with Crohn’s disease and symptomatic controls performed
with the Illumina HumanMethylation450 platform. At the time of publi-
cation [4] this work was the largest epigenome-wide study of IBD, and
described 65 individual CpGs (Bonferroni corrected) and 19 differentially
methylated regions where there were significant CD-associated methylation
changes.
A highly significant (p=1.97×10−15) hypomethylated differentially methy-
lated region (DMR) in the penultimate exon of the critical autophagy gene
VMP1, appearing to correspond to the microRNA mir21, has been repli-
cated in 3 adult cohorts by pyrosequencing, and found in 2 subsequent
Illumina 450k adult epigenome-wide studies.
Hypomethylation of a highly significant CpG (p=4.47×10−15) in RPS6KA2
has also been replicated in 3 adult cohorts by pyrosequencing and 2 adult
cohorts with the Illumina 450k platform.
In line with our previously published work [458] methylation findings were
demonstrated to be enriched in proximity to genetic risk loci, with an im-




Section 3.3.7 demonstrates enrichment of a DNA motif matching the bind-
ing sites for the IBD-associated transcription factors GLI1 and RUNX3 at
significant methylation changes.
Examining methylation at any combination of two significant CD-associated
differentially methylated positions could distinguish between children with
CD and paediatric symptomatic controls requiring colonoscopy to rule out
IBD. These two probe biomarkers were tested in a separate paediatric cohort
with AUCs of 0.79–0.98 (median 0.93)
These data confirm the existence of significant DNA methylation differences
between children with Crohn’s disease and symptomatic controls, offering
potential insight into established genetic risk loci, and novel risk genes and
processes.
Characterisation of the observed DNA methylation changes and power cal-
culations based on experimental results rather than simulated ones, will




Crohn’s disease is a chronic disease that causes severe inflammation of the bowel
and sometimes also affects other organs. It is closely related to another disease,
ulcerative colitis, and together they are called inflammatory bowel disease (IBD).
These diseases may start at any point in life, and although treatments exist to
improve symptoms and reduce inflammation, there is no cure, and many patients
eventually require operations to remove large portions of the bowel. The best
understanding of the cause of Crohn’s disease is that the body’s immune system
reacts abnormally to the bacteria which live in the bowel, with certain inherited
factors and environmental exposures also being partly responsible.
Epigenetics (literally ‘in addition to genetics’) is the field of science that deals
with all mechanisms which affect the level of activity of genes, without changing
the sequence of bases that make up the gene. Epigenetic modifications help us
explain how the same genome can produce many different cell types, how people
with the same genomes (identical twins) may not both suffer from a disease, how
our environment, medications and smoking habits may affect our disease risk,
and part of how genes are turned on and off throughout development. Recent
results have hinted that differences in epigenetic regulation of genes may be in-
volved in the development of complex diseases such as IBD, and others including
schizophrenia, asthma, and type 1 diabetes.
The epigenetic modification studied here is DNA methylation. DNA is made
up of a sequence of four chemicals joined together, there are called bases or
nucleotides and are commonly shown as A,C,G, and T. When a C, (cytosine) is
immediately followed by a G (guanine) this is called a CpG dinucleotide. The C
of a CpG is sometimes modified by the attachment of an extra chemical called a
methyl group with the resulting base being called methylcytosine (5mC). The
modification of cytosine has an effect on the accessibility of the surrounding
genetic sequence to the DNA-reading machinery of the cell, and the function
of special short genetic sequences such as promoters, enhancers, and silencers,
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which are important in fine-tuning the activity of genes.
Using a process called bisulfite conversion, which affects C but not 5mC al-
lows methods to read DNA to distinguish between the two forms and find the
proportion of each which is present for any CpG. We used Illumina 450k chips
to measure the proportions of C and 5mC at over 450,000 CpGs throughout the
genome, and see if any CpGs have different proportions of methylation in people
with Crohn’s disease compared to healthy people.
We investigated DNA methylation in 36 children with Crohn’s disease and 36
children who had symptoms requiring investigation but were found to be healthy
and did not go on to develop any bowel diseases. As epigenetic markers are partly
dependant on age and sex we matched these as closely as possible between the
cases and controls. Even when inflammatory bowel disease is fairly inactive it
changes the proportions of the different cells in blood and so we used statistical
techniques to control for this effect.
The analysis found 65 areas where there was a significant difference in methy-
lation related to the presence of Crohn’s disease. Many of the genes where these
differences were found are known to be involved in processes related to the devel-
opment of Crohn’s disease, or are in regions of the genome where we know there
are some inheritable risk factors for Crohn’s disease.
We have measured methylation in many of the strongest findings in separate
groups of adult patients by the same technique and another technique called
pyrosequencing, thus indicating that these are real findings rather than anomalies.
For two of the strongest results we have also gone on to look for differences in
methylation in other diseases, and to see if we can find any effects the differences
in methylation causes to the levels or activity of the genes in question.
The control children had symptoms suggestive enough of Crohn’s disease that
their doctors performed an endoscopy to investigate — an uncomfortable and
invasive procedure. We have shown that a blood test based on the methylation
readings at any two of the 65 strongest results are sufficient to predict the presence




Signs, symptoms & natural history Inflammatory bowel disease (IBD)
refers to the separate but related conditions Crohn’s disease (CD) and ulcera-
tive colitis (UC). Additionally there is a significant minority of patients in whom
the exact diagnosis is unclear (IBD unclassified – IBDU, previously indeterminate
colitis – IC), most of whom later have a clear diagnosis of CD or UC [716], but
some remain unclassified [632].
History and examination along with inflammatory markers such as C-reactive
protein and faecal calprotectin can be highly suggestive of IBD, but the diag-
nosis is generally made on the macroscopic and microscopic appearance of the
intestine at endoscopy. Crohn’s disease classically causes a patchy transmural
inflammation, most commonly affecting the ileum and colon, but can manifest
anywhere in the gastrointestinal tract, whereas ulcerative colitis generally causes
a diffuse continuous inflammation extending from the rectum. A comparison of
the features of Crohn’s disease and ulcerative colitis is shown in table 1.1.
Crohn’s disease is classified by age of onset, disease location and behaviour,
with young age of onset, extensive disease and stricturing or penetrating be-
haviour associated with worse outcomes [573, 370] (detailed in table 2.5, page
45).
The most common symptoms of Crohn’s disease are abdominal pain and di-
arrhoea (bloody diarrhoea being more strongly correlated with ulcerative colitis)
accompanied by general malaise, fever, anorexia and weight loss [445]. Abscesses,
strictures, fistulae, and peri-anal disease may be present at diagnosis, and become
more prevalent over time [573]. Extraintestinal manifestations of Crohn’s disease
are common. Additionally, the consequences of chronic inflammation, malab-
sorption of vitamins and nutrients, long-term immunosuppressive treatment, and
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shared risks for other autoimmune and inflammatory conditions lead to further
disability (see table 1.2).
The natural history is of a relapsing and remitting inflammatory state, with
periods of remission where patients can be quite well. However, despite reductions
in mortality in some areas [294, 664] long-term mortality remains elevated in
IBD (hazard ratio (HR): 1.1 in UC, 1.5 in CD), after falling from an initial
high risk in the year following diagnosis (HR: 2.43 in UC, 3.69 in CD) [294, 60].
IBD places a significant burden on healthcare systems and economies due to
the resultant morbidity and mortality, requirement for costly ongoing medical
treatments, recurrent hospitalisations and often repeated surgical intervention,
and these factors also place a considerable psychosocial burden on patients [100].
Treatment strategies: medical and surgical The cornerstone of treatment
for Crohn’s disease and ulcerative colitis is medication to control the inflamma-
tory response and induce remission, with ongoing medication to maintain remis-
sion, and surgical resection when required. General immunosuppressants include
glucocorticoids (e.g. prednisolone, methylprednisolone or i.v. hydrocortisone),
methotrexate, 5-aminosalicylic acid (mesalazine) and azathioprine or mercaptop-
urine. In the past 10 years, more targeted biologic therapies against TNFα (e.g.
infliximab, adalimumab) or other molecules (Vedolizumab — anti-integrin α4β7)
have become available [453].
Surgery could be considered curative for ulcerative colitis; for example in a
proctocolectomy with an ileal pouch–anal anastomosis only a small cuff of rectal
mucosa remains, effectively eliminating the site of inflammation and neoplastic
transformation [148]. Despite the effectiveness, safety, high patient satisfaction,
and reasonable cost versus biological therapy, less than 30% of ulcerative patients
require surgery in their lifetime [445, 148]. In contrast, surgery is required in
around 80% of cases of Crohn’s disease [659, 445] and is not curative, with most
patients experiencing symptomatic and endoscopic recurrence — with heightened
risk in smokers, those with penetrating disease and those who have had prior
surgery [659].
In very severe cases with intestinal failure, intestinal transplant [208] or multi-
organ transplant may be considered. Additionally there is interest in autologous
stem cell transplantation [252] and faecal transplantation [123].
Historical perspective Examination of historical sources finds case descrip-
tions and autopsy reports consistent with IBD from the 17th century [330, 524]
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Feature Crohn’s Disease Ulcerative Colitis
Primary location Ileum Colon
Extended location Mouth to anus Terminal ileum to rectum
Rectal disease Rare Common
Perianal disease Common Rare
Distribution Patchy Diffuse & continuous
Inflammation Transmural Mucosal
Fissures Deep Rare & superficial
Abscesses & Fistulae Common Rare
Table 1.1: Comparison of Crohn’s disease and ulcerative colitis
onwards, and possible cases such as Alfred the Great, King of Wessex (849–899)
[130] and King Louis XIII of France (1601–1643) [38]. Ulcerative colitis was a
well established condition in the late 19th century [155], with Burrill Crohn [133]
later attributing the first case description to Sir Samuel Wilks in 1859 [695, 696].
Crohn’s disease was recognized later, described as chronic interstitial enteritis by
Sir Thomas Dalziel in 1913 [141] and regional ileitis by Crohn et al. in 1932 [134].
Intestinal tuberculosis is a differential diagnosis for many of the possible his-
torical cases, and indeed the finding that many intestinal granulomas contained
neither acid-fast bacilli nor foreign bodies was a pivotal event in recognizing
Crohn’s disease as a clinical entity [38].
“The symptoms in all the cases were similar; the characteristic and
most striking feature being most violent colic, causing vomiting and
occasionally an escape of some blood, and also constant mucus from
the bowel [. . . ]
The cases gave the impression that they were probably tuberculous,
and yet from the uniform character of the affection it evidently is not
so. The affected bowel gives the consistence and smoothness of an
eel in a state of rigor mortis, and the glands, though enlarged, are
evidently not caseous [. . . ]
As far as I know the disease has not been previously described, but it
seems probable that many cases must have been seen and have been
diagnosed as tuberculous, and possibly nothing done for their relief.
In regard to treatment, these cases which have come under observa-
tion have pursued their course uninfluenced by dietetic or medicinal
treatment, and apparently only operation can afford relief, and then
only if the disease be limited. Seven out of the nine made a perfect
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recovery after the operation, and one does not hesitate in resecting
large portions of the intestine. The subject has been one of great
interest to me for some years. My friends the pathologists prefer to
call it hyperplastic enteritis, and I can only regret that the etiology of
the condition remains in obscurity, but I trust that ere long further
consideration will clear up the difficulty.”
— T.K. Dalziel, 1913 [141]
Understanding the causes of Crohn’s disease Despite over a century of
further consideration since the words of Dalziel, much of the the difficulty remains.
We have an understanding of some of the processes and pathways involved in the
development of IBD: a disruption in the complex homeostasis [47] between the
host immune system and the intestinal microbiota in a genetically susceptible
individual upon certain environmental exposures leading to an inappropriate in-
flammatory response. However, many details remain obscured and research into
the diagnosis, management and underlying pathology of IBD is of great impor-
tance.
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Table 1.2: Extraintestinal manifestations of IBD
Condition Frequency Risk factors
Musculoskeletal <35%
Seronegative arthritis 5–20% CD>UC
†Type I (Oligoarticular) Colitis
Type II (Polyarticular)
Ankylosing Spondylitis <10% CD>UC, M>F,
HLA-B27
*Clubbing 15% cd, 38% uc




†Erythema Nodosum 10–15% CD>UC, M<F
Pyoderma Gangrenosum <5% uc CD<UC
Psoriasis <10% CD>UC
Aphthous stomatitis <10%
†Sweet syndrome  1% UC: pustular variant
Hepatobillary




Gallstones <30% Ileal CD, ileal resection
*NAFLD / NASH 9% uc, 19% cd GCC, MTX, AZA, TPN
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Kidney stones 5–15% Diarrhoea
Secondary amyloidosis rare CD>UC, M>F
Haematological
Thrombosis hr 2–4 Highly active disease




Restless legs syndrome 30% CD
*Vasculitis Anti-TNF
Stroke / TIA hr:1.28 Young age, M<F
Sensorineural hearing loss UC
*Multiple sclerosis Anti-TNF, CD<UC
*PML Natalizumab, JC virus
low risk 0.01% JCV negative
high risk 1% JCV positive
Table 1.2: Extraintestinal manifestations and non-gastrointestinal se-
qualae of inflammatory bowel disease [529, 360, 373, 474, 578, 414, 102,
440]. Frequency estimates and risk factors are poorly defined for some
extra-intestinal manifestations due to rarity or, e.g. clubbing prevalence
estimates date from 1979 [333], and may now be lower due to improved
inflammatory control. †Denotes extra-intestinal manifestations following
intestinal disease activity, * denotes those partially secondary to drug
treatment or chronic illness. GCC: steroids, MTX: methotrexate, AZA:
azathioprine, 6MP: 6-mercaptopurine, TPN: total parenteral nutrition,




2.1 Genetic factors & missing heritability
Genetic risk factors Families with multiple cases of ulcerative colitis were
identified as early as 1909 but dismissed as coincidence [9]. Later studies found
significantly increased risk of IBD in first-degree relatives of IBD patients, with
a greater risk where the affected relative has CD (relative risk 13–36 for a sibling
with CD, 7–17 for UC), and the highest risk among offspring of two parents with
IBD — with an IBD prevalence of 33–52% [168]. While most multiplex families
were concordant for which form of IBD they displayed, a quarter of families
displayed both, and familial concordance for disease location, behaviour, age of
onset, extraintestinal manifestations and number of surgical resections have also
been reported [168].
Family history for IBD and autoimmune conditions are more common in pa-
tients who develop IBD as children [531, 498]. With decreasing age at which
the signs and symptoms of IBD are discovered, increasing proportions of patients
have been found to have individually very rare mutations causing disruption of
processes such as epithelial barrier function, bacterial clearance, immune cell ac-
tivity, or cytokine signaling, and as well as findings consistent with IBD may
also present other signs of immune system dysfunction. These cases of ‘mono-
genic IBD’ are highly variable, though described cases are often associated with
a severe disease which responds poorly to conventional treatment [641].
Early genetic studies identified areas of significant linkage, with NOD2 re-
ported as the first susceptibility gene for Crohn’s disease in 2001 [466, 275], and
established that the genetic contribution to IBD risk was polygenetic. Genome-
wide association studies (GWAS) were undertaken to search for numerous risk
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loci with small effects, identifying over 200 genetic risk loci [384, 297, 194, 507]
to date (see table 2.1), among the most for any complex disease. The majority of
loci are relevant to both CD and UC (68.2%), with more loci for only CD (18.4%)
than UC (13.4%) [297, 384]. Loci which were initially reported as correlated with
only one disease have shown effects in the other disease with increasingly large
GWAS sample sizes and meta-analyses, and further overlaps may yet be reported.
Alongside NOD2, other genes which make significant individual contributions
to risk such as IL23R and ATG16L1 [297] have been found, and pathways with
significant involvement in pathogenesis elucidated. Despite these successes, the
total disease variance explained by GWAS loci is small (8.2–13.6% in CD and
4.1–8.2% in UC) [297, 384].
Missing heritability The difference between observed heritability of complex
genetic traits and that explained by known genetic risk factors has been dubbed
‘missing heritability’ [166, 741, 405]. Some of this may be explained by assump-
tions inherent to the GWAS technique, such as the focus on common variants or
common biases such as concentration on European-ancestry populations [405]. As
a group, individually rare variants are common but poorly detected by GWAS, as
are deletions, duplications, microsatellite repeat expansions, translocations and
inversions [405, 166]. Therefore sequencing common SNPs overly simplifies the
genetic landscape.
Epistatic and parent-of-origin effects may be underestimated [166], and the
sample sizes needed to characterise epistatic interactions are substantially larger
than the numbers needed to detect susceptibility loci by GWAS [741].
It may be that the total heritability is overestimated due to epistatic inter-
actions, shared familial environmental exposures, gene-environment interactions,
or a small subset of cases being due to undetected Mendelian inheritance with
incomplete penetrance and that the missing heritability is in fact phantom her-
itability [741, 405, 101]. There is also evidence that the heritability of Crohn’s
disease was overestimated by early twin concordance studies [235].
It has been posited that epigenetic mechanisms may be responsible for some
portion of true missing heritability [633]; however, the importance of transgen-
erational epigenetic inheritance to human disease is not well understood and is
somewhat controversial.
Even if the true heritability of Crohn’s disease is not accurately known, it is




Reference Diagnosis Case:Control Replication
Yamazaki, 2005 [710] CD J 484:752 E 363:372,  580
Duerr, 2006 [158] IBD E 547:548 C 401:433,  883
Hampe, 2007 [239] CD E 735:368 498:1032,  380
Libioulle, 2007 [377] CD E 537:913 1266:559,  428
WTCCC, 2007 [693] CD E 1748:2872
Parkes, 2007 [486] CD E 1182:2024
Rioux, 2007 [521] iCD A 946:977 353:207,  530
Franke, 2007 [193] CD E 393:399 942:1082,  375
Raelson, 2007 [507] CD AQ  477 ED 750:828,  521
Franke, 2008 [191] UC E 1167:777 1855:3091
Barrett, 2008 [41] CD M 3230:4829
Kugathasan, 2008 [349] pIBD A 1011:4250 173:3481
UK-IBD & WTCCC, 2009 [642] UC E 2361:5417 2321:4818
Asano, 2009 [27] UC J 752:2031 632:1026
Silverberg, 2009 [572] UC E 1052:2571 A 769:727, EI 633:415
Imielinski, 2009 [284] pIBD A 2784:7315 482:1696, AE 531:4109
Haritunians, 2011 [247] MR-UC A 324MR, 537UC, 2601HC
Franke, 2010 [192] CD M E 6333:15056 15694:14026
McGovern, 2010 [422] UC E 2693:6791 2009:1580
McGovern, 2010 [423] CD E 896:3204 1174:357





Reference Diagnosis Case:Control Replication
Franke, 2010 [194] UC ED 1043:1703 E 2539:5428
Anderson, 2011 [16] UC M E 6687:19718 9628:12917
Okada, 2011 [468] IBD J 979CD, 748UC, 905HC
Umeno, 2011 [643] IBD M 29606:47210
Kenny, 2012 [314] CD CA 907:2345 971:2124
Julia, 2012 [299] CD EE 1341:1518 1365:1396
Huang, 2012 [274] CD Reanalysis of WTCCC, 2007 [693]
Jostins, 2012 [297] IBD M >75000
Yamazaki, 2013 [711] CD J 372:3389 1151:15800
Yang, 2013 [713] UC K 388:739 417:732
Yang, 2014 [714] CD K 533:800 521:732, 1258:977
Liu, 2015 [384] IBD M 42950:53536
Huang, 2015 [273] IBD NA 1511:1797
Table 2.1: Published IBD GWAS studies. Numbers shown after QC. UK-IBD: UK IBD Genetics Consortium,
WTCCC: Wellcome Trust Case Control Consortium.
iCD: Ileal CD, pIBD: paediatric IBD, MR-UC: medically refractory UC.
American: USA primarily or wholly of European ancestry, A: African American, Q: Québécois,
European, D: German, E: Spanish, I: Italian, S: Swedish
C(A) Jewish (Ashkenazi), Japenese, Korean, Meta-analysis
 Trio of proband and parents, (number of family trios, not number of individuals)





The first Crohn’s disease associated gene The IBD1 locus on chromosome
16 was identified as a Crohn’s disease susceptibility locus in 1996 [276] with
multiple independent replications in the following years [138, 75, 20, 617]. NOD2
was identified as the responsible gene when several CD-associated SNPs within
NOD2 were identified in 2001 [466, 275, 238].
NOD2 (previously known as CARD15) is one of 22 members of the NLR
family (‘nucleotide-binding domain and leucine-rich repeat containing’, or com-
monly ‘NOD-like receptor’) [624]. In addition to the nucleotide-binding domain
(NBD or NOD domain) and leucine-rich repeats (LRR) implied by their name,
NLR family members contain an N-terminal effector domain; either an acidic
transactivation domain, pyrin domain, caspase recruitment domain (CARD) or
Baculoviral inhibitory repeat (BIR)–like domain. In the case of NOD2, it has
2 N-terminal CARD domains [624]. Similar LRR domains are found in Toll-
like receptors (TLR) which recognize a variety of triggers to the innate immune
system.
Muramyl dipeptide NOD2 is expressed in many cell types [726] including
monocytes [467] and Paneth cells [733] and responds to the presence of muramyl
dipeptide (MDP) [286], a component of gram-negative and gram-positive bac-
terial cell walls. MDP can be derived from intracellular bacteria, injected into
the cell by bacterial secretion systems (e.g. Helicobacter pylori [666]), trans-
ported into the cell by peptide transporters (including SLC15A1, 2, 3 & 4) or
by endocytosis from peptidoglycan fragments produced by bacterial cell division
[73, 491, 490].
Structure & function The C-terminal LRR of NOD2 is generally thought
to be the site of interaction with MDP [607], although direct interaction with
the NBD has been proposed [432]. Binding of adenosine triphosphate (ATP) to
the NBD allows interaction with MDP and subsequently homo-oligomerisation
of NOD2 facilitated by CARD-CARD and NBD-NBD interactions [432]. In ad-
dition to forming homo-oligomers, NOD2 directly interacts with a large number
of proteins [73] including autophagy proteins (ATG16L1 [631] and BCN1 [298]),
other NLR [674, 73] (NLRC4, NLRP1, NLRP3 and NLRP12) and others includ-
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ing SLC15A3/4 [452] CARD8 [672], CARD9 [272], HSP90 [363], SOCS3 [363],
TLE1 [459] and RIPK2, many of which have CD-associated genetic variants1.
NFkB signalling NOD2 interacts with the serine-threonine kinase RIPK2 by
a CARD-CARD interaction, which in turn leads to the activation of NFκB via
the IκB Kinase (IKK) pathway [467]. Signalling is turned off by hydrolysis of the
NBD-bound ATP by NOD2 and dissociation of the oligomer components [432].
To prevent excessive NOD2 stimulation, MDP causes decreased expression and
increased proteosomal degradation of NOD2 and RIPK2, dissociation of the chap-
erone protein Hsp90, and induction of SOCS3 expression which further degrades
NOD2 [363]. NOD2 has a basal level of NFκB signalling, which is significantly
increased with mutations causing Blau syndrome (page 12) and decreased with
CD-associated mutations, and may represent autoinhibition of the LRR by the
CARD domains when unstimulated [467, 607, 700].
NFκB is a transcription factor with central roles in inflammation such as
regulating the production of inflammatory cytokines (TNFα, IL-1β [254], IL-6,
IL-8) and defensins [606]. It is also involved in cell activation and proliferation
in inflammation and cancer [629] and links inflammation to metabolic pathways
[629] and cancer [152].
MAPK signalling is also induced by NOD2 signalling in a largely IL-1β de-
pendant mechanism [254] and is important in NOD2-induced autophagy [73] and
cytokine release [254].
Genetic variants in NOD2 CD-associated NOD2 variants are less responsive
to MDP [286, 254], do not cause autophagy in response to MDP [432], have a
reduced NFκB response, and impaired recruitment of ATG16L1 to the plasma
membrane [631].
Genetic variants in NOD2 have also been associated with Blau syndrome,
Early onset sarcoidosis [700] and NAID (NOD2-associated autoinflammatory dis-
ease) [718, 717]. Blau syndrome and Early onset sarcoidosis are now recognized
as the autosomal dominant and spontaneous forms of the same childhood-onset
disease [528]. There is an overlapping, but distinct phenotype in NAID, which
occurs in adults [718]. Blau syndrome classically includes a triad of granuloma-
tous dermatitis, polyarticular boggy arthritis and uveitis, but may also include
erythema nodosum and granulomatous disease of various organs, which are his-
1ATG16L1 (see table 2.2), CARD8 [421], CARD9 [735, 297], NLRP1 [137], NLRP3 [137],
TLE1 [459], RIPK2 [297].
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tologically distinct from granulomas seen in Crohn’s disease [700]. NAID causes
intermittent dermatitis and fever, arthritis, dry mouth and eyes (but no uveitis),
and abdominal pain and non-bloody diarrhoea with no evidence of IBD [717].
Blau syndrome genetic variants are mostly found in the nucleotide-binding do-
main and cause overactive NOD2 [607, 700] whereas NAID has some overlap with
CD-associated variants such as R702W, although IVS8+158 predominates [717].
The paradoxical finding of gain-of-function and loss-of-function NOD2 vari-
ants both leading to granulomatous inflammatory diseases has yet to be fully ex-
plained [300]. It may be that in IBD a primary immunodeficiency in macrophages
leads to poor clearance of bacteria and a resultant T cell mediated inflammation
[101, 581]. Additionally pathways other than NFκB signalling such as IL-10 pro-
duction [463], antigen presentation and autophagy may be important.
Other downstream effects NOD2 activation leads to inducible nitric oxide
synthase (iNOS) expression and activation of the Sonic Hedgehog (SHH) sig-
nalling pathway [210]. NOD2 activation also leads to recruitment of NOD2 and
ATG16L1 to bacterial entry sites in the plasma membrane and induces autophagy
in a RIPK2 and NFκB independent mechanism [631]. The identification of CD-
associated genetic variants in ATG16L1 and other autophagy related genes has




Autophagy is a highly conserved process triggered by cellular stressors such as
microorganisms, nutrient starvation, ER stress, hypoxia and tumours. There
are three types of autophagy; chaperone-mediated autophagy (CMA), microau-
tophagy and macroautophagy. CMA is a process in which specific soluble cytoso-
lic proteins are transported across the lysosomal membrane and degraded [472].
In microautophagy cytosolic proteins are included within an invagination of the
lysosomal membrane from which a vesicle is formed and then degraded by the
lysosomal hydrolases [375].
In macroautophagy (commonly referred to as autophagy) substrates are first
enveloped by a phagophore membrane, which then closes to form an autophago-
some before merging with a lysosome to form an autolysosome [182, 372]. Se-
lective processes for the autophagy of mitochondria, ribosomes, peroxisomes and
endoplasmic reticulum have been described, as well as a process for the digestion
of microorganisms - xenophagy [372, 511].
Autophagy allows recycling of cytosolic proteins and organelles to maintain
critical pathways such as the tricarboxylic acid (TCA) cycle in response to nutri-
ent deprivation and to support cells during more quiescent periods when anabolic
processes are not being stimulated by growth factors [399]. Autophagy also func-
tions to remove organelles due to damage, age, or overabundance [399].
Normal autophagy is important to development, non-apoptotic cell death, and
the innate and adaptive immune systems (MHC class II antigen presentation).
Altered autophagy function is frequently described in association with tumours,
ageing and degenerative conditions, autoimmune conditions and inflammatory
diseases including Crohn’s disease [372, 257]. Autophagy genes linked to Crohn’s
disease are shown in table 2.2.
The unfolded protein response (UPR) is closely linked to autophagy, in that
deficits in autophagy cause ER stress, and autophagy being an important path-
way mobilised to clear unfolded and misfolded proteins by the UPR [266]. The
UPR and has also been implicated in CD due to genetic variants in several key
UPR genes being associated with CD (table 2.2). Cellular stress causes the
accumulation of unfolded and misfolded proteins in the endoplasmic reticulum
(ER), and is sensed by three transmembrane ER proteins: IRE1α, which acts via
transcription factor XBP1; PERK, together with eIF2α, acting via transcription
factor ATF4; and ATF6 which is cleaved freeing its cytosolic N-terminal region
ATF6(N), which localises to the nucleus and functions as a transcription factor
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[705]. These lead to broad downstream effects to counteract the ER stress and
clear unfolded proteins, however if homeostasis is not restored then the UPR
promotes apoptosis.
Gene Function
ATG16L1 A core autophagy protein with important roles in Paneth cells
[86], and one of the strongest genetic risk factors for CD [693,
239, 521, 193, 41, 643, 687, 554, 266, 162, 43], particularly ileal
disease [654, 188].
IRGM Involved in the induction of autophagy and clearance of intracel-
lular bacteria including Mycobacterium tuberculosis [107] and is
a well established risk gene for IBD [693, 193, 486, 41, 628, 687,
266, 162, 451, 532]
ITLN1 Like NOD2, ITLN1 responds to cell wall components (galacto-
furanosyl residues) of luminal microorganisms. Involved in au-
tophagy, bacterial clearance and epithelial integrity [637], ITLN1
is found in an IBD risk locus and contains an ileal CD associated
SNP [41, 194, 297, 162]
LRRK2 Has GTPase and Kinase activity and is involved in autophagy
[185, 678], NOD2 function in Paneth cells [733], NFAT activity
[387], NFκB-dependant transcription, phagocytosis and bacterial
killing [202]. The CD risk allele leads to reduced expression, and
exacerbated DSS colitis in mice [387, 193, 239, 41, 628, 643, 687].
Also associated with Parkinson’s disease, leprosy, and ankylosing
spondylitis [630, 142].
MTMR3 Involved in autophagosome formation and phosphatidylinositol
regulation in autophagy, and an IBD genetic risk locus [258, 266]
NOD2 Responds to MDP leading to autophagy and xenophagy via re-
cruitment of ATG16L1 to bacterial entry sites in the plasma
membrane and is the strongest individual genetic risk factor for
CD [693, 239, 521, 193, 41, 687, 266, 43] (section 2.2.1)
ORMDL3 Regulator of the unfolded protein response and IBD risk locus
[41, 422, 266, 284]




PTPN2 Autophagosome formation, regulation of autophagy gene ex-
pression (BECN1, ATG7, IRGM), response to MDP, TNFα
and IFNγ, and clearance of intracellular bacteria, with func-
tion disordered by CD-associated genetic variants [553, 554] also
seen in T1D and RA [693]. Well-established CD risk gene
[693, 193, 486, 41, 643, 687, 553, 554, 43].
ULK1 Mammalian equivalent of yeast Atg1, ULK1, which contains a
CD-associated SNP [256, 439], forms a complex with ATG13 and
RB1CC1 which is central to the initiation of autophagy, partic-
ularly in response to starvation. Regulated by post-translational
modification by MTOR, AMPK and TIP60 [698, 511].
Vimentin A cytoskeletal intermediate filament protein which directly inter-
acts with NOD2 and is required for localisation of NOD2 to the
plasma membrane. CD-associated NOD2 polymorphisms dis-
rupt Vimentin-NOD2 binding [590, 459].
XBP1 Transcription factor activated by IRE1α as a core component
of the unfolded protein response triggered by ER stress [310]
XBP1 is in a risk locus for IBD [240, 37, 665], its deletion causes
spontaneous enteritis, and SNPs within XBP1 are associated
with CD and UC [310, 511].
Table 2.2: Autophagy and unfolded protein response genes which have
been linked to Crohn’s disease or IBD
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2.3 Environmental risk factors
Indications of non-genetic risk factors Incidence and prevalence have con-
tinued to rise for several decades [436, 49] especially in children [259, 262] and
purely colorectal disease has become more common [358].
The prevalence of IBD is highest in North America and northern and western
Europe, but is becoming increasingly common in previously lower-incidence areas
such as Asia, South America, southern and eastern Europe and north Africa [500,
455, 82, 83], and migration to a higher risk country increases risk of developing
IBD [40]. Children of immigrants and non-immigrants have similar risk and a
young age at migration increases the risk in first generation immigrants indicating
an importance of early exposure [51]. Uncertainty regarding the true incidence
of IBD in the originating country and differences between the migrant and native
populations in seeking medical consultation complicate comparisons and there is
also heterogeneity between migrant groups which may reflect differences in risk
factors such as smoking [503].
Smoking Smoking is perhaps the most well-established risk factor for Crohn’s
disease, and yet areas of the world with the highest rates of smoking (up to 65%
in adult African and Asian males) have low incidence of CD, and areas with the
highest incidence have low smoking rates (27% in Canada and 19% in Sweden)
[55]. Additionally smoking cessation is a risk factor for onset and exacerbation
of ulcerative colitis [55] and smoking reduces the risk of developing PSC in both
UC (OR 0.21) and CD (OR 0.17) [70].
Childhood immunity A common theme among many of the reported environ-
mental risk factors for IBD is exposure of the immune system to various triggers
during childhood. One aspect of this is the ‘hygiene hypothesis’, which was pro-
posed in the late 1980s to explain the increasing prevalence of childhood asthma
and eczema [591] beyond the rate explainable by genetic changes [489]. Increasing
numbers of older siblings was found to protect against the development of various
atopic conditions, and it was hypothesised that “allergic diseases were prevented
by infection in early childhood, transmitted by unhygienic contact with older
siblings” [591]. This has become an increasingly important theme in the mod-
ern understanding of allergy and has been proposed as a factor in autoimmune
and inflammatory diseases [484] including IBD [334, 23, 206, 455]. Much of the




Appendectomy has a widely reported strong protective effect against devel-
oping UC [39][341], and to predict a milder clinical course with a reduced risk
of colectomy [129] but an increased risk of PSC [70]. Age <20 at appendectomy
[196] and inflammation of the appendix rather than its removal [196, 46] appear
to be particularly relevant. However, many potential confounding factors such as
smoking and incipient IBD being misdiagnosed as appendicitis have been raised
[195, 341, 577, 307] and other studies have failed to demonstrate the effect [577].
Studies in Crohn’s disease demonstrate no effect [246, 577], a mild protective
effect [84, 506], or an increased risk [307], leaving the importance unclear. Ton-
sillectomy has also been reported to reduce risk of both UC and CD [246, 84] but
many studies have failed to show this effect [186, 431] or shown an increased risk
[206, 706].
A meta-analyses of studies on breastfeeding showed a protective effect for
both CD and UC overall [335] and in early onset disease [35], although some
studies show no effect or an increased risk [39]. There is some evidence of a
duration-response effect, complicating analysis [206].
Andrew Wakefield and colleagues proposed measles virus and measles vacci-
nation as a risk factor for Crohn’s disease [677, 676, 620]. Although this received
less public attention than his claims for a link between MMR vaccination and
autism, and the papers have not been retracted, they did receive considerable
criticism [177, 523] and many studies found no link [495, 564] including a study
he published [442].
Some studies have reported associations between IBD and vaccinations for
Measles [246], Pertussis [246], Polio [246, 495] and TB [39]. Though in these
studies vaccinations are highly correlated with year of birth and geographical
origin, and there are problems with reporting, recall bias [84], and study hetero-
geneity [495].
The recommendation for patients with IBD is to receive normal vaccinations
[106], however several studies have found low vaccination rates in IBD [724, 586].
This is concerning due to increased susceptibility to infection from immunosup-
pressive medication. The reasons for missing vaccinations in addition to those
seen in the healthy population included contraindication due to concurrent im-
munosuppressive medication and disease flares at the time of scheduled immu-
nisation, and gastroenterologists presuming that vaccinations would be managed
in primary care [724, 586, 686].
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Microbiota and infectious agents Recurrence of Crohn’s disease following
surgery is common [659], and depends on the presence of the faecal stream [537].
Presence of bacteria is necessary for inflammation in some animal disease mod-
els [561, 7, 150, 512, 417], and many IBD risk loci contain genes with roles in
responding to bacteria (enrichment p = 2.4 × 10−20) such as NOD2, IL10 and
CARD9 [297].
Mycobacterium avium paratuberculosis (MAP), which can be found in water
supplies, meat, and pasteurised milk, causes Johne’s disease in sheep and cattle; a
fatal progressive chronic granulomatous enteritis with some similarities to Crohn’s
disease [388]. In his 1913 description of chronic interstitial enteritis, Dalziel noted
the similarities between the two conditions
In vol. xx of the Journal of Comparative Pathology and Therapeutics,
McFadyen draws attention to Johne’s disease, a chronic bacterial en-
teritis of cattle [. . . ] In my cases the absence of the acid-fast bacillus
would suggest a clear distinction, but the histological characters are
so similar as to justify a proposition that the diseases may be the
same [141].
In the 1980s unidentified mycobacteria were isolated from the intestines of
CD patients and caused granulomatous disease when injected into mice and goats
[114, 615]. Many studies have since demonstrated a significantly increased rate
of MAP in CD patients [181, 1]. Even if MAP infection is just a consequence
of the impaired barrier function and immune differences in CD with no role in
pathogenesis, its presence shows a highly replicable correlation with CD [388,
181, 1, 29].
Another microorganism that has been linked to Crohn’s disease is Escherischia
coli, specifically adherent invasive E. coli (AIEC). CD patients have increased
numbers of coliforms in faeces and associated with the intestinal mucosa, and the
strains differ from those seen in acute gastrointestinal infections and the healthy
bowel [143]. AIEC are strains characterised by their ability to adhere to intestinal
epithelial cells and invade macrophages where they are able to survive and repli-
cate [143]. AIEC are strongly associated with ileal CD, especially active disease,
and are associated with relapse, greater need for surgery and early recurrence
[412].
AIEC are present in some healthy individuals without causing disease imply-
ing that additional genetic or environmental factors found in CD may be necessary
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to cause inflammation [412]. CD-associated variants in NOD2 reduce the abil-
ity to deal with AIEC by preventing interaction with vimentin and membrane
localisation [590]. CEACAM6 and Gp96 both facilitate AIEC adhesion, and are
overexpressed in ileal CD [146, 525, 412]. AIEC upregulate several microRNAs
leading to a reduction in ATG5 and ATG16L1 and inhibiting autophagy [456],
and Crohn’s disease is linked to several other deficiencies in autophagy (section
2.2.2 & table 2.2).
Other organisms which have been linked to Crohn’s disease include Faecal-
ibacterium prausnitzii [584, 244], Yersinia spp., Chlamydia spp., Listeria spp.,
and Bacteroides fragilis [318, 388]. However, the ability to concurrently assay the
proportions of many bacterial species and the lack of one clear microbial culprit
for IBD has led to a focus on the overall microbiota rather than individual species.
Imbalance in the microbiota of the intestine, or dysbiosis, has been demon-
strated in the gut [209, 190] and stool [480] in IBD, is detectable before treatment
[209], worsens with more severe disease [480, 209], differs between CD and UC
[480], and is not limited to areas of active inflammation [209].
The microbiota is acquired during delivery [281] and shortly after birth, ma-
turing during the first several years of life [336], under influence from early child-
hood environmental factors [446] yet differing substantially in identical twins
[640]. The healthy microbiota has numerous functions including immune home-
ostasis and development, GI development and metabolic functions [120, 190].
Factors which affect the established microbiota include smoking [485], alcohol
[487], medications (particularly antibiotics), eukaryotic parasites, and diet [120].
The common findings in IBD are an overall reduction in diversity, with decreased
Firmicutes and increased Proteobacteria [190, 480, 417, 244], though there is
heterogeneity in specific findings.
Meta-analysis showed that antibiotics in IBD have a statistically significant
benefit in inducing remission, preventing exacerbations and reducing fistula drain-
age [318], yet antibiotics have also been shown to increase the dysbiosis seen in
IBD [480, 209]. Antibiotic exposure at a young age is associated with an in-
creased risk of developing IBD [282, 263], though antibiotics may be given for
incipient undiagnosed IBD, and the relative contributions of antibiotics, the in-
fection that necessitated their use, or the immunological background which may
have predisposed to infection are unknown.
Faecal transplantation has become established as an effective treatment for re-
current Clostridium difficile infection [656], and has garnered interest as a method
to transform the dysbiosis seen in IBD to a healthy phenotype. While it is well
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tolerated and there is some evidence of effectiveness, larger scale trials are needed
[123, 283]. Likewise there is some evidence of benefit from the oral delivery of live
organisms (probiotics), but the evidence is stronger for UC than CD and further
research is required [541, 103]. The possibility of harnessing the immunomod-
ulatory functions of helminths has drawn some interest, but also needs further
research [691, 692, 595].
Other environmental risk factors A number of other environmental factors
which modulate risk or severity of IBD have been reported, some of which such
as westernization or latitude may be surrogates for other environmental risks or
genetic factors. These, and the previously discussed risk factors are shown in
table 2.3.
Factor Effect References
Smoking ↑CD ↓UC [354, 88, 402]
OCP ↑CD ↑UC+smoking [317, 126]
Breastfeeding Protective [500, 335, 35, 206, 39]
Appendectomy ↓UC [159]
Helminths Protective [691, 692, 595]
Dietary fibre ↓CD [14]
Weight ↑CD [438, 315]
Exercise ↓CD [316]
Sanitation Deleterious [159, 334]
Antibiotics Deleterious [500, 282, 263]
NSAIDs Deleterious [12]
Vitamin D ↓CD [13]
Latitude Deleterious [23, 455]
Urbanisation Deleterious [169, 587]
Air Pollution Deleterious [15, 306, 45]
Table 2.3: Summary of evidence for exposures and environmental risk
factors in CD and UC together (deleterious / protective), or individually





Epigenetics is the study of maintainable changes in gene function by mechanisms
other than DNA mutation; “The structural adaptation of chromosomal regions so
as to register, signal or perpetuate altered activity states” — in short “inheritance,
but not as we know it.” [66]. The most studied epigenetic mechanisms are DNA
methylation, histone modification and microRNAs.
2.4.1 DNA methylation
The cytosine-guanine (CpG) dinucleotide occurs in vertebrate DNA at approxi-
mately 20% of the rate which would be expected in a random sequence of bases
[65]. This may be due to the increased prevalence of 5-methylcytosine in CpGs
(60–90% [545, 739]) compared to non-CpG cytosines and that 5-methylcytosine
is prone to spontaneous deamination, leading to a point mutation to thymine
(figure 2.1). CpG islands (CGIs), where CpG frequency can be 10-fold higher
than the rest of the genome [65], and adjacent ‘shores’ [288] were hypothesised
to have biological significance due their apparent preservation. CGIs mainly oc-
cur in 5′ promoter regions and are usually unmethylated [418, 44]; however, in
cancer aberrant methylation and transcriptional silencing of tumour suppressor
gene CGIs are frequently found [44].
DNA methylation causes downstream effects by interfering with the target
recognition of DNA-binding molecules, or by recruiting methyl binding domain
(MBP) proteins [79].
Tissue-specific methylation is more frequently found in intragenic CGIs (24.4%)
than in 5′ promoter CGIs (2%) [418] and methylation within genes (intragenic
methylation) may regulate alternative promoter regions [418] and influence splic-
ing [569].
Artificially causing promoter CGIs to become methylated can cause tran-
scriptional silencing and inactivated genes can be reactivated by inhibiting DNA
methylation [65]. Alternatively, changes in gene regulation or expression, or un-
derlying genetic differences may explain some of the described disease-associated
methylation changes [558] making interpretation difficult and somewhat contro-
versial.
A methyl group may be added to cytosine in CpGs by one of a family of DNA
methyltransferase (DNMT) enzymes from the methyl donor S-adenosylmethionine
(SAM) — requiring dietary micronutrients including folate, B12, and choline [18].
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DNMT1 maintains the previous methylation state after DNA replication, whereas
DNMT3a and DNMT3b produce new methylation. The process of DNA demethy-
lation can occur passively by not maintaining hemimethylation during DNA
replication, or actively by oxidation caused by ten-eleven translocation (TET)
enzymes leading first to hydroxymethylcytosine (5hmC) and then to formylcy-
tosine (5fC) and carboxylcytosine (5caC) which are excised by thymine DNA
glycolase (TDG) and repaired by the base excision repair pathway (figure 2.1)
[504, 48, 633].
Treating DNA with sodium bisulfite causes the conversion of cytosine to uracil
(figure 2.2) unless there is a methyl or hydroxymethyl group. Hydroxymethylcy-
tosine shows greater tissue specificity and is most prevalent in the central ner-
vous system and embryonic stem cells [447, 346], but is less common and less
well studied than methylcytosine. Hydroxymethylation is indistinguishable from
methylation by standard techniques based on bisulfite conversion, however al-
ternative techniques such as using TET and β-glucosyltransferase with bisulfite
conversion can be used to detect both modifications. Hydroxymethylcytosine is
more frequently found in regions undergoing active demethylation [588], poten-
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Figure 2.1: Conversion of cytosine to methylcytosine by DNMT, which can mutate to thymine by spontaneous
deamination, and may be repaired by DNA repair enzymes. In active demethylation 5mC can be further oxidized






























Figure 2.2: Conversion of cytosine residues to uracil by sodium bisulfite. Presence of a 5′ modification prevents










The structural apparatus which packages the DNA double helix operates on mul-
tiple levels, the lowest of which is the wrapping of 145–147bp of DNA around
nucleosome cores. Nucleosomes, comprising an octomer of histone proteins H2A,
H2B, H3 and H4, occur approximately every 200bp in the eukaryotic genome and
are the primary determinant of the accessibility of DNA to other molecules [397]
(illustrated in figure 2.3). Each histone comprises a globular region and a pro-
truding flexible N-terminal tail, which is subject to a number of post-translational
modifications such as acetylation, methylation, ubiquitination, glycosylation and
others [24], which are added and removed dynamically by opposing families of
enzymes, making histone modifications more dynamic than DNA methylation.
These modifications alter chromatin structure, non-specifically influencing the
accessibility of local DNA to DNA binding proteins and directly affecting the
action of proteins which interact with histone tails themselves. Acting as an
impediment to both DNA replication and gene transcription, the nucleosomes
are disassembled in advance of these processes and replaced afterwards [81] with
duplicated modifications [504]. In addition to direct accessibility of DNA, combi-
nations of histone modifications are also correlated with changes in DNA methy-
lation, and with differences in RNA expression separate from DNA accessibility
and DNA methylation [350].
The presence and location of multiple modifications interact in a complex
system, dubbed the ‘histone code’ [592]. The most studied individual modification
in the context of IBD is histone acetylation; H3K27ac and H3K9ac, regulated
by histone acetyltransferase (HAT) and histone deacetylase (HDAC) families of
enzymes, and associated with promoter and enhancer activation, will be the only
modification discussed at length in this review.
Humans have 18 HDACs, classified by their homology to yeast HDACs [709].
Class I (HDAC1, 2, 3 & 8) and II (HDAC4, 5, 6, 7, 9 & 10) are zinc based
[709], class III (SIRT1–7) are dependant on NAD+ for lysine deacetylase activity
[550] and do not share inhibitors with other HDACs, and class IV comprises just
HDAC11, which has some similarities to classes I & II [201]. HDAC isoforms
may vary by tissue, intracellular localisation and cell type [180, 709, 201], have
a variety of non-histone substrates and non-deacetylase functions [709, 550] and
HDAC inhibition only affects a small proportion of genes [409].
The endogenous short-chain fatty acid (SCFA) HDAC inhibitors are produced
by microbial fermentation of dietary fibre [105]. Additionally compounds found in
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garlic, broccoli, nuts, some leaves, dark cherries, red grapes and curcumin (found
in turmeric) alter HDAC and HAT activity [715]. HDACs may also be affected by
neuronal stimuli, immune activity, physical exercise, fasting, smoking and high
salt diets [715] and are therapeutic targets for cancer.
2.4.3 MicroRNA
MicroRNAs are short, non-coding, single-stranded RNA molecules of approxi-
mately 22nt, which regulate expression of multiple mRNAs by guiding Argonaute
proteins to partially complementary target sequences in mRNA [302]. There are
1881 annotated human microRNAs listed in the current version of mirbase2 [344].
In the canonical pathway, microRNAs are processed from primary transcripts
of several kilobases by the RNAse III enzyme Drosha to form a pre-microRNA
hairpin of approximately 75nt, which is further processed by the RNAse III en-
zyme Dicer to produce the mature 22nt microRNA. The sequence complementary
to the mature microRNA is usually degraded, but in some cases can also be a
functional microRNA [42]. The evolutionarily conserved [374] 5′ seed region of the
microRNA is almost always responsible for target recognition, binding to its tar-
get with greatly increased affinity due to the conformation induced by Argonaute
interaction.
Alternative pathways such as the production of microRNAs from excised in-
trons (‘mirtrons’) [352, 649], from the 3′ UTR of a host gene [517], small nucleolar
RNAs [173, 428] and direct processing of microRNA precursors by Argonaute pro-
teins [428] also exist. Additionally, microRNAs are not the only class of small
RNAs to guide Argonaute proteins [327, 428] and small RNA targeted Argonaute
mediated regulation does not target only mRNA [268, 428, 327].
MicroRNAs are regulated by endogenous RNAs (ceRNAs) [309] or ‘sponges’
— RNA transcripts with multiple target sites to reduce the availability of one
or more microRNAs. MicroRNA sponging is a function for some non-coding
RNAs [153], especially stable circular RNAs [546, 245]. Viral RNA has also
demonstrated sponge activity [378, 407] to target host antiviral microRNAs.
Expression and activity of some microRNAs is modified by other epigenetic
mechanisms [543, 241], genetic variants [74, 117], immune activation [736], in-
flammation [704], microorganisms [140, 456], viruses [378, 407], and parasites
[78].
Approximately half of MicroRNAs are found in known genes (normally in the
2www.mirbase.org Version 21, published June 2014
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sense strand) [215] and may be co-transcribed or have independent promoters
and 20% of these were found to either directly or functionally antagonise their
host gene [265].
MicroRNAs have been shown to have roles in development, T cell differenti-
ation and signalling, immune mediation, intestinal homeostasis, autophagy and






Figure 2.4: MicroRNA action and processing pathways
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2.5 Epigenetics in Crohn’s disease
2.5.1 Findings in IBD
Targeted DNA methylation studies Early studies examined overall levels
of DNA methylation, finding global hypomethylation in rectal mucosa of patients
with long-standing UC [214]. Following work looked at small numbers of selected
genes, with a focus on UC and UC-associated colorectal cancer (UC-CRC). Small
study size and the inherent heterogeneity of cancers have led to some conflicting
results, but also a number of reproducible findings.
Methylation changes affecting expression of the anti-tumour CDKN2A prod-
ucts p16ink4a and p14ARF were among the first reported findings. p16INK4a
inactivation by promoter hypermethylation was seen in sporadic CRC and was
strongly associated with long-standing and extensive UC [271]. These regions
were repeatedly found to be hypermethylated in UC [441], and increasingly
methylated in non-dysplastic and dysplastic tissue of patients with UC-associated
dysplasia [289]. p14ARF methylation was shown to be an early event in UC-CRC
[547].
E-Cadherin (CDH1 ) promoter methylation, associated with mucosal inflam-
mation in UC [542], was found in spontaneous and UC-associated CRC [694]
and was hypothesised to have a role in the progression of long-standing UC to
neoplasia [31].
ER (oestrogen receptor) gene methylation is increased in UC and further
increased in UC associated cancer, additionally methylation was greater in non-
neoplastic tissue of UC patients with cancer compared to UC patients without
cancer [289, 627, 198, 22] and has been proposed as a biomarker for risk of cancer
in UC [627].
CEACAM6 is abnormally expressed in the colonic mucosa of CD patients.
CEACAM6 expression is regulated by methylation in mice, and a methyl donor
deficient diet leads to increased expression with resultant susceptibility to coloni-
sation by AIEC and inflammation [146].
A number of other genes have also been shown to be epigenetically dysreg-
ulated in UC (CXCL14, CXCL5, GATA3, IL17C, IL4R [308] & TUSC3 [22]),
or between UC patients with and without dysplasia (MYOD1, CSPG2 [289],
RUNX3, MINT1, COX-2 [203], SLIT2 [32], and HPP1 [548]).
Methylation of CDH1, MYOD1, GDNF, HPP1 [542] & SLIT2 [390] correlated
with disease activity, and MDR1 [596] & PAR2 [597] with disease phenotype.
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IFNG SNP rs1861494 (C/T) disrupts a CpG site. For the C allele, the CpG is
60% methylated and the adjacent CpG (57bp distant) was also hypermethylated
compared to T allele carriers. Methylation of these CpGs was highly correlated
with IFNG promoter methylation, and nucleoprotein binding. The T allele is
associated with a more severe phenotype in both UC and CD, and with higher
IFNG protein expression [218]. It had previously been shown that IFNG methy-
lation differs in IBD [219] and that IFNG hypomethylation correlates with IFNG
secretion, risk of surgery, and increased antibody response to microbial antigens
[217].
Polymorphisms in MDR1 [596], XRCC1, GSTP1, GSTT1 [598], CD14, IL-1β,
p22PHOX, & MBL2 [599] have also been found to correlate highly with certain
methylation changes in UC.
Epigenome-wide association studies A number of epigenome-wide asso-
ciation studies (EWAS) have been published in the past five years (table 2.4)
coinciding with advances in technology allowing characterisation of methylation
changes at high (single-nucleotide) resolution at an increasing number of sites
(103–105). The published EWAS studies are not amenable to meta-analysis, as
they are mostly small studies, with varying tissue types, analysed on a variety of
platforms, by differing techniques. EWAS are subject to complications not seen
in GWAS due to epigenetic plasticity (in response to inflammation, age, smoking,
drugs etc) and the fact that epigenetic markers can vary extensively between cell
types [350].
Epigenetics and GWAS risk loci CD-associated methylation changes are
enriched in proximity to GWAS risk loci [458, 4], as are T cell subpopulation spe-
cific transcriptional differences [508]. Allele-specific methylation has been demon-
strated to be genetically regulated by variants associated with complex diseases
including IBD and may provide further insight into the observed link between
DNA methylation and GWAS risk loci [280].
H3K27 acetylation, a marker of active regulatory elements, is significantly
enriched in proximity to GWAS risk loci for IBD (2.5 – 3.5 times enrichment,
92/163 risk loci) [434]. H3K27 profiles differed between intestine and immune
cells, with immune cell epigenetic regulatory elements colocalising with risk loci
for CD or UC, and intestinal cell regulatory elements enriched in proximity to
UC risk loci and diminished in proximity to CD risk loci [434].
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Study Platforma Tissue Samplesb Resultsc Significanced
Nimmo 2012 [458] 27k Blood 21cd 19hc 1117 FDR<0.01
Harris 2012 [250] 450k Blood 17cd, 11uc, 20hc 1 FDR<0.2
Lin 2012 [381] GG B cells 9cd 9uc 18hc 11 uncorrected
Adams 2014 [4] 450k Blood 36cd 36hc 65 CpGs, 19 DMRs Bonferroni, FDR
Lin 2011 [380] GG Intestine 9cd 17uc 7ibd, 25cd, 13uc uncorrected
Häsler 2012 [251] 27k Colon 10 uc/hc twins 61 Genes FDR
Cooke 2012 [125] 27k Rectum 16cd 16uc 8hc 3604uc 472cd FDR
Koizumi 2012 [337] MS-AFLP Colon 14uc 11hc 251 Probes Holm
Harris 2014 [249] 450k Colon 15cd 9uc 22hc 182cd 3365uc DMRs p<10−4
Kraiczy 2015 [345] 450k IEC 10cd 10uc 10hc 233 Šidák<0.01
McDermott 2015 [420] 450k PBMCs 88cd 61uc 39hc 3196cd 1481uc Bonferroni
Table 2.4: Published IBD EWAS studies. a27k: Illumina HumanMethylation27 BeadChip, 450k: Illumina Human-
Methylation450 BeadChip, GG: Illumina GoldenGate Genotyping Assay, MS-AFLP: methylation sensitive amplified
fragment length polymorphism. bhc: Control cCpGs unless otherwise specified d<0.05 unless otherwise specified,
FDR: Benjamini-Hochberg false discovery rate
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Histone modifications There are fewer data concerning alterations to histone
modifications in IBD than DNA methylation changes, possibly due to increased
technical difficulty and reduced scalability of experiments, the wide range of his-
tone modifications and increased plasticity compared to DNA methylation.
Dynamic changes in H3K9 methylation have been shown to regulate transcrip-
tion of certain inflammatory genes [540], and there is evidence for regulation of
NOD2 [369] and TLR4 [601] expression by histone acetylation. Histone acetyla-
tion [635] and methylation [604] are significantly disrupted by experimental colitis
models and HDAC expression has been shown to respond to inflammation in UC
[461] and exposure to certain microbes [720].
Deletion of both HDAC1 and HDAC2 in murine intestinal epithelial cells
(IEC) led to chronic inflammation [638] and increased sensitivity to DSS colitis
[639], whereas mice with HDAC2 deficient IEC did not have chronic inflammation
and were protected against DSS colitis [639].
HDAC3 expression is significantly decreased in IEC from IBD patients com-
pared to healthy controls. Deletion of HDAC3 in IEC of mice caused alterations
in gene expression and microbiota, loss of Paneth cells, impaired epithelial bar-
rier function, inflammation and increased response to DSS. These changes were
dependant on the presence of commensal bacteria [7].
Mice with intestinal SIRT1 knockout show increased resistance to experimen-
tal colitis and colitis-induced neoplasia [389].
Histone acetylation, by inhibition of HDAC enzymes has a general anti-in-
flammatory effect, including protecting against and promoting resolution of ex-
perimental colitis models [211], hence making HDAC inhibition an attractive
therapeutic target [180].
MicroRNAs A large number of microRNAs have been reported as either up
or downregulated in IBD (see Kalla et al. [302] for a recent review) in response to
immune stimulation [736], inflammation [704], microbial [456] or genetic factors
[74, 117]. MicroRNAs are involved in regulation of both the innate and adap-
tive immune system, as well as numerous other physiological and pathological
processes. Of particular interest in IBD are their roles in regulating NOD2 and
toll-like receptors, T cell differentiation, autophagy, cytokine release and inflam-
mation [302].
IBD related products and pathways linked to microRNAs include ATG16L1
(mir30c, 130a [456], 142-3p [730], 106b and 93[393]), NFκB (mir21 [736]), STAT3
(mir124 [340] and 21 [552]) and NOD2.
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NOD2 activation induces microRNAs 29a, 29b and 29c, leading to a down-
regulation in IL-23 and TH17 response. CD-associated NOD2 polymorphisms
failed to induce mir29 and DSS colitis was worsened in mir29 deficient mice
[74]. NOD2 also induces mir155 [74] and mir146a [210]. NOD2 is itself subject
to regulation by microRNAs: mir122 [111] 192, 495, 512 & 671 [117] directly
inhibit NOD2 by binding to a sites in the 3′ UTR, where disease-associated
polymorphisms may interfere with microRNA binding [117].
Another notable microRNA known to be dysregulated in IBD is mir21, which
is known to be overexpressed [565, 704, 600, 703, 725, 4] and hypomethylated [4]
in IBD and MIR21 knockout mice have been shown to be protected from DSS-
induced colitis [565]. mir21 was one of the first described, and most frequently
dysregulated microRNAs and is regulated by STAT3, BCL6 [552] and NFκB
[736]. It is involved in T helper cell differentiation [552] with activity in other
immune mediated diseases [492] and cancers [347] where it has been proposed




2.5.2 The potential of epigenetics as a diagnostic tool in
IBD
DNA methylation biomarkers Aberrant DNA methylation as a diagnostic
biomarker for cancer is being pursued, for example SEPT9 in colorectal cancer
[227, 685, 119] and GSTP1 in prostate cancer [655]. Despite subtler methyl-
ation changes in complex diseases, multiple DNA methylation changes have been
proposed as biomarkers.
A study of paediatric CD3 (n=71) found multiple diagnostic biomarkers based
on leucocyte DNA methylation at 2 loci capable of distinguishing between dis-
ease and symptomatic control with high accuracy (AUC<0.98) [4]. A combined
assay of BMP3 and NDRG4 DNA methylation in stool detected 100% of can-
cer and high-grade dysplasia, and 67% of low-grade dysplasia at 89% specificity
[332] in patients with inflammatory bowel disease (n=54). Other studies have
demonstrated the feasibility of detecting DNA methylation levels in serum [34],
intestinal biopsies [326] and stool [32] and have shown the possibility of biomark-
ers for disease activity [542, 390] and phenotype [596, 597].
MicroRNA expression biomarkers A large number of microRNAs have
been proposed as biomarkers for a range of conditions, including neoplastic [697],
ischaemic, infective, inflammatory, degenerative, psychiatric, and traumatic [234].
Pritchard et al. found that for 79 microRNAs reported as biomarkers for
solid tumours, 58% were highly expressed in blood cells, and 91% of these were
expressed at high levels in healthy plasma. For these microRNAs corrections
for the variations in cell populations are necessary to ensure that the reported
microRNA is not a proxy measurement for a shift in cell populations, altered rate
of haemolysis, or secondary to malignancy or its treatment [502].
Haider et al. examined 192 microRNAs reported as biomarkers for 57 non-
neoplastic conditions, including IBD, and found that small study size, variable
normalisation and analytical procedures, and failure to replicate findings were
common in the literature. They also point out that many reported microRNA
biomarkers are expressed in numerous cell types, lack a strong rationale for the
cell types assayed given the focus of the disease, and lack specificity. 24% were also
reported as neoplastic biomarkers and 6 microRNAs were reported as biomarkers
for 9 or more diseases (mir21, mir16, mir146-a, mir155, mir126 and mir223)
[234], all of which have been reported as significantly dysregulated in IBD, if not




Despite the general lack of specificity to a particular disease, some microRNAs
have been reported to demonstrate differences in expression between CD and
UC, and to vary by disease site [703, 702]. At this stage, microRNAs have been
identified in blood [481, 702], serum [725] and biopsy tissue [704, 703, 128] which
are differently expressed in IBD, but none have been developed to the point of
clinical utility as biomarkers.
Detecting IBD-associated cancer A field defect, or field for cancerization
is where cell division creates a local tissue environment sharing mutations, with
subfields containing later acquired mutations, eventually producing cancerous
lesions with accumulation of sufficient mutations. This explains the develop-
ment of multiple primary tumours, and presence of pre-cancerous lesions near
tumours. Fields where the defect is epigenetic rather than genetic have been
demonstrated in Barrett’s oesophagus [164], gastric epithelium [460, 278, 338]
and bowel [289, 337, 271]; however, the shared epigenetic dysregulation is pri-
marily due to shared local exposures rather than inheritance. Epigenetic field
defects have been shown to develop in response to DSS exposure [312], microor-
ganisms such as H. pylori [644, 460, 278, 113] and Epstein-Barr virus [594] and
chronic inflammation including IBD [433, 289].
The epigenetic changes in field defects include specific methylation changes
of tumour suppressor genes or oncogenes [165], histone modifications [604], or
more general effects such as global hypomethylation [165, 214] or disruption of
chromatin remodellers [605].
The presence of epigenetic abnormalities in the development of cancer has
been well established, and is detectable prior to histological change [433]. As pa-
tients with IBD who develop cancer have detectable epigenetic differences present
in both neoplastic and non-neoplastic tissue epigenetic biomarkers have been pro-
posed to detect current or imminent cancer [332, 99, 627, 26].
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2.5.3 New potential treatments from epigenetics
DNA methylation Nucleoside analogues are the most developed approach
for DNMT inhibition. These drugs are incorporated into DNA in place of cy-
tosine and due to the presence of a nitrogen at position 5 irreversibly bind to
DNMT leading to its degradation [187]. Examples include 5-Azacytidine (AZA,
Azacitidine) and 5-Aza-2′-deoxycytidine (DAC, Decitabine), which are used in
the treatment of haematological conditions including myelodysplastic syndrome
(MDS), acute myeloid leukaemia (AML) and chronic myelomonocytic leukaemia
(CMML). There is evidence of synergistic activity when combined with HDACi
such as TSA [92] and valproate [187]. Similar compounds designed to improve
speed of onset [269], stability and delivery [187] are also being investigated.
Reversible DNMT inhibitors which do not require incorporation into DNA
are being sought, and anti-DNMT actions of several existing drugs (hydralazine,
procainamide, procaine, disulfram [379] and antidepressants [740]) natural com-
pounds (EGCG, genistein, laccaic acid) and novel compounds (RG108, SGI-1027)
[400, 187, 226] have been tested with varying results.
DNMT expression is known to be regulated by microRNAs, and both syn-
thetic oligonucleotides (MG98) [187] and mir29 [174, 187] are a potential alter-
nate mechanism for modulating DNMT activity, additionally there are numerous
beneficial effects of mir29 unrelated to DNMT [204, 74].
DNMT3A [194] and DNMT3B [297] genes have been identified as IBD risk
loci by GWAS, DNMT expression is increased in active UC [542], and many
DNA methylation changes have been found in IBD; however, there are obstacles
to therapeutic targeting of DNA methylation directly in IBD. DNMT inhibitors
have direct cytotoxic effects [551, 473, 383] and so their activity in malignancy
is not entirely epigenetic and there is insufficient data to draw any conclusions
about long-term risks of DNMT treatment, including the risk of prompting cancer
development by causing global hypomethylation [165]. Tumour suppressor gene
CpG island methylation is more susceptible to treatment with AZA and DAC
compared to gene body CpG islands [699], however DNMT inhibition is largely
untargeted, and methylation changes in IBD show both hypo- and hypermethy-
lation making DNMT inhibition of unclear potential benefit in IBD. Targeting
DNMT inhibition to a particular cellular population, or targeted DNA methy-
lation of specific pro-inflammatory or oncogenic genes using a DNMT enzyme
linked to a DNA binding domain or zinc finger protein [301] may provide a more
controllable therapeutic approach with further development.
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Folate DNA methylation is dependant on the methyl donor SAM, the produc-
tion of which requires micronutrients including B12 and folate, B2, B6, betaine,
choline and methionine [18]. B12 and folate deficiencies are rare in newly di-
agnosed children in the USA [8, 261, 571] but are common in established IBD
patients [228, 670], as are B2 and B6 deficiency [660]. There are multiple possible
causes for these deficiencies, including anorexia, malabsorption, haemolysis, bac-
terial overgrowth, surgical resection and increased epithelial turnover [660, 228].
Rats fed a diet without B12, folate and choline had a significantly increased re-
sponse to DSS exposure [108], and mice treated with folate supplementation were
protected against Helicobacter-associated global hypomethylation, inflammation
and gastric cancer [216].
Treatment of anaemia with B12 and folate supplementation is common in IBD
[670] and several small studies [559] have shown non-significant trends towards
a protective effect of folate against CRC and a dose-response effect. Further
research into the effects of folate and other micronutrients on DNA methylation
and cancer risk are needed, particularly as over-supplementation may increase
cancer risk [328, 651, 21].
HDAC inhibitors Histone acetyltransferases, and enzymes which add or re-
move other histone modifications could also prove valuable targets, however re-
search to date has heavily focused on HDAC inhibitors. There are several classes
of antagonists for class I & II HDACs: hydroxamates (Vorinostat (SAHA), tri-
chostatin A (TSA) and Givinostat), aliphatic acids (valproate, butyrate), cyclic
peptides (Romidepsin) and benzamides (Entinostat) [400]. This review will focus
on inhibitors of non-sirtuin HDACs, however, multiple classes of sirtuin inhibitor
exist and are being pursued for a range of conditions [362]. Sirtuins are also
inhibited by nicotinamide, a byproduct of their histone deacetylase activity [30]
and nicotinamide has been shown to ameliorate bacterial and DSS induced colitis
in mice [59] improve neutrophil killing of S. aureus by up to 1000-fold [351] and is
used as a treatment for acne and dermatitis. Additionally, some HDACs are pre-
dicted to be regulated by microRNAs [180], and could be a target for microRNA
focused therapeutics.
This is a large variety in the targets of HDAC enzymes and their inhibitors.
However HDACi share anti-inflammatory effects, due to reduced inflammatory
cytokine production, and regulation of NFκB and other transcription factors [211,
212, 180] and T cell differentiation [180]. HDACi are also pro-apoptotic and anti-
cancer [211, 212, 180] and are involved in intestinal architecture, epithelial barrier
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function, immune cell infiltration, expression of various inflammatory genes and
microRNAs [638, 180]. Common side effects include fatigue, nausea, vomiting,
diarrhoea and thrombocytopaenia [189, 180], less frequently QT prolongation or
arrhythmia were reported, but resolved spontaneously with dose reduction or
treatment cessation.
Oral administration of HDAC inhibitors valproate, SAHA or Givinostat pro-
tected mice from DSS-colitis and TNBS-colitis by reducing expression of pro-
inflammatory cytokines including TNFα and IFNγ, inhibiting NFκB, and at
higher doses inducing apoptosis [211, 212]. Anti-inflammatory effects of SAHA
were observed at lower doses than required for anti-tumour activity [368].
A small open-label trial of oral Givinostat 1.5mg/kg/day in systemic-onset
juvenile idiopathic arthritis reported an improvement in signs and symptoms,
but no change in ESR and CRP and acceptable safety profile and tolerability
[671]. A single RCT of Givinostat was undertaken in moderate-to-severe active
CD but was terminated for futility after interim analysis of 40/80 patients4.
Butyrate Factors produced by epithelial cells (e.g. TGFβ, IL-10, Retinoic
acid, and prostaglandin E2) promote tolerance to microbial triggers [555], and
the healthy microbiome produces the short chain fatty acids butyrate, propionate,
and acetate [105] by anaerobic carbohydrate metabolism.
Butyrate is implicated in mucin release, electrolyte, water and pH regula-
tion, acts as an energy source for colonocytes, promotes epithelial tight junction
integrity and regulates cellular proliferation and differentiation [496] including
driving regulatory T cell differentiation [200].
Butyrate demonstrates the general anti-inflammatory effects seen with other
HDACi [496, 105, 398] and other anti-inflammatory effects including abolishing
LPS-induced TNF secretion by PBMCs due to inhibition of NFκB expression and
stabilisation of IκBα [560], GPR109A signalling (also caused by niacin) leading
to IL-10 and IL-18 production and Treg differentiation [575], and reducing ROS
production by neutrophils [385].
Butyrate producing bacteria are depleted in IBD [190] and colorectal cancer
[681]. Butyrate oxidation and transport are disrupted in IBD [618, 145, 144]
with evidence of normalisation following anti-inflammatory therapy, indicating
the changes are caused by inflammation [145] and there is impaired sensitivity to




There is some positive evidence for oral butyrate [667], butyrate enemas [236,
237], fibre supplementation [688], and propionyl-L-carnitine to facilitate SCFA
transport [429]. However, study size and design have been criticised [688] and
effectiveness remains questionable [361].
MicroRNA-based therapies Potential microRNA therapeutics could reduce
the expression or activity of a microRNA, increase expression of an endogenous
microRNA, or supply non-endogenous short non-coding RNAs. There are dif-
ficulties inherent in microRNA-based therapeutics: targeting, and reaching the
site of action, resisting degradation, generating an immune response, side-effects
due to the numerous targets of microRNAs, and risk of cancer from gene therapy
[205, 610, 33]. However, the pharmacokinetics of oligonucleotide drugs [622], and
chemical and sequence modifications to increase half-life and reduce immuno-
genicity [470] are generally independent of the specific sequence, making this a
potentially highly adaptable drug class.
Antagomirs are antisense oligonucleotides, modified to increase stability, which
bind to target microRNAs causing degradation or sequestration. In the first phase
2 study of an antagomir in humans, antimir122 (Miravirsen) was given to 36 pa-
tients with chronic HCV infection in 5 weekly injections. The treatment was
well-tolerated, with no discontinuations or dose-limiting effects [293]. The drug
is a complementary sequence to mature mir122, with nucleotides modified to en-
hance binding affinity and increase resistance to nuclease degradation. Antimirs
to microRNAs implicated in IBD such as mir21 [585] are in an earlier stage of
development, but a potential use in various cancers may add impetus.
Similarly, oligonucleotides can be delivered to mimic an endogenous microRNA
[33, 260] or with a sequence designed to target a specific mRNA. Delayed release
preparations combined with permeability enhancers (e.g. sodium caprate) even
allow oral delivery [622]. A phase 2 trial of an oral SMAD7 antisense 21-base
phosphothioate oligonucleotide (Mongersen) in Crohn’s disease [437] showed a
statistically significant induction of remission with good side-effect profile.
A further application of delivering short, stabilised oligonucleotides is to alter
the proportion of transcripts. Splice-switching oligonucleotides (SSO) can be
designed to promote skipping exons during translation [568] which for example
allows a reduction in the membrane-bound functional TNFR2 and an increase in
a secreted Δ7TNFR2 form which antagonised TNFα highly effectively in mouse
disease models [222].
MicroRNA sponges could be used to reduce levels of target microRNAs, with
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the added advantages of stability and ability to target multiple microRNAs. Viral
and non-viral delivery mechanisms are being investigated, with the majority of
animal experiments to date using viral vectors [610].
Some research has found dietarily ingested plant microRNAs are absorbed
and active [732], though an attempt to replicate these findings failed, and the
premise is controversial [110, 151]. Alternatively, immunomodulatory microRNAs
or sponges produced by bacteria [140], viruses [378, 407] or parasites [78] could




The study presented in the following chapter was undertaken in children, concor-
dantly it is important to consider the differences between this group and adult-
onset IBD.
Up to 25% of IBD cases present in childhood or adolescence [370]. The inci-
dence of paediatric IBD is rising and the average age of onset decreasing [259, 50].
The Scottish population has seen a dramatic increase in IBD of 76% from 1990–
1995 to 2003–2008, with a significant reduction in the age of onset (13.2–12.1
years, p<0.001) of Crohn’s disease [259]. The trend of increasing incidence in
Scottish children can be seen since 1969, though methodological differences and
changing diagnostic techniques make robust comparisons with early studies diffi-
cult [259].
The Montreal classification for Crohn’s disease includes three factors, age at
diagnosis, location, and behaviour, with age of diagnosis separated into 616, 17–
40 and >40 [573]. However, there are significant differences between very early
onset (VEO, age <10) and early onset (EO, age 10–17) IBD [469].
Most IBD GWAS studies were undertaken in adults, though some studies
have looked at paediatric disease or compared paediatric with adult-onset disease
[349, 284, 124]. There is a large overlap between the loci found in paediatric
and adult diseases [258, 469], suggesting that genetic differences responsible for
paediatric disease specifically may be poorly detected by GWAS, i.e. rare variants
with large effect sizes, a result of complex epistatic interactions, or that non-
genetic factors may be responsible for earlier onset. Some rare mutations in genes
for IL-10, and IL-10 receptors have been found to be particularly associated with
paediatric disease [213, 567, 57, 339]. In cases where the strength of a disease
association varies strongly between children and adults, and the risk variant is
also correlated with a particular disease distribution (such as ATG16L1 with ileal
disease) the order of causality may be difficult to discern [654].
In younger children ileal disease is much rarer and strongly associated with
NOD2 mutations [425, 371], family history for IBD and autoimmune conditions
are more common [531, 498], and there are differences in serological markers such
as ASCA5 and anti-CBir16 [408]. Paediatric disease affects a higher proportion
of males, the course is more severe and progressive with an increased requirement





to immunosuppressants and increased risk of death [531, 93, 494, 498, 223, 653].
However, surrogate markers of severity such as surgical and medical treatments
can be difficult to interpret due to differences in physician and patient preferences
between children and adults [653].
Children with IBD (particularly CD) are at risk of delayed growth and puberty
due to malnutrition, anorexia, steroid treatment and the effects of inflamma-
tory cytokines on growth hormone and insulin-like growth factor [224]. Impaired
growth is present in more than 35% of paediatric CD patients, and failure to
thrive was present at diagnosis for 44% of CD patients under 5 years old [324].
The Paris classification therefore modified the Montreal classification to in-
clude age at diagnosis <10 and growth failure, as well as several additions to
classification of location and behaviour [370] (see table 2.5)
In addition to these factors, young people with Crohn’s disease may miss
schooling and exams, though without affecting measured outcomes or entry to
tertiary education [419, 183, 401], are at an increased risk of depression, anxiety,
body image issues, sleep disturbance, and negative impacts on social and family
functioning [401, 324]. Many of these outcomes have been shown to be worse in
Crohn’s disease than other chronic illnesses [401, 324].
There are advantages and disadvantages to using children as a study popu-
lation. With a more severe phenotype and a higher genetic component, genetic
variants could be easier to detect, but paediatric disease could also be due to indi-
vidually rare but highly-impactful mutations which are difficult to discover with
GWAS. With regard to epigenetics, children have a far smaller exposure to factors
which affect epigenetic markers such as smoking, comorbidities, polypharmacy,
and age, which could make it easier to find a signal amongst noise. Conversely, if
they have a higher genetic load than adult patients, then the non-genetic factors




Age at diagnosis (A)
A1a: <10
A1: 6 16 A1b: 10–16
A2: 17–40 A2: 17–40
A3: >40 A3: >40
Location (L)
L1: Terminal ileum L1: Distal 1/3 Ileum
L2: Colonic L2: Colonic
L3: Ileocolonic L3: Ileocolonic
L4: Upper GI L4a: Proximal to LoT
L4b: LoT – distal 1/3 ileum
Behaviour (B)
B1: Nonstricturing & B1: Nonstricturing &
nonpenetrating nonpenetrating
B2: Stricturing B2: Stricturing






Table 2.5: The Montreal [573] and Paris [370] classifications of Crohn’s
disease. +L4 and +p (perianal) can be added as modifiers to any location




Despite extensive study of the genetic risk factors for IBD, a large portion of the
disease variability remains unexplained. Epigenetics was predicted to offer some
insight into the ‘missing heritability’ and the interplay between factors such as
environmental exposure, gut microflora, diet, smoking and background genetic
risk. Early studies have identified many epigenetic disturbances, and indeed
abnormalities with core epigenetic mechanisms associated with IBD. In addition,
understanding of the importance of epigenetic mechanisms to biological pathways
critical to IBD is increasing.
Epigenetics remains a developing field, but increasing interest and technolog-
ical developments should improve characterisation of epigenetic changes in IBD
and increase understanding of their causes and interrelatedness. In the immedi-
ate term, these findings can be expected to provide insight to IBD researchers
outwith epigenetics.
In principle, epigenetic marks have strong potential as biomarkers in IBD and
other complex diseases as they reflect a range of biologically significant influences
(such as disease activity, genetics, environmental, microbial and dietary factors).
Unlike genetic risk factors they are changeable, but may be more stable than
measuring expression. A lack of disease-specificity has been noted [502, 234],
however when considering the nature of epigenetic regulation, with large numbers
of targets, complex interactions and multiple feedback mechanisms this is not
surprising. Epigenetic biomarkers for general processes, such as inflammation or
neoplasia, could be of use in the diagnosis and clinical management of IBD —
for example distinguishing IBD from other causes of gastrointestinal symptoms,
monitoring disease activity and response to treatment, and identifying those at
imminent risk of neoplasia.
Epigenetic studies of IBD have examined both blood and intestinal tissue,
with findings reported in each. While studying blood adds a further abstraction
between the sites of disease and the studied tissue, there are reasons to support
studying blood cells in IBD — namely the role of blood derived immune cells
in gut immunity, extraintestinal manifestations of disease, and the response to
autologous stem cell transplantation. The greatest advantage of studying blood
is ease of access, with less invasive methods reducing costs and increasing accept-
ability to patients and controls. The development of clinically useful biomarkers
in blood could offer cheaper and more rapid initial diagnostic tests and allow
increased testing frequency for monitoring response to treatment, and earlier
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detection of exacerbations or neoplastic transformation. Epigenetic biomarkers
have proven feasible in small studies, and it would be reasonable to predict the
successful development of biomarkers based on DNA methylation or microRNA
profiling to accurately diagnose, distinguish phenotypes, and predict outcomes
and response to treatment. However, at this stage very little of the necessary
validation work for clinical deployment has been undertaken.
Growing classes of therapies based on modulating all major epigenetic mech-
anisms are either in use or under active development for a range of conditions.
While the lack of specificity demonstrated by many disease-associated epigenetic
findings is a frequent criticism, this also means that epigenetic treatments mod-
ulating core inflammatory pathways could be of benefit to many diseases.
There is as yet insufficient understanding of the effectiveness and permanence
of reversing histone marks and DNA methylation and long-term safety data is
currently scarce. The ability to deliver endogenous microRNAs or specifically
targeted short non-coding RNAs orally, with reasonable bioavailability and half-




Defining the Methylome of
Crohn’s Disease in Children
3.1 Introduction
Our group had previously published a paper comparing DNA methylation be-
tween 21 adult women with ileal Crohn’s disease and 19 healthy adult female
controls using the Illumina 27k chip, with additional analysis of 16 female children
with Crohn’s disease [458]. The analysis identified methylation changes affecting
known CD pathogenic pathways and susceptibility genes, and other groups have
similarly demonstrated multiple methylation changes in the blood and intestine
of IBD patients (see table 2.4 on page 33).
The aim of the present study was to perform a similar analysis in a larger
group of patients with the recently released Illumina 450k chip allowing much
greater coverage of the epigenome. Some paediatric samples had been included
in the Nimmo et al. analysis [458], but all other published studies had been
in adults. We hypothesized that children would be a superior study population
for epigenetic work as the confounding effects of age, comorbidity, polypharmacy
and environmental exposures would be lessened. However, we also appreciated
that if disease risk in children carried a larger genetic component and epigenetic
changes were predominantly environment-related then epigenetic differences be-
tween cases and controls could be greatly reduced. Finally, appreciating the
differences between adult and paediatric IBD (see section 2.6, page 43), some
proportion of any findings may be specific to childhood-onset disease, and any
results would need to be replicated in adults before they could be interpreted as
important to adult disease.
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The central hypothesis was that there would be significant and reproducible
methylation differences between children with Crohn’s and symptomatic con-
trols. There could be many potential causes for any findings — environmental,
intrauterine, genetic, shifts in leucocyte proportions, or differential expression.
However, any differences would either be correlated with products and pathways
involved in the pathogenesis of Crohn’s, or disrupted by the effects of Crohn’s.
Identifying these differences may identify novel genes of interest.
The previous work by Nimmo et al. found that methylation differences were
enriched in proximity to the 71 then identified GWAS risk loci. We hypothesised
that methylation differences in children would also be enriched in proximity to
GWAS risk loci, and that this may provide more granular information about the
large regions found to carry a genetic risk by GWAS.
The first cohort, consisting of children who were investigated for suspected
IBD and either confirmed to have Crohn’s disease or found to be healthy matches
the population in whom a diagnostic biomarker would be used. We hypothesized
that methylation differences between the two groups would be sufficient to ac-
curately distinguish between children with Crohn’s disease and symptomatic but
healthy controls, and perhaps allow stratification of Crohn’s patients.
Some sections of this chapter have been published in:
Adams AT, et al. Two-stage Genome-wide Methylation Profiling in
Childhood-onset Crohn’s Disease Implicates Epigenetic Alterations




3.2 Materials & methods
3.2.1 Patient recruitment and selection
Paediatric patients Samples were collected in centres across Scotland. The
Bacteria in IBD in Scottish Children Undergoing Investigation before Treatment
(BISCUIT) study provided peripheral blood leukocyte DNA for the discovery
cohort from 18 treatment-naive newly diagnosed patients and 18 age and sex-
matched non-diseased controls from Aberdeen, Glasgow, and Dundee. Controls
were selected from the “normal colon control” subgroup of the BISCUIT study
who had microscopically and macroscopically normal colons, as opposed to the
eosinophilic control, non-specific inflamed non-IBD, proto-IBD, or disease groups.
These children had been rigorously investigated for gastrointestinal symptoms
indicative of IBD but did not have or subsequently develop any organic gastroin-
testinal pathology, including IBD [244, 243]. There was no significant difference
between this control group and children with IBD in rates of abdominal pain,
tenesmus, blood in stool, constipation, nausea, vomiting, heartburn, weight loss
or poor growth; however, there were reduced rates of anorexia (33.3 vs 70.5%,
p=0.001), diarrhoea (59.5 vs 84.1%, p=0.016), and blood when wiping (40.5 vs
65.9%, p=0.03).
There was also no significant difference between the children found to have
IBD and those normal colon controls in rates of previous surgery (gastrointestinal
or otherwise), comorbid atopic conditions, previous use of antibiotics, steroids,
or acid suppression, exposure to smoking or pets in the home, vaginal delivery
and breastfeeding. The normal colon control children did have a lower rate of
concurrent upper GI endoscopy (83.3 vs 100%, p=0.005), and a lower rate of
histological gastritis on upper GI endoscopy (34.3 vs 86.4%, p=<0.001), but had
a higher rate of H. pylori on histology from upper GI endoscopy (11.4 vs 0%,
p=0.035) [243].
The replication cohort comprised DNA samples from 18 children with estab-
lished CD supplied by the Paediatric-onset IBD Cohort and Treatment Study
(PICTS), [653] analysed against a second set of 18 normal colon controls from
the BISCUIT study.
Within both cohorts, patients and controls were matched for age and gender.
The BISCUIT study was approved by the North of Scotland Research Ethics
Committee (09/S0802/24) and PICTS by ethics committees at participating cen-
tres (Edinburgh, Glasgow, Aberdeen, and Dundee, LREC 2002/6/18). Written
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informed consent was obtained from the parents of all participating children and
informed assent was also obtained from older children capable of understanding
the nature of the study. Summary demographics for both cohorts are in shown
in table 3.1.
Discovery Cohort Replication Cohort
Crohn’s Control Crohn’s Control
Female (%) 29 29 22 22
Median Age 12.2 12.7 11.7 11.3
Age range 7.6–15.5 8.4–15.3 5.8–15.4 6.3–15.4
Neutrophils ×109/L 5.0 2.9 4.7 4.0
Lymphocytes ×109/L 1.6 2.2 1.8 1.8
Table 3.1: Age, sex and mean neutrophil and lymphocyte counts for the
two paediatric cohorts
Adult pyrosequencing replication cohort Adult replication was carried out
in samples from patients recruited from gastroenterology clinics at Edinburgh’s
Western General Hospital for genetic research (LREC 2000/4/192) or into the
IBD-BIOM and IBD Character projects. Healthy control samples were obtained
from volunteers. Written informed consent was obtained at sample collection
from all patients and controls.
Crohn’s Control
Male:Female 11:9 10:10
Median Age 34.2 34.2
Age Range 20.8–57.1 20.7–57.0
NOD2 WT (%) 70 75
Non-smoker (%) 100 100
White European (%) 100 95
Table 3.2: Summary demographics of the initial adult replication cohort.
NOD2 WT denotes wild type NOD2 status, defined as not carrying any
of the R702W, G908R, or fs1007insC CD-associated variants.
Reanalysis of biopsy microarray data from Noble et al. Data from two
previous microarray expression studies undertaken by our group [461, 462] were
combined and reanalysed to provide preliminary information regarding expression
in the gut in response to IBD and inflammation for a small number of genes which
contained highly significant CD-associated methylation changes.
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Table 3.3: Montreal classification of disease location in the initial adult
replication cohort (see table 2.5, page 45 for details)
Participants were recruited from the gastroenterology clinic in the Western
General Hospital (Edinburgh, UK), all sample donors gave written informed con-
sent, and Lothian Local Research Ethics Committee approved the study protocol
(REC 04/S1103/22). Non-inflamed biopsies were obtained from normal colorectal
cancer screening colonoscopies, and investigations of gastrointestinal symptoms
which did not reveal any histological abnormality (presumed IBS). Inflamed con-
trol biopsies were obtained from patients with a variety of non-IBD diagnoses
including pseudomembranous colitis, diverticulitis, amoebiasis, microscopic col-
itis, eosinophilic infiltration, and scattered lymphoid aggregates. The IBD pa-
tients included new diagnoses, quiescent established disease, and active estab-
lished disease, and provided combinations of inflamed and non-inflamed biopsies
from locations between the terminal ileum and rectum.
Paired biopsies were taken from each location, allowing histological charicter-
isation of inflammation in one, and extraction of RNA from the other. RNA
extraction was performed using ‘micro total RNA isolation from animal tissues
protocol’ (Qiagen) and analysed using Agilent Whole Genome microarrays (Ag-
ilent), with normalisation against Stratagene Universal Human Reference. Fur-
ther details can be obtained from the original publications [461, 462], and the
raw datasets have been made available online.
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3.2.2 Experimental techniques
Bisulfite conversion was performed using EZ DNA Methylation Kit (Zymo
Research Corporation, Irvine, CA, USA. Cat no. D5001, D5002).
Genome-wide methylation was analysed using the Infinium HumanMethyla-
tion450 BeadChip Kit (Illumina, San Diego, CA, USA), hereafter Illumina 450k.
The samples were prepared and run by the Wellcome Trust Clinical Research
Facility (Western General Hospital, Edinburgh, UK).
Pyrosequencing was performed using a PyroMark Q24 System (Qiagen) Primers
(Table 3.4) were designed using PyroMark Assay Design Software (version 2.0.1.15,
Qiagen) and supplied by Sigma-Aldrich (St. Louis). Data was exported from
the manufacturers software and analysed in R, with significance determined by
Wilcoxon rank-sum test.
Samples were run in duplicate, results with any quality warnings were dis-
carded and repeated, analysis was performed on the mean of two methylation
readings within 2% absolute methylation. Where the variance between repeats
was greater than 2% a further set of duplicate reactions was assayed, if these two
readings and one of the original readings were all within 2% (probably due to a
pipetting error or contamination of one of the original samples) the mean of these
three was used, otherwise the sample was excluded.
Further explanation of pyrosequencing and the factors involved in sequence
quality assessment can be found in section 3.6.1 (page 170). Details of the cohorts

























Table 3.4: Forward (F), reverse (R), and sequencing (S) primers. [Btn]:
5′ biotinylation, 0.05µmol synthesis scale and HPLC purification
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3.2.3 Data analysis
Methylation analysis
No samples met the QC exclusion criteria of 1% of probes having a detection p
value >0.05, but one sample was removed due to a mismatch between the recorded
sex, and the predicted sex based on median intensities of all sex chromosome
probes (illustration of this analysis is shown in figure A.1, page 256). Probes
were removed from further analysis if they had a beadcount <3 in 5% of samples,
if >1% of samples had a detection p value >0.05 for that probe, or if there was a
SNP with MAF ≥ 0.01 in European samples from the Thousand Genomes Project
within 2bp of the probe target, or if they targeted the sex chromosomes, resulting
in a final probe count of 449211. Data were corrected using background removal
and quantile normalization in the ‘lumi’ R package [156, 406] followed by beta
mixture quantile dilation [612]. Batch effects from clinical centre, Illumina 450k
slide and position, and for the combined analysis the cohort, were controlled for
using ComBAT [365].
Differential leukocyte counts from the same day that DNA samples were taken
were available for 24 patients and 19 controls. Linear models were created for all
Illumina 450k probes and disease status in these samples. Probes were selected,
which had F test with P values <10−8 but a P value for disease association of
>0.05. Combinations of 100 random probes meeting these criteria were tested,
and the best performing probe set was used to predict the differential cell counts
for samples without measured differential leukocyte counts. This model is similar
to that described by Houseman et al. [270].
Analysis of the methylation status of cases versus controls was performed us-
ing limma [582] in R using linear modelling of beta values with diagnosis, age, sex,
and neutrophil, other granulocyte, lymphocyte, and monocyte proportions as co-
variates. The Benjamini-Hochberg false discovery rate (FDR) [52] was calculated
for each probe, with a FDR corrected P <0.05 used to define significance in anal-
ysis of broader methylation patterns, such as identifying differentially methylated
regions. For significance of individual probes, the more conservative Bonferroni
correction was used.
Identification of differentially methylated regions
Analysis was performed in R using an algorithm based on the probe lasso algo-
rithm in the ChAMP pipeline [443]. DMRs were defined as 3 consecutive probes
56
3.2
with FDR adjusted p values <0.05 with a shared direction of change in meth-
ylation within a distance threshold based upon average probe density in similar
genomic regions (Promoter region, 5′ UTR, gene body, etc). Further details of
the probe lasso algorithm are shown in section A.3.5 (page 262)
Analysis of GWAS correlation
Data analysis was performed in R. Statistical significance of correlations was
calculated from the Spearman’s rank correlation coefficient. SNPs included in
the initial comparison were those from Jostins et al. [297] and Liu et al. [384]
associated with CD or IBD, but excluding those only associated with UC.
For the comparison with GWAS SNPs for non-IBD conditions the NHGRI-
EBI Catalog of published genome-wide association studies [264] was obtained
using the R package ‘gwascat’ [97].
Comparisons were made based upon the smallest methylation p value within
bins of a defined size, with the analysis repeated for bin sizes of 25kb, 50kb,
100kb, 250kb, 500kb, 1Mb, 2Mb, and 4Mb. Bins were created centred on each
GWAS SNP, and 1000 randomly selected control bins of each size were chosen to
match the probe density found in GWAS SNP-containing bins.
GO term analysis
The R package ‘Goseq’ [723] was used as described by Geeleher et al. [207] to
create a probability weighting function to correct for bias introduced by variation
in the number of Illumina 450k probes per gene. Differential methylation for a
gene was defined as the presence of a FDR significant probe from the combined
paediatric analysis annotated to that gene. P values for GO term enrichment
were corrected for multiple testing with Benjamini-Hochberg false discovery rate
[52].
Transcription factor consensus sites
2kb genomic regions were defined centred on each Illumina 450k probe with a
Bonferroni corrected p<0.05 in the combined analysis. Overlapping regions were
combined into the one containing the most significant methylation result. Se-
quences were obtained for genomic coordinates using the R packages ‘BSgenome’
and ‘BSgenome.Hsapiens.UCSC.hg19’ [477, 616].
The R package ‘BCRANK’ [11] was used to search for DNA motifs in the
defined regions by starting with a random seed and iterating minor alterations
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to find a local optimum for frequency. This was repeated with 1000 random
starting seeds, with each local optimum ranked by its number of occurrences with
a weighting toward occurrences in sequences with more significant methylation
changes and penalties for redundant bases (IUPAC codes other than A,C,G, or
T) and being found in repetitive elements.
A normalised position weight matrix (PWM) was produced for each motif and
these were compared to experimentally derived PWMs for transcription factors
in the JASPAR database (2016 version) [415]. Non-human results were ignored
and where there was overlap between results, the strongest is presented.
The analysis was repeated twice using Illumina 450k probes with FDR ad-
justed p<0.05, and the most significant probe within each DMR as the centre
of each region. The strongest results from each set of sequences were used as
starting seeds for a further analysis in the other groups of sequences to ensure
that they had not been missed by the random seeds.
Power calculation
Power calculations were performed for two-tailed T tests using the difference in
means relative to the population standard deviation for each for the Bonferroni
significant probes for a power of 80% and a significance level of 1.1×10−7, equiv-
alent to a Bonferroni corrected p<0.05, for 449211 probes.
δ = β̄CD − β̄HC√
(σ2CD + σ2HC)/2
CpG Island detection at significant probes
Sequences were extracted and combined as described in section 3.2.3. CpG islands
were defined as 200bp spans containing >0.6× the expected number of CpGs in
a random sequence (7.5 per 200bp) with a GC content >50%. 20 sets of 1000




3.3.1 Combining the two paediatric cohorts
Analysis of the discovery cohort found 9 probes with FDR adjusted p <0.05, of
which only the least significant result failed to be replicated in the second cohort
(see table 3.5).
P Value
Gene Chr Coord Discovery Replication Combined
VMP1 chr17 57915717 2.19×10−10 1.55×10−5 1.97×10−15
VMP1 chr17 57915665 9.11×10−10 9.25×10−5 2.65×10−13
chr3 101901234 3.82×10−9 5.14×10−5 1.59×10−13
RPS6KA2 chr6 166970252 1.17×10−8 3.73×10−6 4.47×10−15
ARHGEF3 chr3 57041402 3.32×10−8 4.69×10−5 1.44×10−12
chr22 50327986 1.71×10−7 3.46×10−3 3.00×10−9
chr6 35696870 4.72×10−7 2.08×10−2 3.05×10−7
MYO1E chr15 59588622 4.86×10−7 1.71×10−2 4.07×10−9
GGT6 chr17 4464400 7.55×10−7 1.02×10−1 6.9×10−7
Table 3.5: Individually significant CpGs from the discovery cohort
(Benjamini-Hochberg FDR<0.05) which replicated in the second cohort
(P<0.05) using recalculated P values including predicted cell counts. All
P values shown uncorrected, ranked in order of significance in the discov-
ery cohort
Overall there was a high degree of correlation in the results between the two
cohorts, with 97.3% of probes with nominally significant disease-associated meth-
ylation changes in each cohort show the same direction of change (see figure 3.1).
The two cohorts were therefore analysed as a combined cohort, a summary
of the number of probes with disease associated methylation changes is shown
in table 3.6, a Manhattan plot of the combined paediatric Illumina 450k data is
shown in figure 3.2 (page 61), and a QQ plot in figure 3.3 (page 62).
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Significance Number Percent




Table 3.6: The number of probes with methylation differences between
Crohn’s disease and symptomatic controls in the combined analysis by
significance threshold.
Figure 3.1: Correlation in direction of change between paediatric co-
horts. All probes with nominal significance in both cohorts included
(n=3620), correlation between log fold-change in the two cohorts for
these probes: ρ=0.87, p<2.2×10−308.
60
3.3
Figure 3.2: A Manhattan plot of the combined paediatric Illumina 450k data. Horizontal lines indicate Bonferroni
and FDR significance thresholds. Probes within the top 20 results which are annotated to a gene are labelled.
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Figure 3.3: QQ plot of the combined paediatric Illumina 450k data.
Bonferroni significant probes are shown in red, FDR significant probes
are shown in blue. The inflation factor (λ) is shown, and the solid line




There was no significant difference in overall mean methylation between the CD
and control samples (p=0.24), however both FDR (n=1319, βCD-βHC=-0.006, T
test p=0.0005) and Bonferroni (n=65, βCD-βHC=-0.043, p=1.14×10−14) signifi-
cant probes showed overall hypomethylation compared to controls.
The methylation probes showed a bimodal distribution with peaks at 12.6
and 83.0% methylation. The peaks for CD were shifted further from the centre
by 0.23% and 0.7% (T test p=1.05×10−10 and 1.80×10−147) for the low and high
peaks respectively. The mean methylation at significant probes is markedly differ-
ent to non-significant probes, with a large enrichment of probes with intermediate
methylation (see figure 3.4).
Overall, more probes were hypermethylated in CD (56.7% hypermethylated,
p<2.22×10−308), however FDR and Bonferroni significant probes were more likely
to be hypomethylated (54.5%, p=0.001 & 76.9%, p=1.42×10−5). Figure 3.5 (page
65) shows a volcano plot of the paediatric Illumina 450k data, demonstrating the
increased prevalence of hypomethylation among the most significant probes.
Overall, hypermethylated probes had a slightly larger difference in means
between CD and controls (βCD-βHC=0.0002, χ2 Test p=1.86×10−14), but in FDR
and Bonferroni significant probes the hypomethylated probes showed a greater
difference between CD and controls (βCD-βHC=-0.007, p=2.77×10−16 and βCD-
βHC=-0.022, p=1.0×10−4).
In 63% of Bonferroni significant probes, the range of methylation values was
larger for CD patients than controls, compared to 41% in FDR significant probes
and 44% in all probes. In the Bonferroni significant probes where the range was
larger in CD the difference was up to 0.29 (mean 0.076), in the probes where
the range was smaller in CD the difference was up to 0.079 (mean 0.027). In all
probes there was a small (Pearson’s product moment correlation coefficient r=-
0.06) but significant (p<2.22×10−308) correlation between a negative β difference
(i.e. hypomethylation in CD) and increased range of methylation results in CD
compared to controls. This correlation was stronger in FDR significant probes
(r=-0.41, p=4.02×10−57) and strongest in Bonferroni significant probes (r=-0.68,
p=6.84×10−10).
Figure 3.6 (page 66) shows probability densities for methylation at Bonferroni
significant probes and figure 3.7 (page 67) shows the β difference and β range
difference in all probes. The general pattern described above of hypomethylation
and increased variance in significant probes can be seen clearly.
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Figure 3.4: Mean methylation results for Crohn’s and control, with
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cg00382138 cg00506299 cg01059398 cg01409343 cg01671681 cg01726890 cg01850135 cg02560388 cg02716826 cg02734358 cg03546163
cg03940776 cg04345034 cg04389058 cg04987734 cg05316065 cg05673882 cg06653632 cg07398517 cg07839457 cg08423142 cg08508455
cg08692676 cg09137630 cg09349128 cg09588020 cg10472711 cg11821200 cg12054453 cg12170787 cg12992827 cg13134297 cg14880894
cg16292768 cg16936953 cg17411016 cg17501210 cg17618872 cg18157896 cg18181703 cg18376497 cg18608055 cg18860310 cg18942579
cg19653417 cg19821297 cg20477259 cg20782117 cg20995564 cg21328643 cg22284398 cg22768358 cg23842572 cg24231380 cg24310395
cg24531955 cg24632582 cg26581729 cg27023597 cg27039118 cg27049094 cg27058497 cg27209729 cg27310092 cg27361520













Figure 3.7: The most significant probes are predominantly hypomethy-
lated in CD and show increased variability in CD
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Group Size
Gene βCD-βHC σpop p<0.05 p<1.5×10−4 p<1.1×10−7
VMP1† -0.134 0.050 3 10 17
RPS6KA2 -0.099 0.045 4 12 22
SOCS3 -0.089 0.048 6 16 28
SBNO2 -0.114 0.083 9 26 47
RUNX3 -0.053 0.064 7 21 38
POLK‡ -0.103 0.049 10 29 52
Table 3.7: The group sizes needed for 80% power to detect methyl-
ation changes equivalent to representative significant findings from this
study including the smallest (†) and largest (‡) results, together with the
β difference and population standard deviation. Significance thresholds
shown are for nominally significant, an estimation for FDR significance,
and Bonferroni significance based on the number of probes in the Illumina
450k platform.
Power calculations were performed using the delta value for each of the Bonfer-
roni significant probes, and the group sizes required to detect differences matching
a selection of these probes at 80% power are shown in table 3.7. Figure 3.8 shows
the group sizes necessary for every probe with power between 50–95% at a sig-




















Figure 3.8: The group sizes required to detect methylation differences
matching the 65 Bonferroni significant results at significance levels equiv-
alent to Bonferroni corrected significance in the Illumina 450k platform.
Coloured by Bonferroni corrected p value.
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3.3.3 Individual CpGs
An initial analysis of the combined paediatric data used neutrophil:lymphocyte
ratios as a covariate rather than the procedure described in section 3.2.3. These
data were presented in abstracts to the British Society of Gastroenterology [2]
and the European Crohn’s and Colitis Organisation [313] (see B.1 and B.2, page
289). In this analysis there were 165 significant probes after Bonferroni correction
for multiple testing versus the 65 probes (table 3.9, page 73) found with the
reimplemented Houseman method in the final analysis. All significant probes in
the final analysis were also significant in the preliminary analysis.
A permutation test (n=1000) was performed by randomly permuting the di-
agnoses and beta values of each sample and repeating the analysis. A p value
cutoff of p<2.0×10−7 would exclude the lowest p value from 95% the random per-
mutations. The uncorrected p value equivalent to a Bonferroni corrected p<0.05
is 1.1×10−7, and the p value cutoff of 2.0×10−7 would class 82 CpGs as significant
— a 26% increase.
Bonferroni significant probes were examined to see if they were in CpG islands.
After combining neighbouring significant probes, 19/61 (31.1%) were in CpG
islands. This is significantly lower (χ2 p=4.58×10−6) than the rate observed in
20 random selections of 1000 non-significant probes (60.7%, 95% CI 60.0–61.4%).
FDR significant probes were also significantly (19.4%, p=1.06×10−166) less likely
to be in CpG islands than the randomly selected non-significant probes. Figure
3.9 shows CpG prevalence, GC content and CGIs in proximity to Bonferroni
significant probes.
Both FDR and Bonferroni significant probes showed a positive correlation
between the β difference in Crohn’s disease and the probability of a probe being
in a CGI (FDR: r=0.20, p=1.47×10−11, Bonferroni: r=0.38, p=0.003, Pearson’s
product-moment correlation). Probes which were not in CGIs were more likely
to be hypomethylated (see table 3.8). There was no correlation between the p
value for the methylation change and the chance of a probe being in a CGI.
A Meth B Meth
↓ ↑ ↓ ↑
CGI N 36 6 N 574 348Y 10 9 Y 87 135
Table 3.8: Hypomethylation correlates with not being in a CGI for (A)




Uncorrected P Value Bonferroni
Gene Chr Coord LogFC Discovery Replication Combined Combined
VMP1 chr17 57915717 -1.33 2.19×10−10 1.55×10−5 1.97×10−15 8.86×10−10
RPS6KA2 chr6 166970252 -1.04 1.17×10−8 3.73×10−6 4.47×10−15 2.01×10−9
chr3 101901234 -1.03 3.82×10−9 5.14×10−5 1.59×10−13 7.13×10−8
VMP1 chr17 57915665 -1.18 9.11×10−10 9.25×10−5 2.65×10−13 1.19×10−7
ARHGEF3 chr3 57041402 -0.56 3.32×10−8 4.69×10−5 1.44×10−12 6.48×10−7
chr2 11969958 -0.56 1.93×10−6 1.60×10−5 8.45×10−12 3.80×10−6
CFI chr4 110723299 -0.68 1.88×10−6 2.60×10−5 3.27×10−11 1.47×10−5
PLCH1 chr3 155421735 -0.56 4.43×10−6 5.23×10−5 4.52×10−11 2.03×10−5
chr19 12890029 -0.72 3.35×10−6 7.09×10−5 1.91×10−10 8.60×10−5
HK2 chr2 75067716 0.57 9.03×10−6 8.62×10−6 2.04×10−10 9.18×10−5
chr1 151945663 -0.47 2.67×10−6 2.56×10−5 2.54×10−10 1.14×10−4
TNFSF10 chr3 172235808 -0.55 9.77×10−6 1.63×10−4 3.28×10−10 1.47×10−4
SOCS3 chr17 76354621 -0.68 3.05×10−5 2.43×10−5 4.56×10−10 2.05×10−4
chr7 38370874 0.47 2.22×10−5 1.50×10−4 6.14×10−10 2.76×10−4
VMP1 chr17 57915773 -0.75 1.69×10−5 2.99×10−4 8.23×10−10 3.70×10−4
ZBTB16 chr11 113947148 0.60 5.09×10−5 8.38×10−5 1.78×10−9 8.01×10−4
chr9 33447032 -0.41 3.33×10−6 2.56×10−3 2.56×10−9 1.15×10−3
ZEB2 chr2 145172035 -0.99 2.88×10−6 5.73×10−4 2.58×10−9 1.16×10−3
chr3 37258149 0.74 7.15×10−6 2.09×10−4 2.92×10−9 1.31×10−3
chr22 50327986 -0.76 1.71×10−7 3.46×10−3 3.00×10−9 1.35×10−3
INPP4B chr4 143488622 -0.69 7.92×10−5 9.35×10−5 3.09×10−9 1.39×10−3
GSDMC chr8 130799007 -0.43 4.65×10−5 9.23×10−5 3.17×10−9 1.43×10−3
WASF2 chr1 27755803 -0.36 3.64×10−4 6.80×10−6 3.24×10−9 1.46×10−3
chr15 41233701 -0.26 2.60×10−5 1.78×10−3 3.56×10−9 1.60×10−3















Uncorrected P Value Bonferroni
Gene Chr Coord LogFC Discovery Replication Combined Combined
chr12 132654924 -0.62 1.16×10−6 5.05×10−3 4.22×10−9 1.90×10−3
chr3 30327579 -0.47 3.99×10−6 2.74×10−3 4.44×10−9 2.00×10−3
CLU chr8 27467783 -0.61 2.45×10−5 3.17×10−4 4.72×10−9 2.12×10−3
SBNO2 chr19 1130866 -0.87 3.63×10−5 4.08×10−4 5.04×10−9 2.26×10−3
chr2 47100912 -0.46 4.53×10−4 9.78×10−6 5.04×10−9 2.26×10−3
NRXN2 chr11 64428925 -0.50 2.89×10−5 2.17×10−4 5.35×10−9 2.40×10−3
SLC25A13 chr7 95865631 -0.58 1.46×10−4 2.14×10−5 5.83×10−9 2.62×10−3
IL18RAP chr2 103038171 0.50 3.35×10−5 3.04×10−3 6.67×10−9 3.00×10−3
LOXL2 chr8 23154691 -0.52 7.67×10−4 1.92×10−5 1.13×10−8 5.09×10−3
CX3CR1 chr3 39309435 0.53 1.87×10−4 1.25×10−5 1.16×10−8 5.21×10−3
RTP5 chr2 242813914 0.70 6.21×10−4 3.57×10−5 1.23×10−8 5.51×10−3
RFTN1 chr3 16469127 -0.79 6.15×10−5 2.84×10−4 1.49×10−8 6.69×10−3
VMP1 chr17 57915740 -0.67 6.28×10−6 2.17×10−3 1.58×10−8 7.08×10−3
SBNO2 chr19 1130965 -0.54 5.85×10−5 6.85×10−4 1.61×10−8 7.24×10−3
PTGER4 chr5 40685989 0.26 4.52×10−5 4.54×10−4 1.88×10−8 8.45×10−3
CDC42BPB chr14 103415873 0.53 1.20×10−4 1.15×10−4 2.17×10−8 9.73×10−3
RUNX3 chr1 25291546 0.63 1.21×10−3 1.72×10−6 2.45×10−8 1.10×10−2
chr7 30737556 -0.33 3.11×10−5 6.18×10−3 2.69×10−8 1.21×10−2
POLK chr5 74862702 -0.44 7.85×10−5 1.36×10−3 3.14×10−8 1.41×10−2
GPRIN3 chr4 90227074 -0.48 2.30×10−4 1.96×10−5 3.20×10−8 1.44×10−2
HEATR2 chr7 797592 -0.59 4.57×10−6 1.16×10−3 3.49×10−8 1.57×10−2
MPRIP chr17 17030253 0.50 3.39×10−5 6.88×10−4 4.37×10−8 1.96×10−2
SLC15A4 chr12 129281444 0.67 1.94×10−3 6.74×10−5 4.58×10−8 2.06×10−2
SLC10A6 chr4 87752504 -0.87 4.10×10−6 1.59×10−3 4.97×10−8 2.23×10−2
MIR21 chr17 57918262 -0.51 4.48×10−5 1.20×10−3 5.42×10−8 2.44×10−2
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Uncorrected P Value Bonferroni
Gene Chr Coord LogFC Discovery Replication Combined Combined
CNOT6L chr4 78697859 -0.62 3.27×10−6 6.39×10−4 5.49×10−8 2.46×10−2
NMRAL1 chr16 4516078 0.60 1.99×10−5 2.05×10−3 5.60×10−8 2.52×10−2
SYNJ2 chr6 158490013 -0.44 2.65×10−5 1.39×10−3 5.82×10−8 2.61×10−2
CBFA2T2 chr20 32235621 0.51 8.80×10−5 2.58×10−3 6.47×10−8 2.91×10−2
PTDSS2 chr11 470429 -0.31 5.16×10−4 5.31×10−5 6.68×10−8 3.00×10−2
NLRC5 chr16 57023022 -0.72 4.83×10−5 2.96×10−3 7.06×10−8 3.17×10−2
ZC3H4 chr19 47618017 -0.37 2.02×10−4 1.08×10−4 7.57×10−8 3.40×10−2
PRKCE chr2 46119607 -0.54 4.40×10−4 7.47×10−4 7.81×10−8 3.51×10−2
FKBP5 chr6 35654363 -0.65 1.76×10−4 6.73×10−4 7.93×10−8 3.56×10−2
TNF chr6 31544960 0.56 3.44×10−5 4.47×10−3 8.31×10−8 3.73×10−2
TRPS1 chr8 116575902 -0.65 1.02×10−4 1.19×10−3 8.51×10−8 3.82×10−2
NPDC1 chr9 139939792 -0.32 5.34×10−4 8.68×10−4 9.01×10−8 4.05×10−2
chr15 70797389 -0.40 3.67×10−4 2.76×10−4 1.00×10−7 4.49×10−2
chr20 2795593 -0.50 2.95×10−4 6.11×10−4 1.01×10−7 4.54×10−2
TBPL1 chr6 134299594 -0.58 1.58×10−4 1.83×10−4 1.03×10−7 4.64×10−2
Table 3.9: Details of all Illumina 450k probes attaining Bonferroni corrected p values <0.05 in the combined
analysis. Uncorrected p values shown for the individual cohorts, and combined, as well as Bonferroni corrected p















Figure 3.9: Number of CpGs within 200bp and GC content for 1kb regions either side of Bonferroni significant
probes. Shaded areas represent CGIs, the horizontal line marks 60% of expected CpGs, the vertical line marks the
probe position and is solid if the probe is within a CGI.
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3.3.4 Differentially methylated regions
There were 77 probes with FDR adjusted p<0.05 in 19 DMRs of consecutive
significant unidirectional methylation change within a distance threshold based
on local probe density (table 3.10).
Direction Gene P (min) Chr Coordinate Length Probes
↓ VMP1 1.97×10−15 17 57915150 1138 4
↑ ZBTB16 1.78×10−9 11 113946633 1241 3
↑ SLC15A4 4.58×10−8 12 129281291 408 3
↑ TNF 8.31×10−7 6 31543764 2126 4
↑ DIABLO 1.17×10−7 12 122711835 306 6
↑ ZFYVE28 1.76×10−7 4 2321442 1151 3
↑ RUNX3 2.19×10−7 1 14181794 351 5
↓ HGF 2.44×10−7 7 81399131 536 3
↓ GPR56 6.43×10−7 16 57662273 536 3
↑ TOLLIP 8.18×10−7 11 1296881 554 3
↑ ITGB2 1.21×10−6 21 46341036 536 3
↑ PIEZO1 1.19×10−6 16 88831961 1086 3
↑ PRF1 1.47×10−6 10 72362714 190 6
↑ ZBTB12 2.23×10−6 6 31867623 330 9
↑ PRF1 6.32×10−6 10 72360292 160 6
↑ CD247 7.59×10−6 1 167486463 1685 4
↓ CETP 1.39×10−5 16 56995572 536 3
↑ UBASH3A 1.45×10−5 21 43823747 1030 3
↑ WRAP73 3.21×10−5 1 3563024 1937 3
Table 3.10: Differentially methylated regions. ↑: Hypermethylation, ↓:
Hypomethylation, P (min): smallest p value within the DMR.
In contrast to significant probes which were not in differentially methylated
regions (see section 3.3.2), DMR probes were significantly more likely to be
hypermethylated. Crohn’s-associated hypermethylation was seen in 83% com-
pared to 56.7% in all probes, 45.5% in other FDR significant probes (χ2 Test
p=3.34×10−11) and 23.1% in Bonferroni significant probes. Including only one
probe per DMR does not change this result (e.g. DMR hypermethylation 79% vs.
FDR hypermethylation 45.5%, p=0.001), and there was no significant difference
in the number of probes in hypomethylated versus hypermethylated DMRs (3.25
vs 4.27, p=0.71). The mean methylation of DMR probes is also higher than other
FDR significant probes which are not in DMRs (9.0%, p=3.05×10−5, see figure
3.10).
In keeping with the earlier observation that hypermethylated probes are more
frequently found in CGIs, in 11/19 (57.9%) DMRs, the most significant probe
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Figure 3.10: Mean methylation values for top (solid) and all (dotted)
DMR probes, compared with all FDR significant probes, Bonferroni sig-
nificant probes, and all probes separated by diagnosis
was within a CGI (see figure 3.11), compared to 19.4% (χ2 p=2.8×10−4) for non-
DMR FDR significant probes, 31.1% (p=0.07) for Bonferroni significant probes
and 60.7% (p=0.99) for all probes. 17/19 (89%) of DMRs intersect with a CGI.
Local context of DMRs
Figures 3.12–3.29 (pages 78–95) show the methylation results for each gene con-
taining a DMR. From top: 1) -log10 p values, with lines indicating Bonferroni
corrected p<0.05 and FDR<0.05. 2) Beta values for each sample, red - CD,
blue - control. 3) Mean beta value for CD relative to mean control. 4) Gene
transcripts. Grey highlight indicates the position of the DMR
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Figure 3.11: Number of CpGs and GC content per 200bp for DMR regions. Shaded areas represent CGIs, the
lower horizontal line marks 60% of expected CpGs, x axis demarcations represent 1kb. The upper horizontal line
represents the DMR boundaries derived from the lasso algorithm.
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Figure 3.13: Methylation results for the ZBTB16 region. See page 76
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Figure 3.15: Methylation results for the TNF region. See page 76
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Figure 3.17: Methylation results for the ZFYVE28 region. See page 76
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Figure 3.19: Methylation results for the HGF region. See page 76
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Figure 3.21: Methylation results for the TOLLIP region. See page 76
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Figure 3.23: Methylation results for the PIEZO1 region. See page 76
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Figure 3.25: Methylation results for the ZBTB12 region. See page 76
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Figure 3.27: Methylation results for the CETP region. See page 76
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Figure 3.29: Methylation results for the WRAP73 region. See page 76
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3.3.5 Correlation with GWAS
Analysis published in Adams et al. Using range thresholds of 25kb, 50kb,
100kb, 250kb, 500kb, 1mb, 2mb and 4mb, the p value of the most significant
methylation probe within range of each GWAS SNP was recorded. The list of
GWAS SNPs were drawn from Jostins et al. [297] and Liu et al. [384], excluding
those which were solely associated with UC.
Across all distance thresholds there is a significant correlation between the
number of probes within a bin and the probability of that bin containing a GWAS
SNP. Likewise, bins with greater numbers of probes are more likely to contain
more significant methylation probes. Therefore, for each range threshold 1000
random bins were selected which matched the distribution of Illumina 450k probe
coverage seen in the CD/IBD SNPs. Matching was based on splitting the range of
the square root of probes per bin into ten groups and establishing the proportions
of bins falling into each group. Non-SNP bins were then chosen at random from
groups of equivalent square root probe number with the same proportion per
decile. Examples of the matching results are shown in figures 3.30 and 3.31 (page
97). The smallest p values within the randomly selected bins were then compared
to those within range of CD/IBD SNPs by Wilcoxon rank-sum test.
Methylation results were more significant within proximity of CD/IBD GWAS
SNPs in all tested range thresholds. The distance thresholds where the correlation
was strongest were 50kb (p = 3.66 × 10−7) and 100kb (p = 2.41 × 10−7). This
result was presented in Adams et al. [4], with a figure (see figure 3.32) showing a
similar analysis to that of Nimmo et al. [458] — i.e. for methylation results with
lower p values there is an increasing likelihood of being near a GWAS SNP.
Illumina 450k probes with significant methylation changes after Bonferroni
correction which are within 1Mb of IBD GWAS SNPs from Jostins et al. and Liu
et al. are shown in table 3.11 on page 99. There were 6 DMRs (table 3.10, page
75) within 1Mb of these SNPs; VMP1, ZBTB16, and TNF are already shown with
other Bonferroni significant probes in table 3.11, additionally TOLLIP, ITGB2,


















Figure 3.30: Probe Density is higher in proximity to IBD GWAS SNPs

















Figure 3.31: Results of Probe Density Matching. Density of probes
within 100kb of IBD GWAS SNPs shown in blue, with the dotted line
showing a matched set of random probes
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Figure 3.32: Enrichment of methylation changes within 50kb of GWAS
SNPs (from Adams et al. [4])
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Gene Chr:Coord P valuea GWAS SNP Distance Probesb Candidate genesc
SBNO2 19:1130866 2.26×10−3 rs2024092 6835 2 GPX4,HMHA1,(20)
IL18RAP 2:103038171 3.00×10−3 rs917997 32397 1 IL18RAP,IL1R1,(7)
VMP1 17:57915717 8.86×10−10 rs1292053 47820 5 TUBD1,RPS6KB1,(9)
RTP5 2:242813914 5.51×10−3 rs35320439 76573 1 PDCD1,ATG4B
NA 1:151945663 1.14×10−4 rs4845604 143983 1 RORC
GSDMC 8:130799007 1.42×10−3 rs1991866 174902 1 (2)
CLU 8:27467783 2.12×10−3 rs17057051 240229 1 PTK2B,TRIM35,EPHX2
TNF 6:31544960 3.73×10−2 rs9264942 270580 1 (22)
PTGER4 5:40685989 8.45×10−3 rs11742570 275405 1 PTGER4,(1)
NRXN2 11:64428925 2.40×10−3 rs559928 278555 1 CCDC88B,(23)
ZEB2 2:145172035 1.16×10−3 rs11681525 320347 1 -
NA 15:41233701 1.60×10−3 rs28374715 330249 1 (11)
NA 3:101901234 7.13×10−8 rs616597 331508 1 NFKBIZ
SOCS3 17:76354621 2.04×10−4 rs17736589 382497 1 -
RPS6KA2 6:166970252 2.01×10−9 rs1819333 403295 1 CCR6,RPS6KA2,(4)
ZBTB16 11:113947148 8.01×10−4 rs561722 439682 1 NXPE1,NXPE4,(5)
ZC3H4 19:47618017 3.40×10−2 rs1126510 494234 1 CALM3,(14)
NPDC1 9:139939792 4.05×10−2 rs10781499 673387 1 CARD9,(22)
CBFA2T2 20:32235621 2.91×10−2 rs4911259 859339 1 DNMT3B,(8)
Table 3.11: Bonferroni Significant Probes within 1Mb of GWAS SNPs from Jostins et al. [297] and Liu et al.
[384]. a Bonferroni corrected b Bonferroni significant probes within the same gene. c Candidate genes identified
by the reporting papers, (additional genes), - no reported candidates
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Re-analysis of correlation Although the randomly selected bins were matched
for probe density, there may be other factors making the regions surrounding
GWAS SNPs different from the randomly selected regions. To attempt to remove
these uncontrolled variables the significance of methylation findings in proxim-
ity to IBD SNPs was compared to the methylation significance in proximity to
randomly selected GWAS SNPs for other conditions using the NHGRI-EBI Cat-
alog of published genome-wide association studies to source both the IBD and
non-IBD SNPs [264].
1000 randomly selected SNPs were chosen to match the density of Illumina
450k coverage and the minimum p value for CD-associated methylation differences
within a range of distances was compared to those seen in IBD GWAS SNPs. This
analysis was performed on 1000 random selections of non-IBD GWAS SNPs. The
summary results of the 1000 repeats are shown in figure 3.33 (page 101), median
p values for enrichment of methylation results in proximity to IBD GWAS SNPs
at 50kb at 100kb bin sizes are 5.89×10−5 and 1.19×10−5.
To demonstrate that the randomly selected regions from the initial analysis
are an inadequate control, the minimum methylation p value in 1000 random
regions was compared with the minimum methylation p value in range of all non-
IBD GWAS SNPs from the NHGRI-EBI Catalog. This showed an enrichment of
significant methylation findings, particularly at 25–50kb (figure 3.34, page 102).
GWAS SNPs for inflammatory and autoimmune traits and some other traits
with extensive GWAS results were also analysed. For each trait the most sig-
nificant methylation results within the GWAS SNP bins were compared to 1000
randomly selected bins containing GWAS SNPs for other non-IBD traits, with
the probe density for the two groups matched. This was repeated for 1000 ran-
dom selections of control SNPs. The results are shown in figures 3.35 and 3.36
(pages 104 and 105).
There was a strong correlation between the methylation results and GWAS
SNPs for HDL cholesterol over a wide range of distance thresholds, with weaker
correlations for LDL cholesterol and lipid metabolism phenotype. Of the in-
flammatory and immune diseases the strongest correlation was for rheumatoid
arthritis, with correlations also seen in type 1 and 2 diabetes, multiple sclerosis
and systemic lupus erythematosus.
There was a weak but significant positive correlation between the P value of
GWAS SNPs for all conditions and the significance of nearby methylation findings
across all bin sizes (see table 3.12).

















Figure 3.33: Box and whisker plot showing that CD-associated meth-
ylation differences are more likely to be found in proximity to IBD gwas
SNPs than randomly selected GWAS SNPs for other traits, with a peak
at distances around 100kb. Whiskers extend up to 1.5 × IQR from the
1st and 3rd quartiles, with any remaining results plotted as points. Sum-
mary results of 1000 random selections of non-IBD GWAS SNPs from
the NHGRI-EBI GWAS Catalog matching the Illumina 450k coverage of
IBD GWAS SNPs.
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Figure 3.34: Box and whisker plot showing that significant methylation
findings are enriched in proximity to all non-IBD GWAS SNPs compared
to randomly selected regions of matching probe density. Whiskers extend











Table 3.12: More significant GWAS SNPs for all diseases collectively,
have more significant methylation findings in proximity to them. ρ: Spear-
man’s rank correlation rho
two showed a significant correlation1 with methylation p values; IgG glycosyla-
tion (p=0.014, Spearman’s ρ=0.16, 699 SNPs) and lipid metabolism phenotypes
(p=0.0036, ρ=0.46, 91 SNPs).
Correlation with predicted functional SNPs Farh et al. [176] attempted
to predict functional variants in proximity to IBD GWAS SNPs. There was no
enrichment of significant methylation results in proximity to these SNPs at any
tested bin range by χ2 test for Bonferroni or FDR significance (p=1) and no
significant correlation between methylation p value and distance to the nearest
predicted functional variant by Spearman’s rank correlation (p=0.34–0.95).
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Figure 3.36: Correlation between CD-associated methylation changes and GWAS SNPs for other traits II, see
page 106
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Table 3.35 and 3.36: Box and whisker plots showing the results for 1000 repli-
cations of comparing methylation within range of GWAS SNPs for well studied
traits and various immune and inflammatory conditions with randomly selected
non-IBD GWAS SNPs. Whiskers extend up to 1.5 × IQR from the 1st and 3rd
quartiles, with any remaining results plotted as points.
BAD and SCZ: Bipolar affective disorder and schizophrenia, BMD: Bone
mineral density, Cognitive perf : cognitive performance, CHD: Coronary heart
disease, RA: Rheumatoid arthritis, SLE: Systemic lupus erythematosus, AMD:
Age-related macular degeneration, Ank Spond: Ankylosing spondylitis, Small-
pox vaccine: IL-6 response to smallpox vaccination, Inflammatory BM: In-
flammatory biomarkers, PBC: Primary biliary cirrhosis, Chagas PR: PR inter-




3.3.6 GO term analysis
Genes containing more probes are more significantly likely to have a probe with an
FDR adjusted p<0.05 (Spearman’s ρ=0.71, p=6.8×10−7, figure 3.37, page 107).
The same pattern is not seen for the small number of genes containing Bonferroni
significant probes (Spearman’s ρ=0.53, p=0.12, figure 3.38, page 108). GO term
analysis was performed on genes containing one or more FDR significant probes
after applying a correction based on the number of probes annotated to that gene
as described by Geeleher et al. [207].
Figure 3.37: Genes assayed by more probes are increasingly likely to
demonstrate significant methylation differences at one probe. Spear-
mans’s ρ=0.71, p=6.8×10−7
Table 3.13 shows the most significantly enriched GO terms amongst probes
with FDR significant methylation differences and table 3.14 shows the GO terms
which were enriched among Bonferroni significant probes. The p values for GO
term enrichment are corrected by the Benjamini-Hochberg method for multiple
testing.
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Figure 3.38: No bias to increasing likelihood of Bonferroni signifi-




GO Term P value Description
GO:0048583 6.86x10−11 regulation of response to stimulus
GO:0002757 6.86x10−11 immune response-activating signal transduction
GO:0048584 6.86x10−11 positive regulation of response to stimulus
GO:0002253 9.59x10−11 activation of immune response
GO:0002764 3.96x10−10 immune response-regulating signaling pathway
GO:0007165 5.19x10−10 signal transduction
GO:0050778 5.46x10−10 positive regulation of immune response
GO:0023052 5.53x10−10 signaling
GO:0044700 5.53x10−10 single organism signaling
GO:0007154 9.93x10−10 cell communication
GO:0050896 2.04x10−9 response to stimulus
GO:0051716 2.04x10−9 cellular response to stimulus
GO:1902531 2.40x10−9 regulation of intracellular signal transduction
GO:0035556 3.46x10−9 intracellular signal transduction
GO:0045089 1.23x10−8 positive regulation of innate immune response
GO:0031349 1.26x10−8 positive regulation of defense response
GO:0009966 1.34x10−8 regulation of signal transduction
GO:0002684 2.06x10−8 positive regulation of immune system process
GO:0002224 2.06x10−8 toll-like receptor signaling pathway
GO:0002218 2.46x10−8 activation of innate immune response
Table 3.13: The most significantly enriched GO terms among probes
with FDR significant disease-associated methylation changes after correc-
tion for probe number. P values corrected for multiple testing (Benjamini-
Hochberg FDR).
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GO Term P value Description
GO:0002252 6.18x10−6 immune effector process
GO:0006659 7.95x10−6 phosphatidylserine biosynthetic process
GO:0045414 1.09x10−5 regulation of interleukin-8 biosynthetic process
GO:0002460 1.27x10−5 adaptive immune response based on somatic re-
combination of immune receptors built from im-
munoglobulin superfamily domains
GO:0042228 1.91x10−5 interleukin-8 biosynthetic process
GO:0006955 1.97x10−5 immune response
GO:2001235 2.20x10−5 positive regulation of apoptotic signaling pathway
GO:0002455 3.06x10−5 humoral immune response mediated by circulating
immunoglobulin
GO:2001238 3.57x10−5 positive regulation of extrinsic apoptotic signaling
pathway
GO:0016064 3.83x10−5 immunoglobulin mediated immune response
GO:0002250 3.94x10−5 adaptive immune response
GO:0019724 4.12x10−5 B cell mediated immunity
GO:0050778 4.22x10−5 positive regulation of immune response
GO:0002376 6.31x10−5 immune system process
GO:0002718 1.80x10−4 regulation of cytokine production involved in im-
mune response
GO:0002682 1.95x10−4 regulation of immune system process
GO:0002253 1.97x10−4 activation of immune response
GO:0045416 2.23x10−4 positive regulation of interleukin-8 biosynthetic pro-
cess
GO:0002684 2.23x10−4 positive regulation of immune system process
GO:0050776 2.28x10−4 regulation of immune response
Table 3.14: The most significantly enriched GO terms among probes
with Bonferroni significant disease-associated methylation differences af-
ter correction for the number of probes per gene. P values corrected for
multiple testing (Benjamini-Hochberg FDR).
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3.3.7 Enrichment of DNA motifs
DNA motifs with high similarity to human transcription factor binding sites
found within 2kb of Illumina 450k probes with Bonferroni significant methyl-
ation changes, FDR significant methylation changes and within DMRs are shown
in tables 3.24, 3.25, and 3.26 respectively (from page 174). Motifs present in a
large proportion of the examined sequences were selected for further investiga-
tion. A prevalence threshold of greater than twice the mean prevalence rate of
all discovered motifs was used. These are shown in bold in tables 3.16 and 3.17
(pages 112–113), however some of the results with the lowest similarity to tran-
scription factors and lowest prevalence in the input sequences have been omitted
to shorten the tables. There was no significant difference in the prevalence of
these motifs between Bonferroni significant regions and FDR significant regions
by χ2 test, and within regions containing Bonferroni and FDR significant probes
there was no significant correlation between p value and the presence of the motif
by Wilcoxon rank-sum test. In table 3.15 the prevalences were also compared to
those that would be obtained from a sequence of random DNA bases, and the
prevalences observed by repeatedly (n=100) randomly selecting 1000 non signif-
icant probes, and constructing non-overlapping regions as described previously.
Motif Bonferronia FDRb Randomc Controld
AVCBTGTTT 24.6* 17.8 7.0 16.3
CCACGBVA 23.1 35.6 28.0 35.8
CCCYTAG 30.8 40.5 25.0 40.7
CTDTGNGGT 30.8 28.1** 9.4 22.8
Table 3.15: The percentage prevalence of each motif within regions con-
taining aBonferroni significant probes, bFDR significant probes, crandom
DNA, and dregions containing randomly selected non-significant probes.
χ
2 test versus control *p=0.038, **p=2.8×10−5
Although they initially appeared to be highly prevalent, CCACGBVA and CCCYTAG
are found at a very similar rate in proximity to non-significant methylation probes.
AVCBTGTTT is modestly over-represented near Bonferroni significant probes, but
the strongest finding is a 23–35% relative enrichment of CTDGNGGT compared to
non-significant methylation probes. The p value for enrichment of CTDGNGGT in
proximity to Bonferroni significant probes is 0.067, reflecting the small number
of regions, though the trend matches that seen in the FDR significant probes.
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Table 3.16: Enriched DNA motifs (left) and matching transcription
factor binding sites (right) I
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Table 3.17: Enriched DNA motifs (left) and matching transcription
factor binding sites (right) II
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AVCBTGTTT CCACGBVA
CCCYTAG CTDTGNGGT
-2000 -1000 0 1000 2000 -2000 -1000 0 1000 2000










Figure 3.39: Position of proposed motifs relative to methylation probe
in 100 random selections of 1000 non-significant probes ∼ and FDR
significant probes ∼
In addition to the prevalence relative to that seen in non-significant probes,
the positions of the proposed motifs relative to each probe was examined and com-
pared to the position seen in the 100 selections of 1000 random non-significant
probes. AVCBTGTTT and CCYTAG were uniformly distributed across the regions,
whereas CCACGBVA and CTDTGNGGT were more likely to be found close to the
probe. In many cases the target of the probe was the CpG contained within
the CCACGBVA motif, or the motif was found within the probe sequence (table
3.23, page 173). However, this same pattern was observed in non-significant
probes. Only CTDTGNGGT demonstrated a different distribution pattern near sig-
nificant methylation differences compared to non-significant probes. The context
of the regions containing Bonferroni significant probes and the CTDGNGGT motif
are shown in table 3.18
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Gene Chr Sequence Position Context
VMP1 17 CTTTGGGGT + 694–702 R§ intron
RPS6KA2 6 CTTTGGGGT - 64–72 R§ intron
3 CTTTGGGGT + 108–116 R no gene
15 CTGTGAGGT - 398–406 R no gene
MYO1E 15 CTTTGGGGT - 642–650 R intron
12 CTTTGGGGT - 94–102 R no gene
2 CTTTGAGGT + 350–358 R no gene
CDC42BPB 14 CTGTGAGGT + 886–894 R intron
RUNX3 1 CTTTGAGGT - 796–804 R intron
MPRIP 17 CTGTGGGGT - 671–679 R§ intron
SLC10A6 4 CTGTGGGGT - 646–654 intron
NMRAL1 16 CTGTGGTGT + 277–285 R exon
SYNJ2 6 CTGTGGGGT - 298–306 R§ intron
PTDSS2 11 CTGTGGGGT - 551–559 R intron
FKBP5 6 CTATGAGGT + 337–345 R intron
TRPS1 8 CTATGGGGT + 520–528 R intron
15 CTTTGAGGT - 440–448 R no gene
15 CTGTGAGGT - 857–865 R no gene
20 CTGTGAGGT + 949–957 § 5′/3′/intron
TBPL1 6 CTGTGTGGT - 101–109 R intron
Table 3.18: Context of the CTDGNGGT motif near Bonferroni significant
probes. Position in bp relative to nominal probe target. R: Regulatory
region (DNA I hypersensitivity, H3K27ac, and transcription factor binding
from ENCODE), § possible alternative promoter region.
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3.3.8 Replication by pyrosequencing
Pyrosequencing of BISCUIT DNA samples
Figure 3.40 shows pyrosequencing analysis of the most significant CpG in a sepa-
rate bisulfite conversion of the DNAs from the paediatric discovery cohort. This
reproduced the results with an r2 of 0.95. Further CpGs were not replicated
in the paediatric DNA because the Illumina 450k platform has been extensively
validated and the paediatric DNA was extremely limited.
Figure 3.40: Illumina 450k beta values for cg12054453, and pyrose-
quencing methylation values for the same CpG (r2 0.95)
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Adult replication by pyrosequencing
Probes were selected for replication by pyrosequencing after the initial analysis
of the paediatric Illumina 450k data. This primary analysis used the ratio of
neutrophils to lymphocytes in the samples which had full blood counts taken the
same day as the DNA sample as a covariate, rather than the methylation-derived
full blood counts.
Probes were chosen based on their significance in this initial analysis, links
with relevant biological pathways or known significance to Crohn’s disease, and
ease of designing pyrosequencing assays which measure the same CpG as the Illu-
mina 450k probe. This resulted in pyrosequencing assays for VMP1, RPS6KA2,
SOCS3, ARHGEF3, SBNO2, CFI, CDC42BPB and TOLLIP. Of these probes,
only TOLLIP lost significance in the final Illumina 450k analysis, where an de-
convoluted cell compositions were used as covariates rather than neutrophil to
leucocytes ratio.
In a cohort of 20 adults with Crohn’s disease and 20 healthy controls, signifi-
cant differences were found in every tested probe (figure 3.41) except for TOLLIP
(not shown). Larger scale replications of VMP1 and RPS6KA2 were undertaken
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Figure 3.41: Box and whisker plot showing the replication of 7 probes
by pyrosequencing in an adult cohort of 20 CD patients and 20 healthy
controls. Whiskers extend up to 1.5 × IQR from the 1st and 3rd quartiles,




3.4.1 Implications for future study design
Power
Rakyan et al. [509] simulated epigenome-wide association studies in mixed cell
populations. Their calculations were based on methylation odds ratio (’methOR’),
calculated as shown in figure 3.42 (page 120). The power calculations were based
on three scenarios, as shown in figure 3.43 (page 121). In scenarios a and b, control
samples exhibited full methylation and case samples (i–iv) showed increasing pro-
portions of unmethylated and partially methylated DNA respectively. In scenario
c there is a small hypomethylation and increase in variance. The resulting power
to detect the methylation change described by the three scenarios are shown in
table 3.19 (page 120). The authors conclude that:
When methOR is around 1.25, a sample size of 800 cases + 800 con-
trols is adequate to achieve 80% power at a significance level of α=10−6
for scenario c but not a or b [. . . ] When methOR is around 1.5, a
sample size of 400 + 400 gives 80% power at α=10−6 for b and c but
not a.
If we regard 1.5 to be a target methOR value, then it would not seem
to be cost-effective to pursue an EWAS with fewer than 400 cases
and 400 controls, and 800 of each would be preferable to achieve good
power [509].
As shown in section 3.3.2, the group sizes necessary to detect results matching
those attaining Bonferroni significance in this dataset are much lower. Table 3.20
(pages 122-125) shows the methOR and md of each probe for comparison with
the simulated results from Rakyan et al. (table 3.19), but with powers for group
sizes from 25–100 instead of 100–800. This table also shows the group size needed
for 80% power at a significance level of 1.1×10−7 (Bonferroni significance).
The methylation changes seen in Bonferroni significant probes most closely
match scenario c from Rakyan et al. The methylation profiles of the six probes
with the smallest and largest group size needed to discover are shown in figures
3.44 and 3.45 respectively (pages 126 and 127). The observed methORs in table
3.20 range from 1.21–1.91 (median 1.38), which match the predicted methORs
from table 3.19. The mean differences are however much greater, ranging from
2.74–15.65 (median 7.16).
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Exposure CD meth 1-meth
(Disease) HC meth 1-meth
methOR = methCD × (1−methHC)
methHC × (1−methCD)
Figure 3.42: The calculation of methylation odds ratio (’methOR’) as
per Rakyan et al. [509]
Group Size
100 200 400 800
α 10−6 10−8 10−6 10−8 10−6 10−8 10−6 10−8
MethOR md
Scenario a
i. 1.24 3.6 0 0 0 0 1 0 20 3
ii. 1.49 7.2 0 0 4 0 66 21 100 99
iii. 1.78 10.8 2 0 55 11 100 98 100 100
iv. 2.10 14.4 18 1 99 78 100 100 100 100
Scenario b
i. 1.24 3.6 0 0 0 0 2 0 33 8
ii. 1.49 7.2 1 0 16 2 85 51 100 100
iii. 1.78 10.8 13 1 84 46 100 100 100 100
iv. 2.10 14.4 60 19 100 97 100 100 100 100
Scenario c
i. 1.27 1.25 1 0 7 1 50 19 98 88
ii. 1.54 2.5 37 10 95 78 100 100 100 100
iii. 1.82 3.75 95 77 100 100 100 100 100 100
iv. 2.11 5.0 100 99 100 100 100 100 100 100
Table 3.19: Simulated power for finding methylation differences between
groups of 100, 200, 400, or 800 at significance levels of 10−6 and 10−8.
From Rakyan et al. [509].
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Scenario a Scenario b Scenario c




























Group Size: 25 50 75 100
α: 10−6 10−8 10−6 10−8 10−6 10−8 10−6 10−8
probe n β̄cd β̄hc MethOR md Power
cg12054453 17 0.23 0.37 1.91 13.39 99.95 98.05 100 100 100 100 100 100
cg17501210 22 0.69 0.79 1.69 9.89 97.57 78.81 100 100 100 100 100 100
cg12992827 21 0.58 0.71 1.77 12.91 98.07 81.37 100 100 100 100 100 100
cg16936953 20 0.39 0.55 1.88 15.65 99.31 89.65 100 100 100 100 100 100
cg04389058 22 0.60 0.68 1.36 7.14 97.05 76.45 100 100 100 100 100 100
cg02560388 24 0.24 0.29 1.33 5.57 92.88 62.64 100 99.99 100 100 100 100
cg00382138 23 0.48 0.58 1.48 9.71 96.33 73.49 100 100 100 100 100 100
cg01671681 27 0.68 0.74 1.32 5.64 86.71 49.50 100 99.92 100 100 100 100
cg19821297 31 0.47 0.58 1.54 10.79 72.58 30.93 99.97 99.14 100 100 100 100
cg27049094 22 0.55 0.46 1.40 8.38 97.21 77.15 100 100 100 100 100 100
cg27310092 23 0.47 0.54 1.29 6.36 95.00 68.82 100 100 100 100 100 100
cg01059398 29 0.44 0.52 1.34 7.36 78.58 37.60 99.99 99.62 100 100 100 100
cg18181703 28 0.42 0.51 1.43 8.91 80.83 40.48 99.99 99.73 100 100 100 100
cg01726890 30 0.81 0.77 1.30 4.26 74.16 32.56 99.98 99.29 100 100 100 100
cg18942579 26 0.50 0.60 1.52 10.29 88.64 53.07 100 99.95 100 100 100 100
cg22768358 26 0.82 0.78 1.34 4.67 88.24 52.30 100 99.94 100 100 100 100
cg02716826 31 0.42 0.47 1.25 5.46 70.51 28.93 99.96 98.90 100 100 100 100
cg20995564 27 0.57 0.69 1.74 12.81 86.87 49.78 100 99.92 100 100 100 100
cg21328643 32 0.82 0.75 1.52 7.16 67.18 25.95 99.93 98.42 100 100 100 100
Table 3.20 Continued overleaf
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Group Size: 25 50 75 100
α: 10−6 10−8 10−6 10−8 10−6 10−8 10−6 10−8
probe n β̄cd β̄hc MethOR md Power
cg09349128 27 0.25 0.33 1.50 8.33 84.18 45.33 100 99.85 100 100 100 100
cg18376497 28 0.31 0.40 1.49 9.00 82.73 43.15 100 99.81 100 100 100 100
cg05316065 32 0.56 0.62 1.29 6.18 68.48 27.08 99.94 98.63 100 100 100 100
cg09588020 32 0.46 0.52 1.24 5.41 65.60 24.64 99.91 98.15 100 100 100 100
cg24632582 35 0.50 0.55 1.25 5.63 56.75 18.27 99.71 95.93 100 99.99 100 100
cg08423142 34 0.82 0.85 1.27 3.37 61.44 21.45 99.84 97.27 100 100 100 100
cg19653417 33 0.67 0.74 1.38 6.66 62.44 22.18 99.86 97.50 100 100 100 100
cg07398517 26 0.51 0.58 1.32 6.90 87.52 50.95 100 99.93 100 100 100 100
cg16292768 38 0.52 0.62 1.49 9.81 47.16 12.84 99.17 91.70 100 99.94 100 100
cg18608055 47 0.50 0.62 1.59 11.36 25.49 4.53 93.34 69.62 99.91 98.40 100 99.98
cg17411016 32 0.43 0.50 1.32 6.83 68.39 27.00 99.94 98.61 100 100 100 100
cg27209729 35 0.61 0.68 1.32 6.29 56.18 17.91 99.69 95.74 100 99.99 100 100
cg20782117 32 0.48 0.57 1.43 8.90 65.97 24.94 99.91 98.22 100 100 100 100
cg27361520 27 0.88 0.86 1.28 2.74 86.24 48.68 100 99.91 100 100 100 100
cg24531955 30 0.30 0.36 1.30 5.84 73.26 31.62 99.97 99.21 100 100 100 100
cg24310395 43 0.73 0.65 1.45 7.94 33.29 6.99 96.76 80.24 99.98 99.49 100 100
cg24231380 35 0.83 0.74 1.71 8.86 56.32 18.00 99.70 95.79 100 99.99 100 100
cg00506299 32 0.64 0.73 1.52 9.01 67.90 26.57 99.93 98.54 100 100 100 100
cg01409343 37 0.62 0.70 1.42 7.86 50.94 14.82 99.45 93.64 100 99.97 100 100















Group Size: 25 50 75 100
α: 10−6 10−8 10−6 10−8 10−6 10−8 10−6 10−8
probe n β̄cd β̄hc MethOR md Power
cg12170787 51 0.51 0.59 1.42 8.70 20.50 3.23 89.45 60.62 99.74 96.69 100 99.91
cg11821200 39 0.61 0.56 1.22 4.76 44.96 11.77 98.96 90.37 100 99.92 100 100
cg04987734 28 0.49 0.41 1.38 7.96 82.03 42.14 100 99.78 100 100 100 100
cg27058497 38 0.60 0.50 1.50 9.96 46.73 12.63 99.13 91.45 100 99.94 100 100
cg13134297 39 0.31 0.35 1.21 4.28 44.41 11.51 98.90 90.01 100 99.91 100 100
cg05673882 52 0.39 0.44 1.24 5.28 18.48 2.76 87.28 56.40 99.6 95.54 100 99.85
cg02734358 35 0.40 0.46 1.28 6.05 57.20 18.56 99.73 96.08 100 99.99 100 100
cg10472711 35 0.59 0.67 1.41 8.02 55.42 17.43 99.66 95.47 100 99.99 100 100
cg23842572 32 0.76 0.68 1.48 7.94 69.07 27.60 99.94 98.71 100 100 100 100
cg06653632 30 0.85 0.80 1.40 4.82 74.62 33.04 99.98 99.33 100 100 100 100
cg18860310 35 0.63 0.73 1.59 10.08 54.85 17.08 99.64 95.27 100 99.98 100 100
cg27023597 50 0.63 0.68 1.27 5.47 21.96 3.59 90.78 63.46 99.81 97.32 100 99.94
cg14880894 42 0.80 0.84 1.25 3.27 36.29 8.09 97.56 83.41 99.99 99.68 100 100
cg01850135 36 0.82 0.74 1.56 7.57 53.40 16.22 99.58 94.71 100 99.98 100 100
cg03940776 34 0.40 0.47 1.32 6.74 60.98 21.12 99.83 97.16 100 100 100 100
cg17618872 36 0.79 0.74 1.35 5.43 51.87 15.34 99.50 94.06 100 99.97 100 100
cg08508455 38 0.63 0.68 1.27 5.42 47.82 13.17 99.23 92.06 100 99.95 100 100
cg07839457 48 0.50 0.60 1.48 9.74 24.37 4.22 92.62 67.77 99.88 98.12 100 99.97
cg09137630 34 0.31 0.36 1.23 4.62 61.53 21.52 99.84 97.29 100 100 100 100
Table 3.20 Continued overleaf
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Group Size: 25 50 75 100
α: 10−6 10−8 10−6 10−8 10−6 10−8 10−6 10−8
probe n β̄cd β̄hc MethOR md Power
cg22284398 40 0.24 0.30 1.37 6.15 40.45 9.75 98.37 87.12 100 99.83 100 100
cg03546163 37 0.55 0.63 1.40 8.20 49.16 13.87 99.33 92.78 100 99.96 100 100
cg20477259 36 0.74 0.66 1.42 7.28 52.04 15.43 99.51 94.14 100 99.97 100 100
cg27039118 35 0.64 0.70 1.36 6.83 55.73 17.62 99.68 95.58 100 99.99 100 100
cg26581729 49 0.51 0.55 1.21 4.77 23.03 3.86 91.65 65.44 99.85 97.71 100 99.96
cg04345034 35 0.27 0.34 1.34 6.25 54.90 17.11 99.64 95.28 100 99.98 100 100
cg18157896 39 0.40 0.47 1.37 7.75 45.17 11.87 98.98 90.50 100 99.92 100 100
cg08692676 32 0.53 0.61 1.39 8.02 68.21 26.84 99.94 98.58 100 100 100 100
Table 3.20: MethORs and power to detect Bonferroni significant probes. n is the group size needed for 80%
power at α=1.1×10−7, β̄cd and β̄hc are the mean methylation values for Crohn’s and control groups; MethOR,






































Figure 3.45: Methylation profiles of the six probes with the least power as shown in table 3.20
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Visual consideration of the observed patterns of methylation change in Bon-
ferroni significant probes reveals two broad patterns when agnostic to groups and
direction, with a small minority showing an intermediate pattern. Examples of
probes demonstrating each of these patterns are shown in figure 3.46 (page 130);
the changes in mean methylation and standard deviation have been normalized
against a standard representative control pattern for ease of comparison.
Pattern Description
Slip One end of range unchanged, other end extends
Large increase in variance
Slide Both ends of range shifted
small or no change in variance
Intermediate Both ends of range shifted
Medium increase in variance
Table 3.21: Patterns of methylation change
Pattern DMRTop DMRAll Bonf FDR
Slip 52.6 59.5 60.0 49.7
Slide 36.8 35.4 35.4 49.1
Indeterminate 10.5 5.1 4.6 1.1
Total probes 19 79 65 1319
Table 3.22: Percentage of probes matching each pattern of disease
associated methylation change for the most significant probe within each
DMR (DMRTop), all DMR probes (DMRAll), Bonferroni significant probes
(Bonf), and FDR significant probes (FDR)
The differences in proportional prevalence of the two main patterns between
groups were not statistically significant, however probes exhibiting the ‘slip’
pattern were slightly more significant (p=8.02×10−6, Spearman’s rank correla-
tion ρ=0.13), and required slightly smaller group sizes for 80% power at esti-
mated FDR significance levels (p=9.52×10−5, ρ=0.11). There was only a weak
correlation between methylation pattern and absolute β difference (p=0.039,
ρ=0.059), but the methylation pattern was strongly correlated with β difference
including direction (p=8.03×10−18, ρ=0.24) and hypomethylation in general (χ2
p=1.33×10−16, OR:1.56 for hypomethylation with the ‘slide’ pattern).
The ‘slip’ pattern is symmetrical — at some probes there is an increase in the
variance seen in CD, in others the variance is higher in controls. In Bonferroni
significant probes 69.2% of probes exhibiting this pattern have a higher variance




In probes where the mean methylation for all samples was <50%, 88.2% of
probes showed hypomethylation in CD, whereas in probes where the mean methy-
lation for all samples was >50%, 67.0% of probes showed hypermethylation in CD
(χ2 p=1.67×10−78). This finding of methylation moving away from 50% in CD















Figure 3.46: Representative examples of the observed patterns of methylation change (orange) normalised against
control samples for the top pattern (red), with 3 equidistant weaker results. Top: ‘slip’ with a large increase in
variance, and only a small change at one end of the range. Middle: ‘slide’ with a large shift in values, but a
non-significant change in the range. Bottom: an example of an intermediate result.
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Correction for multiple testing
One shortfall of the published EWAS studies in IBD is the inconsistency in the
chosen significance thresholds (see table 2.4, page 33) compared with GWAS,
where a threshold of 5×10−8 is generally accepted. IBD EWAS studies have used
methods including the Bonferroni, Holm, and Šidák corrections, the Benjamini-
Hochberg false discovery rate (α=0.01, 0.05, or 0.2), and uncorrected p values
(<0.05 or 10−4). This, and other varying factors in analysis and design such as
cell type correction and the reporting of CpGs or DMRs makes it difficult to see
the literature as a cohesive whole, and assess the consistency of results.
The analysis reported in this chapter uses two significance thresholds, The
Bonferroni correction and the Benjamini-Hochberg false discovery rate [52]. The
justification for this decision and an explanation of the methods used in the IBD
EWAS literature follows.
Familywise error rate The Bonferroni method corrects for the familywise
error rate (FWER) α, this is the probability of rejecting at least one true null
hypothesis. For a set of m p values and associated null hypotheses
P1, P2, . . . , Pm
H1, H2, . . . , Hm




The Šidák (or Dunn-Šidák) correction is similar to the Bonferroni correction
[570]. If the probability of a type I error in an individual test is αt, then the
familywise error is αf
αf = 1− (1− αt)m
∴ αt = 1− (1− αf )
1
m
Each null hypothesis Hi is rejected if
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Pi ≤ 1− (1− αf )
1
m




and therefore the Šidák correction is less conservative than the Bonferroni
correction, however the difference is minimal especially as m becomes large, and
would not change the significance of any result in the combined paediatric Illu-
mina 450k dataset.
The Holm method (also called Bonferroni-Holm or Holm-Bonferroni) takes an
ordered list of m p values and associated null hypotheses.
P1 ≤ P2 ≤ · · · ≤ Pm
H1, H2, . . . , Hm




Null hypotheses H1 . . . Hk−1 are rejected and Hk . . . Hm are accepted. Again,
although this is less prone to type II error than the Bonferroni correction, no addi-
tional probes would be considered significant in the combined paediatric dataset.
False discovery rate Correction for the false discovery rate is a newer tech-
nique than FWER correction. An acceptable false discovery rate is chosen by the
experimenter, usually as in this case q=0.05. FDR significance is then calculated
in a stepwise manner on the sorted list of p values for an associated list of m null
hypotheses.
P1 ≤ P2 ≤ · · · ≤ Pm
H1, H2, . . . , Hm
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and reject this and all preceding equivalent null hypotheses
H1, H2, . . . Hk
Thus for the combined paediatric Illumina 450k data, where the total number









∴ k = 1319
This is shown graphically in figure 3.47. By accepting up to 5% false positive
results, the number of significant results increases from 65 by any of the FWER
methods detailed above to 1319. Benjamini and Hochberg point out in their
original paper
Often the control of the FWER is not quite needed. The control of
the FWER is important when a conclusion from the various individual
inferences is likely to be erroneous when at least one of them is [. . . ]
The overall conclusion that the treatment is superior need not be
erroneous even if some of the null hypotheses are falsely rejected [52]
The permutation test described in section 3.3.3 tested the FWER. In 1000
simulated experiments using random permutations of diagnosis with methylation
results there were no p values <2.0×10−7 in 95% of the simulated experiments.
The FWER correction methods do not account for the correlation observed be-
tween neighbouring CpGs. The DMR analysis (section 3.3.4) only identified
19 DMRs from the whole genome, but this understates the correlation between
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neighbouring probes. DMRs had to contain at least 3 consecutive probes within
a short distance2 with FDR significant methylation changes between CD and
control sharing the same direction of methylation change. This excludes regions
where the probe density is too low to be classified as a DMR, where the methyl-
ation direction varies, or where there is no disease-associated methylation change,
yet the probes are still correlated with each other.
However, there are benefits to using an overly conservative correction as it
may only be possible to follow-up a limited number of ‘hits’. The approach
taken with this work was to correct for the familywise error rate, to produce a
smaller list of highly significant results suitable for detailed analysis or functional
work, but also a larger list with an acceptable small proportion of expected false
discoveries, to allow analysis of wider patterns such as GO term enrichment,
colocalisation with genetic risk loci, and defining DMRs. The Holm correction
is undoubtedly superior to the Bonferroni correction; however, there were no
differences in probe significance between these methods in this dataset and so the
p values are presented as Bonferroni corrected because the technique was felt to
be more widely known and understood.
Probes per gene As discussed above, the familywise error rate of 0.05 corre-
sponds to a 5% probability of a type I error in the Bonferroni significant probes,
and a false discovery rate of 0.05 corresponds to a probability of type I error in
5% of the FDR significant probes. However, much analysis takes place at the
level of genes, rather than probes. GO term enrichment and methylation-GWAS
correlation is biased by the varying numbers of probes per gene, and an increasing
probability of finding a probe with a significant disease-associated methylation
difference after FDR correction (but not Bonferroni correction) in genes with
more probes (as shown in figure 3.37, page 107).
Although this is recognized [207], and efforts were made to control for this bias,
pathway analysis of methylation data remains problematic. Unlike examining
expression data for pathway enrichment, methylation changes may not relate to
expression, or could act at a distance, and it can not be assumed that methylation
would be correlated to the regulation of genes at every level of a pathway.
In the GO term analysis a probability weighting function was used to correct
for the expected probability of each gene containing an FDR significant probe,
based on the number of probes that gene contained, and in the GWAS colocalisa-
2Adjusted for CpG density in various genomic regions
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Figure 3.47: -Log10 Pi from the combined paediatric Illumina 450k
dataset plotted against i/m ×q, the line is where Pi = i/m×q and therefore
all results before the line is crossed are significant. Blue points are FDR
significant probes, red points are Bonferroni significant.
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tion analysis probe density over genomic regions rather than genes was corrected
for. This is more rigorous than our group’s previous analytical technique [458].
The number of methylation measurements made by arrays has increased from
approximately 27,000 to over 480,000, and the Illumina 450k will be discontinued
at the end of 2015 to be replaced by the Illumina Infinium MethylationEPIC
Kit which measures over 850,000 CpGs. Concurrently costs of bisulfite NGS are
falling. This will make corrections for multiple testing and for variations in probe
density increasingly important in epigenome-wide association studies.
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3.4.2 β values & M values
The analysis of DNA methylation using the Illumina Infinium range of technolo-
gies involves several idiosyncrasies, which must be appreciated in order to produce
a dependable analysis, and also in order to understand the limitations of the anal-
ysis and the assumptions upon which it is based. The analysis presented in this
chapter was performed on β values, whereas many similar analyses are performed
using M values. This section will explain the two, demonstrate a minimal impact
on results between them, and discuss potential alternatives.
Linear models using β values, and transformed β values
Methylation is reported by the Illumina 450k platform as a β value, which is
conceptually equivalent to the proportion of methylated cytosine at a particular
base. Where M and U are the methylated and unmethylated signal intensities,
and α is a constant (100 for the 450k platform) preventing erroneous values when
M and U are small:
β value = M
M + U + α
Asymmetry is frequently seen in measures of proportions [184], with β values
demonstrating a skewed bimodal distribution (as shown in figure 3.4, page 64).
There is frequently a degree of heteroscedasticity — with variance tending to be
smaller near extremes of methylation compared to central values, undermining
the assumption of homoscedasticity in statistical procedures such as Gaussian
regression [690]. Finally, β values are bounded between 0 and 1, which produces
non-linear relationships between explanatory variables and β, as a linear relation-
ship would not be bounded between 0 and 1 [675].
The use of logit-transformed β values ( “M values”) was proposed to deal with
the shortcomings in β values [157]. Using a default value of α = 1;










Du et al. [157] did show that M values improved the heteroscedasticity and
distribution of β values, however they only considered a single dataset and feature
selection was based on fold change rather than test statistics or p value. Trans-
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formation to M values only partially deals with heteroscedasticity, and to an even
lesser extent, the asymmetrical distribution of methylation data [539]. Zhuang
et al. [738] performed a more in-depth study of 7 datasets and showed compara-
ble false discovery rates when analysing β values and M values, and only found
the use of M values to be advantageous when the number of samples of each
phenotype was very small (2–3). The authors also show that supervised PCA
with β values outperform M values as “it appears that the correlation structure
between biologically relevant CpGs is compromised leading to worse modelling of
the biological variation” [738].
Analysis of the combined paediatric dataset (figure 3.48, page 139), as well
as the IBD Character dataset3 (figure 3.49, page 140) show strong correlations
between the results obtained in either analysis (ρ=0.92–0.99), with differences in
whether a probe is found to be significant limited to a small proportion of probes
close to the limit of significance.
M values lack the intuitive meaning of β values, as they can take any value
−∞–∞, and the relationship between covariates and methylation can only be
considered on the transformed scale [184]. Additionally heteroscedasticity in the
data may be biologically relevant [539, 738], and disease-associated changes in
methylation variance as well as changes in mean methylation are notable in the
results presented in this chapter. Using alternative analytical techniques which
do not depend on symmetry and uniform variance, rather than attempting to
correct heteroscedasticity may be a superior approach [184].
The arcsine square root transformation is often used in ecological studies
to address heteroscedasticity, and has seen some use with methylation results
[64, 483], however results remain bounded though between 0 and π/2 [675], as and
with M values it may be a better option to use alternative regression methods,
rather than using different transformations to reduce the complexity of the data.







Figure 3.48: Comparison of results from analysis of the combined pae-
diatric data using β values and M values. Points coloured by whether the
probe was significant only when using M values (n=8), only using β values
(n=3), or in either analysis (n=65). Spearman’s ρ= 0.99, p<2.2×10−16
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Figure 3.49: Comparison of results from analysis of the IBD Character
dataset (see appendix /refch.rep) with β values and M values. Points
coloured by whether the probe was significant only when using M val-
ues (n=12), only using β values (n=6), or in either analysis (n=114).
Spearman’s ρ= 0.92, p<2.2×10−16
140
3.4
Alternative models for analysis of methylation data
A number of alternative models have been proposed for proportion data, or meth-
ylation specifically including beta regression [184], GAMLSS4 [519], and ratio of
corrected gammas [690]. These share an approach of finding models which fit
within the constraints of the data, rather than trying to reshape the data to fit
the constraints of the model.
Ferrari and Cribari-Neo [184] proposed a regression method for data which are
constrained to the unit scale, such as rates, probabilities, and proportions, using
the beta distribution, which is itself constrained to the unit scale. The models
produced deal well with heteroscedastic and skewed data, and model parameters
are directly interpretable in terms of the response variable.
The beta distribution can take on a variety of shapes to fit data by varying
the two parameters it takes, α and β, e.g. the predicted methylation profiles
created by Rakyan et al. (and reproduced in figure 3.43, page 121). The beta
distribution’s probability density function (PDF) is given by:
f(x;α, β) = Γ(α + β)Γ(α)Γ(β)x
α−1(1− x)β−1
where:
0 ≤ x ≤ 1, α > 0, β > 0
and Γ(·) is the gamma function: Γ(y) = (y−1)! extended to all complex numbers
except non-positive integers.
The mean and variance of x are related to the parameters α and β like so:
E(x) = α
α + β V ar(x) =
αβ
(α + β)2(α + β + 1)
Defining µ = α/(α+ β) and φ = α+ β [184] and substituting gives the mean
and variance of x as:
E(x) = µ V ar(x) = µ(1− µ)1 + φ
As the variance of x is related to the mean µ, heteroscedasticity is assumed
[131]. The probability density function can be redefined in terms of the mean
and precision parameters µ and φ as:
4Generalised additive models for location scale and shape
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f(x;µ, φ) = Γ(φ)Γ(µφ)Γ((1− µ)φ)x
µφ−1(1− x)(1−µ)φ−1
where:
0 < x < 1, 0 < µ < 1, φ > 0
The beta regression model is shown below for a random sample (x1, . . . , xn)
of X, which is beta distributed xi ∼ B(µi, φ), with a vector y = (y1, . . . , yk)T
of k covariates, and a vector β = (β1, . . . , βk)T of k regression parameters found
by maximum likelihood estimation. Where g(·) is a link function which maps
(0, 1) 7→ R:
g(µi) = yTi β
This model was extended to incorporate variable dispersion by Simas et al.
[574] allowing a second set of covariates and regression parameters for the preci-
sion parameter φ. The covariates for µ and φ can overlap if desired.
An underlying assumption of beta regression is that β follows a beta distribu-
tion, implying that M and U are independent [690]; however, this is frequently
untrue [353]. Weinhold et al. propose a model which does not assume the inde-
pendence ofM and U which they call the ratio of corrected gammas (RCG) [690].
Using Kibble’s bivariate gamma, with the following probability density function:









where Γ(·) is the gamma function, and:








r!Γ(k + r + 1)
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× (λmb+ λu(1− b))
((λmb+ λu(1− b))2 − 4ρλmλub(1− b))α+0.5
and the following log-likelihood function for methylation values and a vector
of covariates (b1, XT1 ), . . . , (bn, XTn ):
n∑
i=1




log(Γ(2α))− 2 log(Γ(α)) + αXTi γ
+ α log(1− ρ) + log((exp(XTi γ)− 1)bi + 1) + (α− 1) log(bi(1− bi))
− (α + 0.5) log
(
((exp(XTi γ)− 1)bi + 1)2 − 4ρ exp(XTi γ)bi(1− bi)
) ]
These alternative techniques for modelling methylation data are clearly more
computationally expensive, and it will be important to establish whether they
offer a substantial improvement over currently used methods.
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3.4.3 GWAS correlation
Nimmo et al. [458] assayed disease-associated methylation differences in 40 adult
female non-smokers (21 ileal CD, 19 healthy controls) using the Illumina 27k plat-
form. These results demonstrated an increased proportion of significant methyl-
ation differences within 25, 50 and 100kb of the 71 then-described CD GWAS risk
loci [194] (figure 3.50, page 145). There was an 8.6 fold enrichment of methylation
results with FDR corrected p<0.0005 within 50kb of the known CD GWAS SNPs
(p=0.021). The methylation results from Illumina 450k analysis of the combined
paediatric cohort were analysed to see if this finding was replicated, and similar
results were obtained and presented in Adams et al. [4] (figure 3.32, page 98).
In this figure, methylation results with p<10−10 were not shown because at
smaller p value thresholds the list of significant probes becomes dominated by
VMP1/MIR21, which is 47kb from the IBD GWAS SNP rs1292053 (figure 3.51,
page 145). The correlation remained significant at thresholds of 45kb and 25kb,
indicating that the result is not solely due to the effect of VMP1/MIR21 meth-
ylation.
The direct comparison between the smallest p values within range of GWAS
SNPs and random regions of matching probe density by Wilcoxon rank sum test
is resilient to outliers. Additionally, randomly selecting control regions containing
the same density of Illumina 450k methylation probes addresses the previously
uncorrected bias due to the correlations between probe density and methylation
results (figure 3.37, page 107), and between probe density and GWAS SNPs.
A portion of the bias is due to false positives, i.e. if more measurements of
methylation are made in a region, there is a greater chance of a false positive
result. However, the bias inherent to the design of the Illumina 450k chip is that
genes which are known to be involved in disease or critical pathways, such as
those implicated by GWAS studies, have better coverage by methylation probes.
The use of GWAS SNPs for other conditions, also matched for probe den-
sity, offers another potential improvement to the analysis. There was a weak,
but highly significant relationship between the significance of methylation results
and the significance of nearby GWAS SNPs for any trait (table 3.12, page 103),
demonstrating that random regions of matched probe density are not a sufficient
control for GWAS SNPs, and that GWAS SNPs for other traits should be used in
similar analyses. There is some overlap between GWAS risk loci for inflammatory




Figure 3.50: At lower p value thresholds an increasing proportion of
methylation findings are within 25, 50 and 100kb of GWAS risk loci.
From Nimmo et al. [458]
Figure 3.51: Enrichment of methylation changes within 50kb of GWAS
SNPs including results with p < 10−10
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Cholesterol
In addition to CD and IBD, significant CD-associated methylation findings were
significantly enriched in proximity to GWAS findings for HDL cholesterol, LDL
cholesterol, and lipid metabolism phenotype (see figures 3.35 and 3.36, pages 104
and 105). Cholesterol levels are known to be deranged in IBD, with decreased
total cholesterol and increased triglycerides. Differences increase in more severe
disease and possibly become more normal with treatment [342].
Lower cholesterol levels were found to be associated with younger age at di-
agnosis, male sex, use of biologics, surgery and hospitalisations. Higher levels
of triglycerides were associated with surgery, hospitalisations and median CRP
[342]. Conversely, there is evidence that treatment with statins may reduce steroid
requirements in IBD [132].
There are several gastrointestinal factors in IBD which would predispose to
lower cholesterol levels such as malabsorption, intestinal resection, altered bowel
transit, and anorexia, with possible interference from altered gut flora. Changes
in lipid profile are more profound in CD compared to UC, possibly due to ileal
disease interfering with bile acid and lipid absorption [342, 576]. However, similar
lipid changes seen in systemic lupus erythematosus and evidence of a role for
TNFα, IFNγ, and interleukins in lipid metabolism point to a non-gastrointestinal
contribution [72].
Despite lower cholesterol levels, an increased risk of thrombosis and stroke is
a recognized extraintestinal manifestation of IBD (table 1.2, page 6), with a two-
to threefold increased risk of venous thromboembolism — an observation which
has been dubbed ‘the lipid paradox’ [576]. Subclinical atherosclerotic changes
are detectable in paediatric CD, including an increased carotid intima media
thickness and reduced brachial flow-mediated dilation [10].
Chronic inflammation is an independent risk factor for atherosclerosis and
thromboembolism, and is also seen in rheumatoid arthritis, systemic lupus erythe-
matosus, ankylosing spondylitis, psoriatic arthritis, antiphospholipid syndrome,
systemic sclerosis, and Sjörgen’s syndrome [448]. Chronic inflammation has ef-
fects on endothelial function, immune cell activity (involved in atherosclerotic
plaque formation and rupture), and levels of thrombotic and antithrombotic fac-
tors. CRP and calprotectin are frequently elevated in IBD, and beside use as
inflammatory markers may be actively involved in atherogenesis. Other products
which are increased in IBD have been linked to atherosclerosis, such as antiphos-
pholipid antibodies, homocysteine and lipoprotein [576, 448].
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NOD2 mutations also predispose to premature atherosclerosis and destabili-
sation of coronary plaques and IBD patients have thrombocythaemia, with small
platelets containing increased granules and demonstrating a propensity for spon-
taneous aggregation [576].
Glucocorticoids increase hypertension, weight gain, poor glucose control, dys-
lipidaemia and cardiovascular events, though in inflammatory conditions the pos-
itive effects on inflammation may partly or wholly offset this. Additionally anti-
TNFα drugs, methotrexate and 6-mercaptopurine may also have beneficial effects
on atherosclerotic risk [448].
The relationship between cholesterol, atherosclerosis, and IBD is clearly com-
plex, and incompletely understood, but consistent with the finding of methyl-
ation changes enriched in proximity to GWAS loci with established links to HDL
cholesterol, LDL cholesterol and lipid metabolism. Aloi et al. described subclin-
ical atherosclerotic findings in children with IBD [10] and if these methylation
findings support an ongoing atherosclerotic process in these children it would
lend weight to investigating very early interventions to reduce lifetime risk for
CHD, VTE, and stroke.
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3.4.4 Transcription factors
Stadler et al. described low-methylated regions (LMRs) in murine embryonic
stem cells and neural progenitors and human stem cells [588]. These LMRs
were found distal to promoters and TSS, were mostly outwith CGIs and had
low CpG density. They associated with DNA-binding factors, contained DNase
hypersensitivity sites, and histone marks associated with active enhancers such
as H3K4me1 and H3K27ac, but with little RNA polymerase II activity indicating
they were unlikely to act as promoters. Transcription factor binding was shown to
cause locally reduced methylation, LMR formation was strongly correlated with
increased expression of the nearest gene (p=2.3×10−197) and LMRs were shown
to be cell type specific. LMRs have also been shown in differentiated cells such
as B cells and to correlate with numerous DNA-binding factor motifs [80].
For the transcription factor CTCF, DNA methylation surrounding binding
sites was shown to be decreased in CTCF-bound DNA segments regardless of
whether the binding site itself contained a CpG, and it was found that CTCF
bound to both methylated and unmethylated regions but with an inverse correla-
tion between methylation and binding strength [179]. Decreased methylation and
increased hydroxymethylation subsequent to transcription factor binding suggests
an induction of DNA methylation turnover [179].
LMRs were described as having intermediate methylation (mean 30%, but
highly variable) [588, 179], and as shown in section 3.3.2 the strongest methylation
findings in this study demonstrate intermediate methylation levels (figure 3.4,
page 64) which is a significantly different (p<2.2×10−308) pattern to other probes
which are almost all nearly fully methylated or unmethylated. The most signifi-
cant probes predominantly showed hypomethylation in CD (76.9% vs 43.3% for
all probes, χ2 p=9.03×10−8), and section 3.3.3 showed that Bonferroni and FDR
significant probes were significantly less likely to be in CGIs compared to random
non-significant probes — 31.1% (χ2 p=4.58×10−6) and 19.4% (p=1.06×10−166)
versus 60.7% (95% CI 60.0–61.4%).
It would therefore be consistent for a portion of the highly significant meth-
ylation differences described in this study to represent increased occupancy of
enhancers or other distal regulatory regions by DNA-binding factors. Further
work would be required to confirm this, such as CHIP-seq or assaying 5hmC.
The DNA motif CTDGNGGT was identified as being enriched among Bonfer-
roni (35.1%, p=0.038) and FDR significant (23.2%, p=2.8×10−5) probes (section
3.3.7). As shown in table 3.18 (page 115), 30% of these probes had no nearby
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transcripts, and none were in a clear promoter site, though 20% could be in al-
ternate promoters for shorter transcripts, or in the case of VMP1, a microRNA.
However, there were indications of an active regulatory region at 90% of the
motifs, with ENCODE finding transcription factor binding sites by ChIP-seq,
H3K27 acetylation and DNaseI hypersensitivity. This motif was identified as
sharing high homology with binding sites for two human transcription factors —
GLI2 and RUNX3 (table 3.16, page 112).
GLI
GLI2 is a glioma-associated oncogene and zinc-finger transcription factor, also
associated with holoprosencephaly, pituitary abnormalities, cleft lip and poly-
dactyly [56, 121]. The GLI family have a shared binding site, overlapping ex-
pression and function, but some important differences in regulation and targets
[513, 533, 311]. There is also intrafamily regulation, with GLI2 activating GLI1
[147].
GLI proteins are critically important to the Hedgehog signalling pathway
[311], which is involved in embryonic development, bone growth, stem cell main-
tenance, cell cycle regulation, apoptosis, and cancer [147, 513]. Hedgehog sig-
nalling is also involved in inflammation leading to increased expression of IL-6,
TNFα, IL-12, CCl5, and CXCL9 [210]. Non-Hedgehog-related consequences of
GLI mutations, and expression during embryonic development in regions without
Shh production imply that GLI proteins have some Hedgehog-independent ac-
tions [147]. GLI1 and GLI2 have been shown to act independently of Hedgehog
signalling, and are induced by TGFβ in a SMAD3 dependent manner [147].
The GLI1 gene is within the IBD2 risk locus (12q13) and sequencing revealed
a nonsynonymous SNP reducing the activity of GLI1 by half [366]. This SNP
was associated with IBD, particularly UC, with a meta-analysis of 5352 patients
finding an odds ratio of 1.19 [366]. GLI1+/lacZ mice were more severely affected by
DSS colitis, with increased expression of pro-inflammatory cytokines IL-23, IL-12
and IL-17 [366]. NOD2 activation leads to iNOS expression and subsequently
SHH signalling via NFκB and NOD2-induced mir146a reducing levels of NUMB
– a negative regulator of GLI [210].
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RUNX3
The Runt-related transcription factors RUNX1, RUNX2, and RUNX3 have high
sequence homology and a shared binding site. RUNX proteins form a heterodimer
with CBFβ [69] and bind specific DNA sequences through the terminal 128aa
conserved from Drosophila transcription factor runt — the runt homology domain
(RHD) [475]. The binding site is commonly cited as 5′-RACCRCA-3′, 5′-TGYGGT-3′,
or 5′-AACCACA-3′.
The RUNX proteins are exchangeable in vitro, but have different expression
profiles and regulation in vivo [475]. In mice RUNX1 KO prevents mature haem-
atopoietic differentiation [475], RUNX2 KOmice have no bone development [475],
and loss of RUNX3 causes spontaneous colitis and gastric mucosal hyperplasia
[76].
All RUNX genes are regulated by retinoids and vitamin D [475]. RUNX3
is involved in T cell and proliferation and differentiation into CD8+ T cells by
Th-POK suppression [562] and together with T-bet into TH1 [728], with critical
functions and high expression in both lineages [321, 154, 608]. RUNX3 is tar-
geted by TGFβ1 [689] and is involved in TGFβ signalling and the maturation of
dendritic cells and activation of macrophages [689]. RUNX3 also functions as a
tumour suppressor and apoptosis inducer, and has a role in neural development
[287].
A potential role for RUNX3 has been proposed in several inflammatory dis-
eases including IBD, RA, SLE, ankylosing spondylitis and psoriasis [689]. RUNX3
is in an IBD risk locus (IBD7, 1p36) with possible epistatic interactions with
NOD2 [115, 116, 711]. Weersma et al. identified a significant association with
UC for RUNX3 SNP rs2236851, and epistatic interactions between RUNX3 and
SLC22A4/5 polymorphisms were implicated [689]. One study showed no associa-
tion between 11 examined RUNX3 SNPs and IBD (10 promoter and one intronic
SNPs), however the authors acknowledge that the SNP from Weersma et al. was
not tested and was not in LD with the tested SNPs [229].
RUNX3 is also in a GWAS locus for ankylosing spondylitis [669] — a chronic
inflammatory condition of the axial skeleton which is frequently comorbid with
IBD (5–10%) [661], shares family histories [619] and genetic risk factors [518].
SLC22A4 and SLC22A5 are associated with CD (IBD5) and a polymorphism
in SLC22A4 disrupting the RUNX binding site has been linked to rheumatoid
arthritis [626]. RUNX3 has been reported as down-regulated in CD [248] and
overexpressed in inflamed colonic mucosa [689], with IHC showing nuclear stain-
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ing in sub-epithelial T-lymphocytes in small and large intestine [689].
RUNX3 hypermethylation has been found in UC-associated CRC (UC-CRC)
patients compared to UC patients and healthy controls, both in the tumour and
in distant biopsies [203], and in UC versus controls [231]. RUNX3 inactivation is
implicated in multiple types of cancer, more frequently due to promoter methyl-
ation than mutation [644, 230], and has been proposed as a marker of CpG island
methylator phenotype (CIMP) type tumours [433]. A methyl donor enriched
diet in mice caused transgenerational RUNX3 hypermethylation and increased
response to an allergic disease model [267].
Each RUNX gene is transcribed from two promoters, each containing RUNX
binding sites [475, 69, 321]. The RUNX3 protein derived from the distal pro-
moter is highly expressed in CD8+ and TH1 cells and exhibits a greater ability to
induce transcription due to a novel activation domain in the 19 N-terminal amino
acids [118, 321]. The proximal product is expressed at lower levels in developing
thymocytes, naive CD4+, and TH2 cells [118, 321].
RUNX3 contains a Bonferroni significant CD-associated hypermethylation
(p=2.45×10−8, table 3.9, page 73) within a DMR (table 3.10, page 75) at the start
of the distal transcript (see figure 3.18, page 84), and the associated GLI/RUNX3
motif identified in section 3.3.7 is a confirmed RUNX site. Additionally, analysis
of a microarray study on intestinal biopsies previously performed by our group
[462] shows increased expression in inflamed biopsies from CD patients (figure
3.52).
RUNX3 interacts with known IBD associated mechanisms including NOD2
interactor [459] TLE to epigenetically silence CD4 in CD8+ cells [719], CD-
associated genes SLC22A4/5 [689], IBD associated [77, 652] MDR1 [230] and
increases expression of mir30a which directly targets the 3′ UTR of CD-associated
gene vimentin (page 16 and Stevens et al. [590]) leading to a decrease in expression
[386]. Additionally RUNX3 causes expression of IFNγ, eomesodermin (EOMES),
granzyme B (GZMB) [321], and 15 microRNAs [386], suppresses expression of
IL-4 [321], MRP1, and core apoptosis gene BCL2 [230].
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Figure 3.52: Box and whisker plot showing RUNX3 expression in in-
flamed and non-inflamed biopsies from controls (56 vs. 17), Crohn’s
disease (48 vs. 51), and ulcerative colitis (65 vs. 64) [462]. Whiskers
extend up to 1.5 × IQR from the 1st and 3rd quartiles, with any remain-
ing results plotted as points. P values for inflamed vs non-inflamed by
Wilcoxon rank sum test shown for each diagnosis. Reanalysis of data




3.4.5 Genes of interest
This section contains a brief description of genes drawn from both individual
CpGs and DMRs, which are of interest to IBD. Those genes which are discussed
at length in other sections are only briefly mentioned here, and genes which are
part of our groups ongoing research are examined in more depth.
VMP1 The DMR within VMP1 is the most significant, containing the most
significant individual CpG, and is entirely composed of Bonferroni significant
CpGs, it is also located within a GWAS risk locus for IBD. VMP1 is an essential
component of the autophagy pathway, and the position of the DMR around the
11th exon corresponds to the primary transcript of microRNA mir21, which has
been implicated in various cancers and inflammatory conditions, including IBD.
VMP1 and mir21 are discussed at greater length in chapter 4.
RPS6KA2 RPS6KA2 contains the second most significant individual CpG, it
is a kinase involved in the MAPK/p38 pathway found in an IBD GWAS risk
locus, and is discussed at length in chapter 5.
RUNX3 The RUNX3 DMR is located within the 5′ UTR of the longer tran-
script, and contains a Bonferroni significant probe (p=2.19×10−7). The RUNX3
gene is located within an IBD risk locus, loss of RUNX3 function in mice causes
spontaneous colitis and gastric mucosal hyperplasia [76], analysis of putative DNA
binding sites in proximity to methylation results (section 3.3.7, page 111) shows
an enrichment of the RUNX3 binding site. RUNX3 function and findings relating
to IBD are discussed further in section 3.4.4 (page 150).
TNF Tumour necrosis factor (TNFα) is a critical inflammatory cytokine, which
is central to many pathways involved in IBD pathogenesis as discussed in chapter
2, and inhibition of TNFα by monoclonal antibody drugs such as infliximab is
a highly valuable treatment for IBD and other inflammatory conditions such
as rheumatoid arthritis, psoriasis, and ankylosing spondylitis. The TNF gene is
located in one of the strongest genetic risk loci for IBD, and many products which
interact with or modulate TNF have also been identified as being in genetic risk
loci [297].
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SOCS3 Suppressor of cytokine signalling (SOCS)5 proteins act a negative feed-
back and regulatory mechanism to cytokine signalling [722]. The SOCS box do-
main of SOCS family proteins combines with elongin B and C to function as a
ubiquitin E3 ligase which marks bound substrates for proteosomal degradation
[320, 197, 382]. SOCS protein specificity is determined by the central SH2 domain
which interacts with the cytoplasmic portions of gp130-related cytokine receptors
after specific tyrosine residues have been phosphorylated [320, 722],
The JAK-STAT pathway is activated by multiple cytokines including inter-
leukins, interferons and haematopoietic growth factors [722]. SOCS3 acts as
a negative regulator of the JAK-STAT signalling pathway by interacting with
STAT3 [530], the gene for which is in a gwas risk locus for IBD [297] and by
direction inhibition of JAK tyrosine kinase activity through the kinase inhibitory
region [722]. Many other JAK-STAT genes can be found in IBD risk loci including
JAK2, SOCS1, STAT1 and STAT4 [297].
SOCS3 is important in NOD2 tolerance to MDP. SOCS3 expression is induced
by MDP in an NOD2 and RIPK2 dependent manner. SOCS3 then binds to the
CARD domain of activated NOD2 and causes proteosomal degradation of NOD2
and RIPK2 [363].
SOCS3 also regulates other pathways such as IFNβ signalling in the innate
antiviral response [382] and IL-1 induced NFκB activation by TRAF6/TAK1
signalling [197].
SOCS3 is induced by IL-6/STAT3 [737, 135], all three of which are increased
in inactive and active UC biopsies compared to healthy controls [376] and acts to
shorten and regulate the response to IL-6 [135, 356]. Elimination of SOCS3 bind-
ing allows IL6R to generate an IL10-like anti-inflammatory response [170]. Loss
of SOCS3 in mice increased the oncogenicity of DSS and TNFα mediated NFκB
activation [520]. SOCS3 expression in known to be regulated by DNA methyl-
ation and microRNAs in various cancers [71] and SOCS3 promoter methylation
and loss of expression was found in the progression to UC-associated colorectal
cancer [376]. MicroRNA mir19b directly downregulates SOCS3 expression lev-
els and is underexpressed in Crohn’s disease, and delivering mir19b to the colon
protected against TNBS-induced colitis in mice [112].
Silencing mir122 is a therapeutic strategy in hepatitis C (HCV) and is the first
use of an antimir drug (Miravirsen) in humans [293]. Silencing mir122 has been
found to significantly increase methylation at the SOCS3 promoter in a DNMT1
5Also called SSI (STAT-induced STAT inhibitor)
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independent mechanism, decreasing SOCS3 expression and enhancing STAT3
activation [721], it is also notable that mir122 directly inhibits NOD2 expression
[111] (see page 34). Increased hepatic expression of SOCS3 is correlated with a
poor response to treatment in HCV and HIV and is a stronger predictor than viral
genotype, and higher levels of SOCS3 in African-Americans could explain a worse
response to antiviral therapy in African-Americans [322]. The reduction in SOCS3
by antimir122 causing an increase in IFNα signalling could be partially responsible
for the antiviral effects of this compound [721] in addition to abolishing the direct
stabilising effect mir122 has on the HCV genome [293].
Inflammatory cytokines such as TNFα and IL-6 are important promoters of
tissue repair, and it has been proposed that the increased expression of SOCS3
seen in IBD may limit epithelial repair, perpetuating an inflammatory state de-
spite its anti-inflammatory actions [614].
Evidence from mice shows that an appropriate response to cytokines depends
on the proper balance of SOCS proteins, and that deficiency in one may lead to
the activation of alternative responses; for example SOCS3 prevents an IFNγ-
STAT1 expression pattern in response to IL-6 [135, 356]. There are also interac-
tions between the different SOCS and STAT proteins such as SOCS2 degrading
SOCS3 [609]. IL6 antagonist drugs such as tocilizumab6 and sirukumab7 have
recently become available, with more in development, and are in use for rheuma-
toid arthritis and systemic juvenile idiopathic arthritis. Anti-IL6 has also been
explored as a treatment for CD [291].
In addition to IL-6 and MDP [363], there are many reported inducers of
SOCS3 including TNFα, LPS [68], NFκB [197], IFNγ[135, 482], IL-2 [122], IL-10
[171] and TSH [482]. Other reported SOCS3 targets include IGF1 receptor [149],
insulin receptor [149], epidermal growth factor receptor [707], JAK1 [122], STAT1
[135] and growth hormone receptor [510].
Polymorphisms in SOCS3 have been linked to infantile asthma, Graves’ opthal-
mopathy, chronic hepatitis C, atopic dermatitis, insulin resistance and obesity
[175, 712]. A recent EWAS study of type 2 diabetes in a Qatari population
also found significant hypomethylation of the same SOCS3 Illumina 450k probe,

























































Figure 3.53: Methylation results for the SOCS3 region
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Figure 3.54: Box and whisker plot showing microarray data for SOCS3
expression in non-inflamed and inflamed biopsies from controls (56 vs.
17), Crohn’s disease (48 vs. 51), and ulcerative colitis (65 vs. 64).
Whiskers extend up to 1.5 × IQR from the 1st and 3rd quartiles, with
any remaining results plotted as points. P values for inflamed vs non-
inflamed by Wilcoxon rank sum test within each diagnosis. Reanalysis of
data from two papers by Noble et al. [461, 462], see section 3.2.1, page
52 for further details.
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SBNO2 SBNO2 is located within a CD GWAS risk locus [297, 194, 41] with
negative [17] or weak [643] findings in UC. Although this finding has been well
replicated there is very little published research on this gene in humans. Increased
expression was found in a B-cell derived cell line in response to very high fluoride
exposure [253], there was one report of a link to schizophrenia [364], and a role
in osteoclast fusion [413].
SBNO2 is a homologue of the Drosophila gene strawberry notch (sno), a
downstream positive regulator of the Notch signalling pathway expressed in the
nucleus [404]. Activation of the Notch receptor causes the release of the Notch
intracellular domain which migrates to the nucleus and regulates transcription
of downstream genes. The Notch signalling pathway is evolutionarily conserved
and is involved in development, differentiation, barrier function, immune response
and apoptosis [416, 465]. Notch knockdown worsened colonic response to DSS,
dampened the chemokine response to colonic injury [416]
SBNO2 is is a potent inhibitor of NFκB-mediated transcription [171], and
is induced by IL-6, IL-10, IL-1β, LPS and TNFα [225, 279, 171] and in E. coli
sepsis in mice [61]. SBNO2 has a level of background expression which is STAT3
independent, but IL-10 upregulation is STAT3 dependent [171].
Transcription factor STAT3 binds to SBNO2 resulting in increased expression
and a change in transcript [279] and there is evidence of transcript switching
after IL-6 signalling in mouse astrocytes [225]. There are two recognized SBNO2
transcripts in humans, with one having a shortened N-terminal end. Zebrafish
have 3 sno genes; sbno1, sbno2a (chromosome 2) and sbno2b (chromosome 22)
[603], with sbno1 and sbno2a showing similar expression profiles and functions
and sbno2b exhibiting a different pattern and a role in neurodevelopment [602].
In humans, SBNO1 has been identified as a GWAS risk locus for lipid levels
[613] height [357], and schizophrenia [522] and infant head circumference [67]
possibly indicating a preserved role in neurodevelopment. Despite high homology
and related functions SBNO1 does not compensate for a loss of SBNO2 [171].
Mutations in STK11, adjacent to SBNO2, cause Peutz-Jeghers syndrome
(PJS) — an autosomal dominant condition causing hyperpigmented mucocu-
tanous lesions and generally benign hamartomatous gastrointestinal polyps, but
with a high life-time cancer risk. In 30% of cases there is a large deletion which can
affect multiple genes including SBNO2, however, haploinsufficiency for SBNO2
in these patients did not alter the PJS phenotype [515].
IL-10 has a critical role in limiting inflammation [708]. IL10 -/- mice were
found to develop spontaneous enterocolitis, and their CD4+ cells caused colitis
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when transplanted into immunodeficient mice [514]. The colitis appeared to be
due to uncontested IL-12 and IFNγ signalling and overproduction of TH1 cells,
and could be prevented by anti IL-12 or anti-IFNγ. As a side effect of decreasing
IFNγ production, IL-10 does however also retard bacterial clearance [514]. IL-10
deficient mice are healthy in germ-free conditions, but develop inflammation in
response to normal bowel flora [561].
IL-10 reduces inflammatory mediators (IL-12, TNFα, IL-1α, IL-1β, and IL-6
[170]), inhibits antigen presentation and promotes epithelial integrity. JAK1-
STAT3 signalling is essential for IL-10 induced anti-inflammatory effects [170,
450]. The main sources of IL-10 are monocytes, macrophages, dendritic cells and
multiple TH subsets (including TH1, TH2, TH17, and all Treg subtypes) [538, 450].
There is significant evidence for the involvement of IL-10 in IBD. IL10 is in
an IBD GWAS locus [297, 191] and IL-10 production is impaired in severe IBD
[127, 410]. The CD-associated NOD2 mutations 3020insC, R702W, and G908R
actively inhibit IL10 transcription by reducing p38-mediated phosphorylation of
IL-10 promoting transcription factor hnRNP-A1 [463].
Glocker et al. described IL10RA and IL10RB mutations in cases of very se-
vere enterocolitis occurring in the first year of life. These patients had a reduced
STAT3 response to IL-10 and increased production of TNFα and other inflam-
matory cytokines. These patients also showed a lack of SOCS3 up-regulation in
response to IL-10 as opposed to their unaffected siblings [213]. Further studies
have replicated the findings of IL10 and IL10RA/B variants being strongly cor-
related with onset of IBD in the first year of life, a positive family history and
sometimes consanguinity, a severe clinical course, and poor response to conven-
tional treatment but positive response to autologous haematopoietic stem cell
transplantation [567, 566, 57, 339].
Several studies have examined IL-10 as a therapeutic agent in Crohn’s disease.
A Cochrane review in 2010 [85] found no statistical difference from placebo -
although the authors only considered three studies [650, 178, 557]. A review of
the literature including animal studies found a mild benefit to IL-10 treatment,
but overall the results were disappointing [410]. It was already known that IL-10 is
effective in preventing inflammation, but once a TH1-mediated inflammatory state
is established, it is insufficient to reverse the inflammation [514]. There is evidence
that delivery of IL-10 to the intestinal lumen by Lactococcus lactis engineered to
secrete IL-10, adenoviral vectors, or gelatine microspheres containing IL-10 is
more effective than systemic administration. Finally, some IBD patients have
been shown to have normal or elevated levels of IL-10, and the treatment may
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only be effective in those with deficient IL-10 production [410], as seen in the
extreme phenotype of children with IL10 or IL10R mutations and a subset of
adult cases.
Figure 3.55: Box and whisker plot showing microarray data for SBNO2
expression in non-inflamed and inflamed biopsies from controls (56 vs.
17), Crohn’s disease (48 vs. 51), and ulcerative colitis (65 vs. 64).
Whiskers extend up to 1.5 × IQR from the 1st and 3rd quartiles, with any
remaining results plotted as points. Reanalysis of data from two papers























































Figure 3.56: Methylation results for the SBNO2 region
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NLRC5 NLRC5 is in the same subtype of the NLR family as NOD2 (CARD
containing NLRC, NOD2 is NLRC2). Also known as NOD27 [624], NLRC5 is the
largest of the NLR family [355] and is most closely related to NLRC1 (NOD1),
NLRC2 (NOD2), NLRC3 (NOD3), and NLRA (CIITA) [454, 444]. NOD2 is
the strongest genetic risk factor for Crohn’s disease is discussed in section 2.2.1
(page 11). Several other NLR family members have been associated with chronic
inflammatory diseases [348, 623], SNPs in the region of NLRP3 have been linked
to CD [668] and NOD1 SNPs show a correlation with IBD in under-40s [395].
NLRC5 is a well-conserved cytosolic and nuclear [53, 426] protein expressed
in immune tissues (bone marrow, lymph nodes, thymus, and spleen), organs with
mucosal surfaces (small intestine, colon, lung, and uterus) [355, 53], and immune
cells [454, 53].
Like other NLRCs, NLRC5 contains an N terminal CARD domain (though
only one as opposed to two in NOD2, and with an atypical [444, 233], highly
conserved [53] structure), a central NACHT-NOD domain and a LRR domain.
The LRR is unusual in that it is much longer than typical [348, 444] containing 33–
43 LRRs as opposed to 9–10 in NOD1 and NOD2, though they are not irregularly
positioned [444] as previously reported [348].
There are 5 cDNA splice variants differing in LRR length and tissue distri-
bution [454] and possible translational modifications [348] both of which could
contribute to the conflicting results observed in functional studies.
NLRC5 expression is strongly induced by IFNγ via JAK/STAT1 and NFκB
[348, 53, 426]. Response to other triggers such as LPS, CMV8, and poly(I:C)9 is
inconsistent and may be cell type specific [348, 136, 53].
NLRC5 is a potent negative regulator of NFκB which prevents activation by
multiple signals including TNFα, LPS, IL-1β, and MyD88 [136, 53]. One proposed
mechanism is that NLRC5 competes with NEMO to form a complex with IKKα
and IKKβ, (dependant on the LRR domain) and inhibits their kinase activity
and their own phosphorylation [136].
The most closely related NLR gene to NLRC5 is CIITA (NLRA), is well
established to play a vital role in regulating MHC class II genes [444, 427, 426].
IFNγ-induced NLRC5 has been shown to trigger the expression of MHC class
I, and antigen processing and presentation genes including HLA-A, –B, –C, –E,
β2M, LMP2, and TAP1 by interacting with promoters regions [426, 427].
NLRC5 has also been proposed to be a negative regulator of type I inter-
8Cytomegalovirus
9polyinosinic:polycytidylic acid - a TLR3 activator with similar structure to dsRNA
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feron signalling in the antiviral immune response by inhibiting IFNβ signalling
by blocking binding of MAVS to RIG-1 and IRF3 phosphorylation [136, 454, 233],
though this could not be confirmed in NLRC5-deficient mice [355].
The methylation results in the NLRC5 region are shown in figure 3.58 (page
164). This has been extended to show the DMR in an intron of the adjacent
gene CETP10 (highlighted in grey). Analysis of previously published expression
data from intestinal biopsies shows increased NLRC5 expression in response to
inflammation in CD, UC, and controls (figure 3.57, page 163).
Figure 3.57: Box and whisker plot showing microarray data for NLRC5
expression in non-inflamed and inflamed biopsies from controls (56 vs.
17), Crohn’s disease (48 vs. 51), and ulcerative colitis (65 vs. 64).
Whiskers extend up to 1.5 × IQR from the 1st and 3rd quartiles, with
any remaining results plotted as points. P values for inflamed vs non-
inflamed by Wilcoxon rank sum test within each diagnosis. Reanalysis of
data from two papers by Noble et al. [461, 462], see section 3.2.1, page
52 for further details.
10table 3.10, page 75
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Figure 3.58: Methylation results for the NLRC5 region, including the
DMR annotated to adjacent gene CETP (grey highlight)
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ITGB2 ITGB2 (Integrin β2 or CD18) combines with ITGAL (Integrin αL
or CD11a) to form LFA-1 (lymphocyte function-associated antigen-1), which is
widely expressed on neutrophils, macrophages, T cells and B-cells; is important
in leukocyte adhesion and may be altered in IBD [54, 242].
The autosomal recessive disorder type 1 leukocyte adhesion deficiency (LAD-
I) is caused by a variety of mutations in the ITGB2 gene which reduce expression.
The condition is characterised by recurrent infections of skin and mucosa, with
reduced pus formation, and retarded wound healing. Severity is positively corre-
lated with reduction in CD18 expression [242]. The level of expression of CD11a
and CD18 is used as a predictor of severity, and in the most severe cases with
less than 1% of neutrophils expressing these markers the average life span is 10
years compared to 40 years with 1–10% [172].
Although colitis in patients with LAD-1 may appear clinically and macroscop-
ically similar to CD there is a major histological difference in that the underlying
defect means there is no recruitment of neutrophils or formation of granulomas
[645]. One study looked at 3 patients with inflammatory bowel disease with mild
LAD-I and found that on top of the original mutation they had mutations in a
subset of their T cells which produced a functional CD18 [646].
Efalizumab, a monoclonal antibody against CD11a, was tested in patients
with moderate or severe CD in a small open-label pilot study and showed a
positive effect on disease severity [292], however, the drug was withdrawn in 2009
due to cases of progressive multifocal leucoencephalopathy [292, 403].
Although these two effects act in opposition – loss of CD18 from a mutation
causing colitis and treatment of colitis with an antibody against CD11a – this
fits with the concept of a delicate homeostasis of immune activation at the in-
testinal epithelium. It should also be remembered that while the cases of IBD
in patients with LAD-I may have appeared similar, they may well not share the
same underlying abnormality which causes CD.
PRF1 Perforin 1 — or lymphocyte pore forming protein — is critical to the
pro-apoptotic function of NK and cytotoxic T cells by forming pores across the
membrane of target cells [501] allowing passage of granzymes such as GZMB
which then induce apoptosis. Hypomethylation has been reported in CD4+ T
cells from SLE patients [392], as opposed to the two hypermethylated DMRs in
the promoter and gene body observed here and also in the 27k study by Nimmo
et al. (p=1.2×10−7) [458]. The PRF1 promoter is unmethylated in cytotoxic
T cells which express it highly, but also in other tissues which do not express
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PRF1 [679], and the expression of PRF1 is not straightforward in that NK cells
have been shown to maintain a reservoir of PRF1 and GZMB mRNA which is
translated upon activation and is under microRNA regulation [325]. Mutations
in PRF1 are found in 20–50% of patients with the recessive condition familial
haemophagocytic lymphohistiocytosis, and the similar complication of systemic
onset juvenile idiopathic arthritis, macrophage activation syndrome [658]. Poly-
morphisms have been linked to a variety of other immune, autoimmune, and
inflammatory conditions such as MS [95] and response to HIV infection [424].
TOLLIP Tollip has been shown to have a variety of immunomodulatory actions
[94] and it has been proposed that failure to upregulate Tollip in response to
inflammatory stimuli may be involved in the pathogenesis of inflammatory bowel
disease [589].
SLC15A4 SLC15A4 is a transporter for a variety of substrates including pep-
tides, sugars, and ions. As discussed in section 2.2.1, SLC15A4 is involved in
transportation of MDP into the cell, and directly interacts with NOD2. It is
additionally required for TLR7 and TLR9 signalling, and knockdown protects
against DSS colitis in mice [319, 452, 491, 490].
ZBTB16 A zinc finger transcription factor also called promyelocytic leukaemia
zinc finger (PLZF), due to the identification of a translocation causing a fusion
product with retinoic acid receptor (RARα) in promyelocytic leukaemia. Impli-
cated in several other cancers, adipogenesis [430], and T cell development [167].
Expressed in invariant natural killer T cells (iNKT), γδ T cells, NK cells, 5% of
CD8+ T cells, and 2% of CD4+ T cells for a total of 10% of human PBLs [167].
DIABLO Also called SMAC (second mitochondria-derived activator of cas-
pase), DIABLO is a pro-apoptotic mitochondrial protein which is released into
the cytoplasm during apoptosis where it blocks inhibitor of apoptosis (IAP) pro-
teins from performing their anti-apoptotic role of inhibiting caspases. DIABLO
appears to be important in TRAIL-induced apoptosis [731]. TRAIL (TNF-related
apoptosis inducing ligand, also called TNFSF10) exhibited Bonferroni significant
CD-associated hypomethylation. The DIABLO DMR is hypermethylated and




At the time of publication this work was the largest epigenome-wide association
study in Crohn’s disease, and has provided numerous targets which are forming
the basis of ongoing work by our group. The results summarized below are of
interest to IBD researchers and those planning epigenome-wide association studies
for other complex traits.
1. Analysis strategies for EWAS
(a) Combining the analysis of suitable cohorts is more powerful than sep-
arate analyses
(b) Methylation results can be used to accurately characterise the con-
stituents of blood in healthy and diseased individuals
(c) Reference datasets may not be suitable for this purpose if the study
population or tissue is unusual
(d) Probe density must be controlled for when analysing genes or genomic
regions
(e) Familywise error rate correction methods are suitable for identifying a
small group of ‘hits’ for further study, but are more conservative than
the threshold derived from random permutations of this dataset and
do not account for correlation between neighbouring probes
(f) Equivalent results were obtained with any method of FWER correction
(g) False discovery rate correction is suitable for identifying the larger
numbers of results required to study broader patterns, though it may
be insufficiently conservative as a basis for detailed or costly follow-up
of individual results
(h) β values and M values give very similar results, but other analytical
techniques may be more appropriate than either
2. Small epigenome-wide association studies appear to be more powerful than
predicted by simulations
(a) The methylation findings are larger than those used to predict the
group sizes needed to adequately power an EWAS
(b) Groups of 17 would have 80% power to detect the strongest finding,
and groups of 52 would have 80% power to detect all epigenome-wide
significant findings
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(c) All 7 significant genes which were assayed by pyrosequencing replicated
with group sizes of 20
3. The profile of epigenome-wide methylation changes in Crohn’s disease
(a) There is a pattern of hypomethylation and increased methylation vari-
ance in significant disease associated findings
(b) Significant findings are predominantly found in regions of intermedi-
ate methylation, as opposed to most probes which are either highly
methylated or mostly unmethylated
(c) Differentially methylated regions contain probes with a distinct char-
acter compared to other probes of similar significance. They are sub-
stantially more likely to be hypermethylated, and associated with CpG
islands
4. Highly significant disease-associated methylation differences
(a) 65 CpGs were identified which survived Bonferroni correction for mul-
tiple testing
(b) These include genes known to be involved in the pathogenesis of IBD
and genes with biologically plausible links to IBD-related pathways
5. Methylation findings colocalise with GWAS risk loci
(a) Methylation findings are significantly enriched in proximity to known
genetic risk loci for IBD
(b) Significant methylation probes are also significantly enriched in prox-
imity to known genetic risk loci for several traits concerning cholesterol
and lipid metabolism, as well as rheumatoid arthritis and type I and
II diabetes
(c) The analysis presented here offers a significantly improved approach
to exploring this relationship
6. Inflammatory pathways and processes including ones known to be involved
in IBD are enriched among genes with significant methylation changes




(a) Methylation probes are frequently designed to assay regulatory regions,
and careful control is necessary
(b) There is evidence that a DNA binding motif for GLI1 and RUNX3 is
enriched in significant probes, both of which have links to IBD
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3.6 Supplemental
3.6.1 Pyrosequencing
Pyrosequencing is a method for rapidly and accurately sequencing short sequences
of single stranded DNA. An initial PCR reaction incorporates biotin at the end
of the target DNA strand. Biotin binds strongly to streptavidin in a manner that
is resistant to a wide range of temperature, pH and denaturing conditions. The
biotinylated DNA from each reaction is bound to streptavidin beads, which are
then adhered to individual filters with a vacuum pump and dipped in sequential
baths to denature and wash the products.
Once the vacuum is removed the beads fall into separate wells of a plate
containing sequencing primer and buffer. This mixture is heated and allowed
to cool, which anneals the sequencing primer to the biotinylated DNA. Once
placed in the pyrosequencer, enzyme and substrate mixtures are added and then
bases are added one at a time, causing a proportional release of light if they are
incorporated. Any unincorporated bases are enzymatically degraded.
The sequencing reaction is detailed in figure 3.59 (page 171), and an example
section of pyrogram is shown in figure 3.60 (page 172). This allows measurement
of the relative proportions of various bases present at variable positions, such
as those induced by bisulfite conversion of CpG sites. The measurement uses
the surrounding sequence as a reference (and therefore the sequence must be
known, and any variable bases taken into account), and is highly accurate and
reproducible with a between measurement variation of <1%, but performs poorly
with long target sequences (>200–300bp).
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Figure 3.59: Pyrosequencing reaction: The sequencing primer is an-
nealed to the target single-stranded biotinylated DNA molecule. dNTPs
are released into the reaction mixture in a predefined order. Unincorpo-
rated dNTPs are degraded by apyrase, whereas dNTPs which are com-
plementary to the target sequence are incorporated by DNA polymerase,
resulting in the release of pyrophosphate (PPi), which is subsequently
converted to ATP by ATP sulfurylase, which is used by luciferase to
generate light in proportion to the amount of ATP present.
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Figure 3.60: An example of a section of pyrogram from the pyromark
Q24 software (Qiagen) for the DNA sequence AAGGGATTYGGAT. The back-
ground bars show the expected signal from the known sequence, and the
line trace shows the level of recorded light signal. The blue shaded box
containing TC is a methylation variable position, and the methylation
(70%) is calculated by comparing the peak heights for T and C in refer-
ence to the fixed bases.
The dispensation order is shown along the x axis, positions with no cor-
responding bar for expected signal correspond to control bases to ensure
specificity, to ensure full bisulfite conversion (highlighted yellow), and the
initial addition of enzyme and substrate mixtures (E and S).
The colour of the box showing the measured methylation denotes the
quality (blue - good, yellow - warning, red - failed). This is based on
factors such as how well the measured fixed bases match the expected
sequence, the shape and height of the peak traces, and whether there
is any unconverted DNA detected at the bisulfite control base. Details
of the quality assessment for each methylation reading are included in
reports generated by the PyroMark Q24 software, with the colour coding




Tables 3.24, 3.25, and 3.26 (pages 174–176) show DNA motifs in proximity to
Bonferroni significant probes, FDR significant probes and DMRs respectively.
The context of DNA motif CCACGBVA in Bonferroni significant probes is shown in
table 3.23 below.
Gene Chr Sequence Position Context
ZBTB16 11 TTACGTGG -2 – +5 intron 2/3–6
RTP5 2 TGGCGTGG + 694–701 intron 1/1
RUNX3 1 TGGCGTGG - 710–717 § intron 1–2/1–6
HEATR2 7 † TCACGTGG - 550–557 § intron 6/12
MPRIP 17 TGCCGTGG - 734–741 § intron 3/22–23
SLC15A4 12 TCACGTGG - 40–47 intron 7/7
CNOT6L 4 † TCACGTGG + 242–249 § intron 1/6–11
NMRAL1 16 TCACGTGG - 3–10 intron 4/5
CBFA2T2 20 TTGCGTGG + 242–267 3′ UTR
PTDSS2 11 TGGCGTGG - 172–179 intron 2/3–11
NLRC5 16 † TCACGTGG + 374–381 promoter
TNF 6 TGGCGTGG -2 – +5 intron 3/3
TRPS1 8 TCACGTGG -2 – +5 intron 4/5
NPDC1 9 TGGCGTGG - 902–909 § intron 1/8
- 15 TGCCGTGG + 151–158 no gene
Table 3.23: Sites near Illumina 450k probes with Bonferroni corrected
p<0.05 which contain the DNA motif CCACGBVA. Sequence shown in
sense orientation unless indicated with †, or no transcript is known. §
possible alternative promoter for a shorter transcript. Context shows
intron out of total number of introns, with a range if there are multiple
transcripts. Position in bp relative to nominal probe target.
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Consensus Prevalence (%) TF Similarity (%)
CCACGBVA 24.6 CREB3L1, CREB3 95.3
XBP1 91.5
EGR4, EGR3 89.8
GBARRGGTCA 7.7 RARA 93.3
RARA::RXRA 91.1
NR2C2, NR2F1 88.7





HTGACACC 12.3 TBX2 90.1
SMAD2::SMAD3::SMAD4 89.3





GCGNCATYD 15.4 E2F2, E2F3 89.9
YY2 88.6
AVCBTGTTT 26.2 FOXA1 89.8
CWAACBAAC 9.23 RREB1 89.7






RTTTGGCARC 10.8 NFIA 88.3




CHCCTTTGT 9.2 KLF13 87.2
CTDTGNGGT 32.8 GLI2 86.8
RUNX3 86.5
SDATCCANTC 12.3 NFYB, NFYA 86.2
DYTAGTGGT 12.3 CTCF 85.0
NKX2-3 82.7
CTNCTGAGAA 12.3 STAT3 84.9
AAGATYGBNY 13.8 YY1 84.6
GCTCTTTDW 18.5 POU6F2 84.4
MEF2B 83.4
Table 3.24: Shared DNA motifs near Bonferroni significant probes with
the highest similarity to human transcription factors. Composite tran-
scription factors are joined by two colons, family members with similar
results are listed together. Motifs with prevalence greater than twice the
mean of all discovered motifs are shown in bold.
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Consensus Prevalence (%) TF Similarity (%)
CCACGBVA 35.6 CREB3L1, CREB3 95.3
XBP1 91.5
EGR4, EGR3 89.8





AVCBTGTTT 17.8 FOXA1 89.8






DTCTGACAMVT 1.44 SMAD2::SMAD3::SMAD4 88.3
TGGAACHT 5.94 HSF4, HSF1, HSF2 88.0
TP63 85.8
CCTTNAGATG 1.97 RARA 88.0
CTDTGNGGT 28.1 GLI2 86.8
RUNX3 86.5




YATGCCTGGA 1.66 TP53 86.2
CDATTGYTVAM 1.22 MAFF, MAFG, MAFK 86.0
NRL 85.6
MAF::NFE2 83.7
CACKRTAAVC 3.23 PPARG 85.9
ESR1 82.7
TTGCGGAWC 0.44 CEBPB, CEBPD, 85.3
CEBPE, CEBPG
KAGGAGTTCC 1.31 BCLB6 84.4




DTTAGTGGR 7.69 NKX3-2, NKX2-3 84.1
GCCCTKGNAAV 5.55 RFX5, RFX3, RFX2, RFX4 84.0
TATTWTCKTR 1.57 MEF2C 83.7
RTTTGYCAVC 4.63 NFIA 83.2
SMAD2::SMAD3::SMAD4 80.8
Table 3.25: Shared DNA motifs near FDR significant probes with the
highest similarity to human transcription factors. Composite transcription
factors are joined by two colons, family members with similar results are
listed together. Motifs with prevalence greater than twice the mean of
all discovered motifs are shown in bold.
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Consensus Prevalence (%) TF Similarity (%)
TSHAAVRTCA 21.1 RXRB, RXRG, RXRA 95.9
NR1H2::RXRA, RARA 95.6
NR2C2 91.9
CCACGBVA 47.4 CREB3L1, CREB3 95.3
XBP1 91.5
EGR4, EGR3 89.8
CBCAGCVGGG 26.3 ZIC1, ZIC3, ZIC4 93.1
BDANCCANTC 15.8 NFYB, NFYA 90.8
ANCAWAATDT 26.3 BHLHE23, BHLHE22 90.3
OLIG1, OLIG3, OLIG2 89.9
NEUROG2 89.1
TAL1::TCF3 86.8





CMGTTGA 21.1 NR2F1 88.9
MYBL2 88.0
CGAACDC 31.6 RXRA::VDR 88.2
TGGCGGCWC 10.5 E2F3, E2F2, E2F7, 87.9
E2F8, E2F1, E2F4
ZBED1 87.2
GTGCNGHC 21.1 REST 87.7
CTDTGNGGT 31.6 GLI2 86.8
RUNX3 86.5
AAGATSGYNCC 21.1 YY1 86.7
DWTAGNGGK 26.3 INSM1 86.6
CTCF 86.2
CCCYRGNAAG 26.3 GLIS3, GLIS2:GLIS1 86.5
BCL6B 84.0
GTAAAHAKAAC 15.8 FOXA1 85.5
YTCCTTTKT 26.3 SPIC 85.3
TGCCTGGAA 10.5 STAT3, STAT1 85.2
BTAAGYTG 26.3 NKX3-2 84.2
GGAGTCGBCR 21.1 EGR1 84.0
Table 3.26: Shared DNA motifs near DMRs with the highest similarity to
human transcription factors. Composite transcription factors are joined
by two colons, family members with similar results are listed together.





The most significant individual probe from the analysis presented in chapter 3
was cg12054453 (p=1.97×10−15) located in the gene VMP1 on chromosome 17.
Five CpGs from VMP1 were found to have significant differences in methylation
following Bonferroni correction out of 65 total CpGs reaching this significance
threshold — making up 8% of all Bonferroni significant probes. Additionally
two neighbouring probes survived FDR, but not Bonferroni correction. Four
consecutive significantly differentially methylated probes within VMP1 met the
criteria for a differentially methylated region (DMR, see sections 3.2.3 page 56
and A.3.5 page 262), and VMP1 also lies within a GWAS risk locus for IBD [297]
(see table 3.11, page 99).
Hypomethylation of this region in association with Crohn’s disease is therefore
the strongest novel finding of the work presented in chapter 3, and has prompted
ongoing work to further characterise these findings and explore their implications.
The following chapter will examine the context of the methylation findings within
VMP1, propose possible biological changes that could cause or be caused by
this hypomethylation, and demonstrate replication of the methylation findings in
other IBD cohorts.
4.1.1 Context of VMP1 Illumina 450k results
Methylation results for all Illumina 450k paediatric results are shown in table 4.1
(page 179) and figure 4.1 (page 178). VMP1 is relatively sparsely covered by
the Illumina 450k chip compared to the average of 17 per gene region (promoter,
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Figure 4.1: Methylation results for all 450k probes within the VMP1
promoter (top) and gene body (bottom). The median value is repre-
sented by a line and the total range by the shaded ribbon. FDR (*) and
Bonferroni (**) significance are indicated and the DMR is represented by
the grey shaded area. X axis is not to scale. Adapted from Adams et al.
[4, Figure 4C]
5’UTR, first exon, gene body, and 3’UTR) quoted by the manufacturer3 and
the high proportion of significant probes within the gene body is clearly visible
in figure 4.1. This also shows that the promoter region of VMP1 is largely
unmethylated in both CD and control samples, with all of the significant results
occurring within the gene body.
The significant methylation results within VMP1 were defined as a differen-
tially methylated region (DMR) by our criteria (page 56), which required con-
secutive FDR significant probes with a shared direction of methylation change
within a variable distance threshold based upon normal CpG density for different
genomic environments. The probes included in this DMR are indicated in figure
4.1. The position of all Illumina 450k probes within VMP1 and their signifi-
cance is shown in figure 4.2, where it can be seen that the significant methylation




Probe Coord P Value βCD-βHC
cg13655923 57784442 0.94 0.00
cg05265306 57784459 0.16 0.00
cg08793459 57784647 0.99 0.00
cg26671554 57784674 0.01 -0.01
cg20202881 57784779 0.61 0.00
cg07852793 57784794 0.59 0.00
cg25953464 57784812 0.85 0.00
cg06747916 57784835 0.69 0.00
cg05371867 57784854 0.47 0.00
cg11698899 57785008 0.27 0.00
cg03823539 57785039 0.79 0.00
cg11251069 57785042 0.37 0.00
cg23838308 57785056 0.56 0.00
cg17544904 57785087 0.18 0.00
cg27298559 57785523 0.20 -0.01
cg12395919 57787151 0.54 0.01
cg00040016 57833286 0.97 0.01
∗ cg24174557 57903544 2.22×10−7 -0.05
cg20458044 57904327 0.02 0.00
∗∗ cg16936953 57915665 2.65×10−13 -0.17
∗∗ cg12054453 57915717 1.97×10−15 -0.15
∗∗ cg01409343 57915740 1.58×10−8 -0.08
∗∗ cg18942579 57915773 8.23×10−10 -0.12
∗ cg02782634 57916643 5.63×10−6 -0.04
cg14032089 57917589 0.05 0.04
cg06471491 57917974 0.65 0.01
∗∗ cg27023597 57918262 5.42×10−8 -0.05
cg04276626 57918500 0.90 0.02
cg02515217 57918600 0.78 0.02
cg15759721 57918630 0.25 0.03
cg07181702 57918682 0.54 0.02
Table 4.1: Paediatric Illumina 450k results for all probes across VMP1
ordered by genomic coordinate, showing the p value and difference in




Figure 4.2: The position and significance of Illumina 450k probes with
an overlaid schematic of VMP1, with the y position of introns demarking
Bonferroni significance (top) and a zoomed view showing the significant
probes and the position of MIR21 (bottom). Adapted from Adams et al.




Localisation was first mapped in rats using EGFP-tagged VMP1, showing it as
a transmembrane protein located in the Golgi apparatus, endoplasmic reticulum
(ER) and in vacuoles, whose formation it promotes [163]. VMP1 has also been
shown to be expressed in the ER in Drosophila, where it is known as TANGO5
[36], C. elegans [621], and Arabidopsis [161], in mammalian autophagosomes [527]
and in the plasma membrane of cancer cells [549]. Homologues are absent in
fungi but present in some protists implying a loss during early fungal evolution
[89]. Its high conservation means human VMP1 is able to replicate the function
of its homologue in C. elegans (EPG-3) [621], and rat VMP1 in Dictyostelium
discoideum [89].
Expression and induction VMP1 is expressed in rat acinar cells during acute
[163, 647] and chronic pancreatitis [295] where it has been shown to promote the
formation of intracellular vacuoles and cause apoptotic cell death. It is expressed
in foetal rat pancreas but is then undetectable by northern blot until induction
of pancreatitis [163, 647].
In WBN/Kob rats, which spontaneously develop chronic pancreatitis, RT-
PCR detected VMP1 mRNA from age 8 to 20 weeks, peaking at 12 weeks, coin-
ciding with maximal vacuole formation and the onset of pancreatitis. However,
levels were undetectable by 24 weeks, at which point vacuolisation and apoptosis
were still evident, although reduced [295].
In control animals, VMP1 transcripts of 1.9 and 2.7kb [163, 295] were highly
expressed in intestine, kidney, ovary and placenta, moderately expressed in liver,
lung, stomach, thymus, brain, and testis and, slightly expressed in thyroid and
retina. A band of 3.5kb was also observed in intestine, liver, lung, kidney, stom-
ach, thymus, ovary and placenta [163].
A 30 minute period of ischaemia to rat kidney caused a large increase in ex-
pression of VMP1 in that tissue, but VMP1 remained undetectable in pancreas in
those animals, and increased expression following induction of acute pancreatitis
was restricted to pancreas [163].
Autophagy VMP1 has also been shown to be induced by autophagy triggers
such as starvation and rapamycin [305]. Autophagy is highly relevant to Crohn’s
disease (see section 2.2.2, page 14) with many of the most strongly CD-associated
genes such as NOD2 and ATG16L1 being involved in autophagy (see table 2.2,
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page 15). VMP1 localises to the site of autophagosome formation in the ER
independently of other autophagy proteins including ULK1, WIPI-1, DFCP1
and ATG16L [290], but is critical for the proper formation and maturation of
autophagosomes in Dictyostelium discoideum [89, 90, 91], mouse embryonic fi-
broblasts [290], Chlamydomonas reinhardtii [611], C. elegans [621], and humans.
VMP1 interacts with other members of the Class III PI3K complex (Beclin-
14, Vps34, Vps15, and ATG14L), via direct interaction between the Beclin-1 BH3
domain and the 20aa C-terminal hydrophilic domain of VMP1 where it is re-
quired for recruitment of the PI3K complex to the autophagosomal membrane,
which is in turn responsible for recruitment of other autophagy proteins such as
ATG16L1 and LC3 [435, 305, 91, 290]. Additionally, VMP1 interrupts the inter-
action of BCL2 with the Beclin-1 BH3 domain, which removes the autophagy-
diminishing influence of BCL2 [435], and directly interacts with other proteins
such as PT53INP2 [464].
VMP1 is required for elongation and closure of the isolation membrane [331,
Figure 8], reduced expression of VMP1 leads to disrupted autophagosomal mat-
uration, with persistent omegasomes (an early stage in autophagosome forma-
tion) and delayed onset of autophagy [91, 621], whereas overexpression causes
autophagy and apoptosis regardless of starvation or rapamycin [163, 527, 648].
Other functions Apart from the vacuole formation observed in pancreatitis
[647], VMP1 is required for formation of the contractile vacuole in Dictyostelium
discoideum, an organelle responsible for osmoregulation [89]. Other proposed
roles for VMP1 include cell adhesion [549], cell death [90, 647], ER integrity,
membrane traffic, organelle organisation, [89], protein secretion [36], cytokinesis,
cell cycle, morphology in Chlamydomonas reinhardtii [611], and zymophagy —
a protective response to pancreatitis leading to autophagy of zymogen granules,
involving USP9x and p62 (SQSTM1) [221]. In cancer decreasing VMP1 expres-
sion correlates with increased malignancy, metastasis, invasion, and proliferation





Chapter 2 contains background information on microRNAs:
Section Page Contents
2.4.3 28 general background
2.5.1 34 findings in IBD
2.5.2 36 as biomarkers
2.5.3 41 as therapeutic targets
As shown in figure 4.2 (page 180), the primary transcript of mir21 (Pri-mir21 )
overlaps with the 3′ end of VMP1. This region is highly conserved, exhibits DNase
I hypersensitivity and is associated with the promoter-associated histone marks
H3K4Me1 and H3K4Me3 [220]. There is evidence of genomic instability in this re-
gion with tandem duplication in breast cancer leading to VMP1-RPS6KB1 fusion
and worsened prognosis in these patients. This fusion transcript was detectable
at very low levels in healthy controls, possibly indicating trans-splicing [285]. The
region is also a site of HPV integration in cervical cancer (fragile site 17B) [556]
and a frequent site of duplications in neuroblastomas [544].
A promoter region forMIR21 has been described around the penultimate exon
of VMP1 and contains a TATA box and binding sites for transcription factors in-
cluding STAT3, p53, C/EBP, NFI, and AP-1 [199, 552]. Alternative independent
transcription start sites have been found in the same region, with some evidence
of cell type specificity [87, 391, 476, 199, 516], or even 135kb upstream — over-
lapping the upstream region, 5′ UTR, first exon and first intron of VMP1 [411].
The primary transcript of mir21 extends beyond the 3′ UTR of VMP1 with the
mature sequence also located beyond the 3′ UTR. There is clear evidence that
mir21 has promoters which are independent from VMP1 [199]; however, an alter-
native, independently regulated source of mir21 has been described from VMP1
transcripts which are extended beyond the normal polyadenylation signal and
processed to produce mature mir21 — ‘VMP1-mir21 ’ [517].
Multiple VMP1 transcripts (1.9, 2.7 and 3.5kb, section 4.1.2) were found in
rats [163, 295] although alternative splicing of VMP1 has not been demonstrated
and these may represent the products of pri-mir-21 or VMP1-mir21 cleavage by
Drosha [517]. The varying levels of the different rat VMP1 transcripts between
tissues, and pri-mir21 :VMP1-mir21 ratios between cell lines may indicate this



























Figure 4.3: Position of VMP1 probes, CpGs, SNPs with MAF>0.01
in the European population, TATA box, STAT3 binding sites, reported
mir21 TSS (>) [199, 476, 87], introns, and EXON 11
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The production of a mature microRNA from a transcript which overlaps with
a gene transcript does decrease the expression level of that gene as the remain-
ing gene transcript has a naked 3′ end and is not processed normally [87, 517].
However, allowing the processing of a luciferase mRNA containing a microRNA
only decreased the luciferase twofold [87], and Ribas et al. showed that knocking
down Drosha, preventing the processing of VMP1-mir21, led to increased VMP1
mrna levels [517].
If an ongoing inflammatory condition such as CD drove both mir21 and
VMP1-mir21 and the ratio of the two varied in some cell types due to the pres-
ence of certain genetic or epigenetic variants affecting processing, then this could
impact autophagy via levels of VMP1.
Function Mir21 was one of the earliest described microRNAs and has been im-
plicated in numerous cancers, including lung, breast, ovarian, pancreatic, prostate
colorectal and IBD-associated colorectal cancer [303, 304, 396, 199, 347, 697, 516,
585], by reducing apoptosis and affecting growth, transformation, invasion, and
metastasis, and therefore prognosis [471, 457, 697, 98]. Mir21 has also been impli-
cated in numerous non-neoplastic conditions including myaesthenia gravis [505],
SLE [492], type 1 diabetes [492], cardiac conditions (ACS, MI, aortic stenosis,
cardiac arrest), MS, HCV infection, as well as both Crohn’s disease and ulcera-
tive colitis [234]. Mir21 is also involved in T cell differentiation and development
[394, 104, 552, 396]. Mir21 is overexpressed in IBD [565, 704, 600, 703, 725], and
in mouse colitis models. However, MIR21 knockout in mice has been shown to
be protective against DSS-induced colitis [565], but deleterious in TNBS-induced
colitis and T cell transfer colitis [701].
Regulation VMP1 and mir21 do share some regulators, such as androgens, AP-
1 [517], and possibly IL-4 [534, 535]. Other known regulators include PMA/AP1
[199], IL-6 (via STAT3 [391]) STAT3, BCL6 [552], NFκB [736], androgen receptor
[516] and TLR4 [471]. Expression of mir21 in healthy rectal mucosa has also been
shown to increase in response to a high red meat diet [277].
Mir21 targets Mir21 has 2522 targets with a “good” mirSVR score of <-0.1
— from an algorithm based on experimental data correlating the characteristics
of mir binding sites with changes in expression after microRNA transfection. The
algorithm includes factors such as predicted accessibility, flanking sequences, seed
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type, position within the target 3′ UTR, and conservation [58]5.
Though intragenic microRNAs do sometimes regulate expression of their host
genes, VMP1 does not contain a mir21 binding site, however a feedback mecha-
nism could involve intermediaries such as STAT3 which has binding sites in the
VMP1 promoter (figure 4.3) and has 4 mir21 binding sites in its 3′ UTR. NFIB is
both a negative regulator of mir21 expression, and directly negatively regulated
by mir21 [199].
There was no significant enrichment of mir21 targets among Bonferroni signif-
icant methylation results (15.7% vs 13.2% overall, p=0.69), but there are many
genes relevant to IBD among those mir21 has been shown to target, or with strong
but untested mir21 binding sites. Figure 4.2 shows some of the best characterised
mir21 targets and targets of greatest relevance to IBD.
Having identified the VMP1 exon 11 / pri-mir21 region as the most signifi-
cant result from the genome-wide methylation analysis, work was undertaken to
measure methylation of this same region in independent IBD cohorts and in other
diseases, and to examine expression.




PDCD4 A highly studied mir21 target, PDCD4 (programmed cell
death 4, or neoplastic transformation inhibitor protein) is
a tumour suppressor which has been proposed to explain a
substantial portion of mir21 oncogenic and prognosis wors-
ening behaviour in cancer.
SPRY2 Homologue of Drosophila gene Sprouty with roles in epider-
mal growth factor and MAP kinase signalling. Also pro-
posed as a link between mir21 and cancer [680].
PTEN Involved in ROS-induced NOD2 and IL-6-STAT3-mir214
signalling, both leading to NFκB expression [625, 499, 471].
SMAD7 A negative regulator of TGFβ involved in TH17 differenti-
ation [471]. A phase 2 trial of oral anti-SMAD7 oligonu-
cleotide has shown positive results in CD [437]
NFIB A negative regulator of mir21 expression, which is itself neg-
atively regulated by mir21 [199]
VIM Vimentin is involved with membrane localisation of NOD2,
which is disrupted by CD-associated NOD2 variants, reduc-
ing AIEC clearance [590].
STAT3 STAT3 is known to upregulate mir21 expression in response
to IL-6 and IL-21, and competes with negative regulator
BCL6 for a shared binding site in theMIR21 promoter [552].
CARD8 Interacts with NOD2 and has CD-associated polymorphisms
(see section 2.2.1) [672, 421]
IL10 Anti-inflammatory cytokine, discussed in relation to SOCS3
and SBNO2 in section 3.4.5
TLE1 A transcriptional corepressor which opposes NFκB, directly
interacts with NOD2 and has CD-associated genetic vari-
ants [459].
LRRK2 Autophagy gene which functions with NOD2 in response to
bacteria, and has genetic links to CD, ankylosing spondylitis
and leprosy (section 2.2.2).




PTPN2 Autophagy gene involved in response to TNFα, IFNγ, and




Bonferroni significant probes INPP4B, POLK, MPRIP,
NLRC5, PRKCE, and FKBP5
Epigenetic DNMT3B, an IBD GWAS [297] risk locus, responsible for
new DNA methylation (with DNMT3A, also a GWAS risk
locus [194]), and DNMT1 indirectly via RASGRP1 [478].
Also targets HDAC8, HDAC9, and SIRT5.
Interleukins As well as IL10 (above) IL1B, IL1RAP, IL9, IL12A, and
IL22
TNFRSF Multiple members of the TNF receptor superfamily in-
cluding TNFRSF6B, TNFRSF10B, TNFRSF10D, TN-
FRSF11B, TNFRSF17, with varied roles in immunity, apop-
tosis and NFκB signalling, often as decoy receptors. E.g.
TNFRSF10B, 10D and 11B are decoy receptors for TN-
FSF10 (TRAIL), which had Bonferroni significant methyl-
ation changes (p=3.28×10−10).
TGFβ Effects on differentiation and proliferation [329] through tar-
geting multiple TGFβ related products such as TGFB1, and
TGFB2, and TGFβ receptors TGFBR2, and TGFBR3.
Table 4.2: Transcripts with experimentally validated or predicted mir21
binding sites, focusing on products with proven or suspected importance
to CD or IBD
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4.2 Materials & methods
4.2.1 Pyrosequencing
Sample collection Initial pyrosequencing replication in 20 adults with Crohn’s
disease and 20 age and sex-matched controls was performed as described in sec-
tions 3.2.2 (page 54) and 3.3.8 (page 117), further details on pyrosequencing are
shown in section 3.6.1 (page 170).
Samples were obtained for genetic research (LREC 2000/4/192) and inclu-
sion in the IBD-BIOM and IBD Character studies from patients recruited from
gastroenterology clinic at the Western General Hospital and healthy volunteers.
The three large adult pyrosequencing replication cohorts were obtained from this
same source, with the initial cohort of 20 CD and 20 controls being included in
the first large replication cohort. Summary demographics are shown in tables 4.3
and 4.4.
Samples of whole blood DNA from groups of 20 patients with ankylosing
spondylitis, rheumatoid arthritis, and systemic lupus erythematosus were kindly
provided by the Rheumatological research group6. Demographics are shown in
table 4.6.
Initial Extended
CD HC CD HC
Age range 20.8–57.1 20.7–57.0 18.7–75.7 18.5–74.7
Median 34.2 34.2 37.7 37.3
Male(%) 45 50 44 45
NOD2 WT (%) 70 85 78 84
Non-smoker (%) 100 100 100 100
White European (%) 100 95 98 90
Table 4.3: Demographics for the initial 20v20 pyrosequencing replication
(figure 3.41, page 118) and the first large pyrosequencing replication
(figure 4.4, page 196). NOD2 WT denotes wild type NOD2 status,
defined as not carrying any of the R702W, G908R, or fs1007insC CD-
associated variants.




Montreal % -L4 +L4 -L4 +L4
L1 15 0 L1 15 1
L2 55 0 L2 41 1
L3 15 5 L3 30 3
L4 5 L4 2
Oral 5 Oral 1
Unknown Unknown 15
Table 4.4: Montreal classification (see table 2.5, page 45 for explana-
tion) of disease location in the the initial adult 20v20 replication cohort
(figure 3.41, page 118) and the first large adult replication cohort (figure
4.4, page 196).
IBD CD UC Con SC HC
Age
Range 18.0–79.1 18.0–79.1 18.1–74.5 18.3–75.0 18.3–69.5 18.5–75.0
IQR 26.4–48.2 26.2–47.3 26.8–48.7 27.5–43.0 25.7–36.7 30.8–49.6
Median 33.2 32.8 34.0 32.8 29.2 38.2
Female (%) 37.0 37.4 36.7 53.7 70.5 36.7
Smoking (%)
Current 20.4 30.8 10.0 19.0 24.6 13.3
Ex 30.9 24.2 37.8 28.9 23.0 35.0
Never 47.0 42.9 51.1 51.2 52.5 50.0
Table 4.5: Demographics for the second adult replication cohort. Con:
all controls, SC: symptomatic controls (IBS), HC: healthy controls (vol-
unteers).
Age
N Range Median Male(%)
AS 18 22–90 62.5 62.5
RA 19 18–82 67.0 29.2
SLE 19 28–86 53.0 8.3
Table 4.6: Rheumatology cohort demographics
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Bisulfite conversion The initial adult cohort (n=40) for replication by pyrose-
quencing was bisulfite converted with the column-based EZ DNA methylation kit
(Zymo Research Corporation, Irvine, CA, USA. Cat no. D5001), the other larger
replication cohorts were bisulfite converted using 96-well EZ-96 DNAMethylation
kits (ibid. Cat no. D5003) with 500ng input DNA per sample.
Pyrosequencing The first large adult replication cohort was analysed using
a PyroMark Q96 ID system (Qiagen, Hilden, Germany), all other cohorts were
analysed using a PyroMark Q24 system. The assays (table 3.4, page 55) were
designed using PyroMark Assay Design Software (version 2.0.1.15, Qiagen) and
ordered from Sigma-Aldrich (St. Louis). Methylation values and sequence quality
were exported from the manufacturers software and analysed in R, with signifi-
cance determined by Wilcoxon rank-sum test.
Samples were run in duplicate, results with any quality warnings were dis-
carded and repeated, analysis was performed on the mean of two methylation
readings within 2% absolute methylation. Where the variance between repeats
was greater than 2% a further set of duplicate reactions was assayed, if these two
readings and one of the original readings were all within 2% (probably due to a
pipetting error or contamination of one of the original samples) the mean of these
three was used, otherwise the sample was excluded.
Further explanation of pyrosequencing and the factors involved in sequence



















Table 4.7: Pyrosequencing primers for three assays covering the VMP1
5′ UTR CGI (top) and the previously described DMR assay (bottom,
see also table 3.4, page 55). Forward (F), reverse (R), and sequencing





MIR21 primary transcript expression was analysed in patients with CD
(n=44) recruited from gastroenterology clinics and endoscopy lists (Western Gen-
eral Hospital, Edinburgh, UK), and compared with healthy volunteers (n=22).
Written informed consent was obtained prior to sample collection7.
Blood was collected in a 9ml K3 EDTA Vacuette tube (Greiner) and RNA
was extracted from 1.5ml of this within 2 hours at 4°C using a QIAamp RNA
Blood Mini Kit (Qiagen). RNA was stored at -80°C until cDNA conversion with
SuperScript Vilo cDNA Synthesis Kit (Invitrogen). Primers were ordered from
Sigma-Aldrich (table 4.8) and qPCR was performed with a Rotor-Gene 6000
(Corbett life science) and DyNAmo Flash SYBR Green (ThermoFisher). Ct
values were measure in duplicate reactions, and analysed by the δδCt method.
Normalisation was performed as described by Vandesompele et al. [657],













Table 4.8: pri-mir21 and control qPCR primers
4.2.3 Microarray expression data from Noble et al.
Reanalysis of raw microarray data previously generated by our group, and pub-
lished by Noble et al. [461, 462], was used to examine VMP1 and pri-mir21 ex-
pression in inflamed and non-inflamed biopsies from controls (56 vs. 17), Crohn’s
disease (48 vs. 51), and ulcerative colitis (65 vs. 64). see Section 3.2.1, page 52
for further details.




4.3.1 Replication of methylation findings
Replication by pyrosequencing As shown in figure 3.40 (page 116) there was
sufficient DNA to replicate one finding by pyrosequencing using the paediatric
DNA. VMP1 probe cg12054453 was chosen and replicated well with an r2 of 0.95.
Secondly as shown in figure 3.41 (page 118), initial replication was performed
in a cohort of 20 adults with CD and 20 healthy controls, on seven significant
results including VMP1 which replicated with p=0.0038. As presented in Adams
et al. [4], replication was also successfully performed in a cohort of 172 adults
with a p value of 6.6×10−5 (shown in figure 4.4, page 196).
In the same cohort methylation of a CpG island in the presumed VMP1
promoter region was also assessed by pyrosequencing. Longer PCR products
were produced due to low availability of primer binding sites and higher densities
of CpGs in the CpG island compared to the regions assayed to confirm significant
Illumina 450k findings. This allowed the use of multiple sequencing primers with
the same PCR product to assay a wider area. As shown in table 4.7 (page 192)
there were in effect six assays. These were used on 95 of the 172 adult samples
above, but there was no difference between disease and controls and all samples
measured <2% methylated (results not shown), further pyrosequencing of this
area was therefore not undertaken.
Two further replications by pyrosequencing have since been performed using
the same assay of the mir21 region, both successfully demonstrating the same
hypomethylation in association with Crohn’s disease, and also for IBD overall
(p=1×10−8, n=1418 & p=1×10−6, n=2669) [663].
Replication by Illumina 450k Our group have performed two further Illu-
mina 450k studies. The first by NTV as part of the IBD-BIOM project also found
hypomethylation of the same probes within VMP1 among the strongest results
(CD p>1.15×10−13, IBD p>2.15×10−11, both Holm corrected) [663].
Pre-publication analysis of the Illumina 450k data from the IBD Character
study shows significant hypomethylation at the same five probes as the paediatric
data for IBD in all samples (p=2.40×10−7–3.66×10−20) and in samples from
centres other than Edinburgh (p=3.56×10−6–7.73×10−15), in CD (p=8.70×10−9–
8Assay design: ATA, Patient selection: ATA, Experimental work: NTV & ATA
9Assay design: ATA, Patient selection: NTV, Experimental work: WTCRF
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1.58×10−17) and in UC (p=1.49×10−7–4.01×10−15). VMP1 was the strongest
result for UC, third strongest for CD (after two SBNO2 probes), and was the
strongest result for IBD in the non-Edinburgh samples. Further results from the
IBD Character project are shown in appendix A.1, page 253.
Methylation in rheumatological conditions VMP1 methylation was as-
sayed in groups of 20 samples from patients with ankylosing spondylitis (AS),
rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE), using the
same assay as in figure 4.4. The results are shown in figure 4.5 (page 197). None
of the other tested conditions were significant differently methylated compared
to healthy controls. Crohn’s disease samples were hypomethylated compared to




Figure 4.4: Box and whisker plot showing pyrosequencing of VMP1
corresponding to probe cg16936953 in 87 adults with CD and 85 healthy
adult controls, as reported in Adams et al. [4, Figure 5A]. Whiskers
extend up to 1.5 × IQR from the 1st and 3rd quartiles, with all results
also plotted as points.
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Figure 4.5: Box and whisker plot showing pyrosequencing of VMP1
corresponding to probe cg16936953 in ankylosing spondylitis, rheuma-
toid arthritis, and systemic lupus erythematosus, compared with Crohn’s
disease and controls. Whiskers extend up to 1.5 × IQR from the 1st and




Analysis of blood and biopsy microarray data Data generated by our
group and published in Noble et al. [462, 461] was used to assess VMP1 and
pri-mir21 expression in inflamed and non-inflamed biopsies from patients with
CD and UC, and from healthy controls and controls with non-IBD inflammation.
These results are shown in figure 4.6.
VMP1 showed increased expression in CD samples with inflammation com-
pared to CD samples without inflammation (p=2.6×10−3), which was not ob-
served in either UC patients or controls.
Both CD and UC samples showed a significant increase in pri-mir-21 expres-
sion (p=1.4×10−6 and 5.1×10−7 respectively) in response to inflammation. There
was a trend toward increased pri-mir-21 expression in inflamed controls but this
was non-significant, possibly as a result of small number of inflamed controls.
The only differences in baseline expression were between CD and UC, with
MIR21 having a slightly lower expression (p=0.003) and VMP1 having slightly
higher expression (p=0.03) in CD.
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Figure 4.6: Box and whisker plots showing microarray data for VMP1
and MIR21 expression in non-inflamed and inflamed biopsies from con-
trols, Crohn’s disease, and ulcerative colitis as reported in Adams et al.
[4, Figure 5C]. Whiskers extend up to 1.5 × IQR from the 1st and 3rd
quartiles, with all individual results also plotted as points. P values for
inflamed vs non-inflamed by Wilcoxon rank sum test by diagnosis and
target shown in each facet. Sample numbers given at the top. Reanaly-
sis of data from two papers by Noble et al. [461, 462], see section 3.2.1,
page 52 for further details.
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Primary transcript expression Pri-mir-21 expression was assessed in whole
blood by qPCR (figure 4.7). There was a 41.5% increased expression of the
primary transcript (p=0.008) in Crohn’s disease (n=44) compared to healthy
controls (n=22).
Figure 4.7: Box and whisker plot showing pri-mir21 expression in whole
blood measured by qPCR, as reported in Adams et al. [4, Figure5B].
Whiskers extend up to 1.5 × IQR from the 1st and 3rd quartiles, with any




Methylation Hypomethylation of the region surrounding the 11th exon of VMP1
has now been demonstrated in 3 cohorts using the Illumina 450k platform and 3
cohorts using pyrosequencing. A subgroup analysis of the IBD Character study
replicated the findings even when excluding all Edinburgh samples, leaving a
primarily Scandinavian cohort.
The finding has not been reported in other IBD EWAS studies (table 2.4,
page 33), although as discussed in section 2.5 the variety of platforms, analytical
techniques, and tissues studied makes comparisons between studies difficult.
Expression We have demonstrated increased expression of pri-mir-21 in blood
by qPCR and inflamed biopsy specimens by microarray. These findings are con-
sistent with a growing number of reports of increased mir21 expression in IBD
[704, 600, 703, 725, 565]. Unfortunately, before the paediatric methylation results
and their initial replication drew our attention to mir21 and other microRNAs,
the RNA extraction kits we used for biobanking did not adequately preserve small
RNAs, preventing immediate assessment of mature mir21 levels.
We have since added microRNA collection to our biobanking protocols and
work by RK is ongoing examining microRNA expression in leucocytes and serum
in IBD. Initial unpublished observations confirm that mir21 is highly expressed
in IBD. On the basis of the preliminary results presented here our group obtained
funding for further investigations10 into VMP1 and mir21. This ongoing work,
particularly focused on VMP1, mir21, and their relationships with autophagy and
IBD, covers many of the natural follow-up experiments which would have fitted
well into this thesis, but my role in the work is insufficient for their inclusion here.
The microarray expression data presented in Adams et al. [4] and in figure
4.6 (page 199) assumes that the mRNA corresponding to VMP1 intronic se-
quence within the pri-mir21 sequence measures pri-mir21, and that the probe
corresponding to VMP1 sequence measures VMP1. However, the existence of an
independently regulated alternate VMP1 transcript extending beyond the usual
polyadenylation signals (VMP1-mir21 ) as shown by Ribas et al. [517] which is
processed to produce mature mir21 complicates this picture. Further work should
be undertaken to assess if the VMP1-mir21 transcript is found in the blood or
bowel in IBD, and whether DNA methylation in the 11th exon of VMP1 impacts




Genetics The VMP1 DMR is within a genetic risk locus for IBD (table 3.11,
page 99) [297], within which no causal variants have been identified. A short-
coming of this experiment was that funds were not available for sequencing the
surrounding region in detail or to perform genotyping arrays. This has been
addressed in following studies. Work currently underway within our group is se-
quencing the entire pri-mir-21 sequence and flanking regions in an adult cohort of
>700, in whom VMP1 methylation will also be assayed11. Pre-publication results
from NTV 12, with further confirmation in the IBD Character project (appendix
A.1, page 253) show a strong correlation between VMP1 DMR methylation and
local SNPs rs8078424 and rs10853015, which are in LD with the marker SNP
(rs1292053) for the GWAS risk locus described by Jostins et al. [297].
Biological relevance of MIR21 to IBD Overexpression of mir21 has now
been repeatedly shown in IBD [704, 600, 703, 725, 565] and in mouse colitis
models [565, 701], and in response to diet [277].
Mir21 has been implicated in many diseases (section 4.1.3) and is clearly not
specific to IBD, but part of fundamental inflammatory pathways. This does not
detract from its relevance to IBD, which is clear when considering the broad
mechanism of action of many of the most potent anti-inflammatory drugs in IBD
and their widespread utility in other conditions.
Analysis of VMP1 exon 11 methylation in rheumatological samples shows
significant differences between Crohn’s disease and the other complex inflamma-
tory conditions rheumatoid arthritis and systemic lupus erythematosus, which
themselves were indistinguishable from healthy controls. Ankylosing spondylitis
could be concluded to be intermediate between Crohn’s disease on one hand and
RA, SLE and controls on the other. Given the established overlap between AS
and CD in genetic and other risk factors, and their co-occurrence within families
and individuals (5–10%) [669, 661, 619, 518], this finding does appear interesting;
however, there are too many uncontrolled variables to draw any conclusions from
these data. A specifically designed study of adequate size would be required,
capable of matching or correcting for gender, age, disease activity, medications,
smoking status and ethnicity, where rheumatological, IBD and control samples
were all collected and processed identically.
11KRO & ATA
12Ventham et al. [663]
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A large number of genes contain conserved mir21 targets in their 3′ UTRs,
including many of high relevance to IBD (table 4.2, page 188). However, only
a small proportion have been experimentally confirmed, and the complexities
of feedback and regulatory systems is barely explored. This could explain the
varying effects of mir21 knock-down in different mouse colitis models [565, 701].
There is a clear impetus to undertake further work examining the downstream
effects of altered mir21 expression in IBD, and the potential therapeutic avenues
in disrupting this.
Although the DMR within VMP1 appears to be related to mir21, relation-
ships between intragenic microRNAs and their host genes can be complex and
interrelated, and there is some evidence for this with mir21 and VMP1 (see sec-
tions 4.1.2 and 4.1.3). The essential role of VMP1 in autophagy, a core pathway
in CD pathogenesis, strengthens the impetus to include VMP1 in the ongoing
work by our group rather than focusing solely on mir21. Work by KRO is cur-
rently ongoing investigating the role of VMP1 and mir21 in autophagy in Crohn’s
disease.
Conclusions In conclusion, this work presents novel evidence of a highly sig-
nificant and replicable hypomethylated region around the 11th exon of VMP1
associated with both Crohn’s disease and ulcerative colitis. Additionally these
data support the previously reported finding of increased expression of mir21 in
IBD. Future work to examine the downstream effects of altered mir21 expression
in IBD, and the potential therapeutic implications of disrupting this would be
highly valuable. Further work by NV, KRO and AA is examining this region,
known to exist within a large GWAS risk locus for IBD, for genetic variants






The second most significant individual probe from the combined paediatric Illu-
mina 450k analysis presented in chapter 3 was cg17501210 (p=4.47×10−15) within
the gene RPS6KA2. This chapter presents replication of this methylation finding
in three adult cohorts comprising a total of 264 patients with Crohn’s disease,
174 patients with ulcerative colitis, and 268 healthy controls, and replication of
the finding in adult IBD patients and healthy controls using Illumina 450k data
from the IBD-BIOM study [663]1 and the IBD-Character study (pre-publication,
see appendix A). Secondly, to look for functional differences associated with the
highly replicable methylation change associated with IBD, expression data for
RPS6KA2 in biopsies, whole blood and separated blood cells are presented, and
cellular starvation is used to look for an effect of RPS6KA2 knockdown on au-
tophagy.
Background RPS6KA2 (ribosomal protein S6 kinase A2, also known as RSK3)
is a serine/threonine kinase in the highly related 90kDa ribosomal S6 kinase family
(RSK1–4). Additional family members and related enzymes are shown in table
5.1; note that RPS6KB1 neighbours VMP1 within the same GWAS risk locus
(see section 4.1.3).
The RSK family is included in the larger AGC kinase family, which have highly
conserved catalytic kinase domains closely related to those found in protein kinase
A, G, and C (PKA, PKG, and PKC) [488].




that they contain two, highly-conserved, kinase domains which were separately
acquired rather than duplicated [296]. The N-terminal kinase domain (NTKD)
matches other AGC kinases and phosphorylates substrates; the C-terminal kinase
domain (CTKD) matches the calcium/calmodulin dependent protein kinase fam-
ily and activates the NTKD [488, 139]. These kinase domains are separated by
a linking region of approximately 100aa with essential regulatory domains, with
greater variability found in the N- and C-termini which may relate to specificity
[593, 526]. The overall sequence similarity for RSK1–4 is 73–80% [593, 526], upto
90% in the kinase domains [359], with RSK3 being most closely related to RSK
(84% homology), and containing a unique N-terminal sequence not found in other
RSKs [734].
Two longer isoforms of RSK3 have been described, though expression has
been reported as <1% of the shorter, first described isoform [63]. There is little
information about the function of these alternate transcripts, however the unique
N-terminal sequence of RSK3, possibly required for nuclear localisation [734],
would be disrupted in the longer transcripts.
Activation and function The RSK family were identified when searching for
the enzymes responsible for phosphorylating ribosomal protein S6. Although
RSKs were found to perform this function in vitro, and derive their name from
it, they do not play a significant role in RPS6 phosphorylation in vivo where it
is primarily performed by the 70kDa S6 kinases (S6K1 and S6K2) [526].
RSK1–3 are present in the nucleus and cytoplasm, with nuclear translocation
following activation [109, 139] by ERK1/22 together with PDK1, another AGC
kinase. The related proteins MSK1 and MSK2 are activated by p383 in addition
to ERK1/2 and PDK1. Phosphorylation of certain residues in the RSK protein as
well as autophosphorylation are also required for enzymatic activity [488, 593, 19,
139]. RSK1–3 are also activated by PMA4, other MAPK activated kinases (MK2
and MK3 [727]), and general MAPK signalling — hence the alternative name
MAP kinase-activated protein kinases [139]. RSK4 is different from the other
RSK enzymes in that it is expressed at low levels (5–10% of other isoforms),
does not require PDK1 for activation, and basal levels of ERK are sufficient for
maximal activation [160].






in isoform proportions [63, 359, 526]. RSK1 mRNA is most highly expressed in
lung, bone marrow and T cells; RSK2 in T cells, lymph nodes and prostate; and
RSK3 in lung, brain, spinal cord, and retina [359].
Mutations in RSK2 leading to lost kinase activity cause Coffin-Lowry syn-
drome, which features severe mental retardation, facial and digital abnormalities,
kyphoscoliosis, and cardiac defects [634] with similar findings in RSK2-null mice
[497]. These findings are not obviously linked to the tissue distribution of RSK2
mRNA, and indeed, apart from RSK4 which is present at similar levels in all tis-
sues, constitutively active and possibly regulated at the level of transcription, the
RSK family appear to be regulated by activation rather than expression [160, 359].
Although protein motifs recognized by RSKs have been characterised [139,
367], as shown with RPS6, predicted or in vitro kinase activity may not represent
significant in vivo activity. Additionally, isoform specific information is sparse
due potential redundancy between family members [727], and mainly concerns
RSK1 and RSK2 [359].
However RSKs have been shown to be involved in the regulation of widespread
processes and pathways including MAPK signalling, transcription, apoptosis,
glycogen metabolism, cytoskeletal structure, and cell growth, proliferation, motil-
ity and survival [526, 727, 734, 583], through phosphorylation of numerous targets
[19, 526, 359]. These include IκB Kinase, leading to NFκB activation [479, 323],
SRF and c-FOS, JUN, CREB, and NFAT3 (Reviewed by Lara et al. [359]).
Genetic variants within the RSK family have been linked to increased risk
of colon cancer (RPS6KA1, RPS6KA2, and RPS6KB2 ), and variants within
RPS6KA2 linked to increased risk of rectal cancer [580], possibly mediated by
diet [579].
RPS6KA2 and smoking An association has been reported between RPS6KA2
methylation at probe cg22717080 and smoking (uncorrected p=1.68×10−7, 1.7%
hypomethylation in current smokers, 0.3% hypomethylation in ex-smokers)5 [636].
This CpG is in the same intron as the CpG found to be hypomethylated in CD
(10.7kb distal) but no significant association between CD and methylation at this
probe was found in the paediatric Illumina 450k data, and there was also no cor-
relation between the methylation at cg22717080 and cg17501210, the probe were
we found CD-associated methylation changes. The reported smoking-associated
methylation change displayed no correlated change in expression, and was not
5Bonferroni corrected p=0.06 for m=355628
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Gene Enzyme Class Location
RPS6KA1 RSK1 90kDa 1p36.11
RPS6KA2 RSK3 90kDa 6q27
RPS6KA3 RSK2 90kDa Xp22.12
RPS6KA4 RSKB/MSK2 90kDa 11q13.1
RPS6KA5 RSKL/MSK1 90kDa 14q32.11
RPS6KA6 RSK4 90kDa Xq21.1
RPS6KB1 S6K1 70kDa 17q23.1*
RPS6KB2 S6K2 70kDa 11q13.2
Table 5.1: RSKs and related enzymes. *Within the same region as
VMP1/mir21.
found to be correlated with changes in blood cell counts [636].
Context of 450k results The Illumina 450k results for the RPS6KA2 re-
gion are shown in figure 5.2 on page 210. There was a single significant probe
(cg17501210), which is located in the first intron of the short transcript (2nd–3rd
of longer transcripts, see figure 5.1). This was the second most significant probe




Figure 5.1: All experimentally validated and predicted isoforms of
RPS6KA2, named as per ensembl.org. TSL: transcript support level (en-
sembl.org and UCSC genome browser), *: non-coding, dotted lines: mi-
croarray probes for expression (red) and methylation (blue), solid colour
blocks show qPCR targets (for TSL 1 transcripts only) against all tran-
scripts (red), transcript 1 (green) and long transcripts (blue). Numbered









































Figure 5.2: Context of RPS6KA2 Illumina 450k results. From top: 1)
-log10 p values, with lines indicating Bonferroni corrected p<0.05 and
FDR<0.05. 2) Beta values for each sample, red - CD, blue - control. 3)
Mean beta value for CD relative to mean control. 4) Gene transcripts.
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5.2 Materials & methods
5.2.1 Sample collection
Initial pyrosequencing replication with 20 adults with Crohn’s disease and 20 age
and sex-matched controls was performed as described in section 3.3.8 (page 117).
Cohorts 1–3 (figs. 5.3 & 5.4, pages 216 – 217, and table 5.4, page 215) samples
were obtained for genetic research (LREC 2000/4/192) and inclusion in the IBD-
BIOM and IBD Character studies from patients recruited from gastroenterology
clinic at the Western General Hospital and healthy volunteers. Summary demo-
graphics are shown in sections 3.2 and 4.2
Bisulfite conversion The initial adult cohort for replication by pyrosequenc-
ing was bisulfite converted using the column-based EZ DNA methylation kit
(D5001), the samples for larger replications were performed using 96-well EZ-96
DNA Methylation Kits (Zymo Research Corporation, Irvine, CA, USA. Cat no.
D5003) with 500ng input DNA per sample.
Pyrosequencing was performed using the PyroMark Q24 System (Qiagen,
Hilden, Germany). The assay (table 5.2) was designed using PyroMark Assay
Design Software (version 2.0.1.15, Qiagen) and ordered from Sigma-Aldrich (St.
Louis). The assay covers 3 CpGs, two of which are measured by the Illumina 450k
Methylation probe cg17501210, and one adjacent CpG (figure 5.11, page 227).
Methylation values and sequence quality were exported from the manufacturers
software and analysed in R, with significance determined by Wilcoxon rank-sum
test.
Samples were run in duplicate, results with any quality warnings were dis-
carded and repeated, analysis was performed on the mean of two methylation
readings within 2% absolute methylation. Where the variance between repeats
was greater than 2% a further set of duplicate reactions was assayed, if these two
readings and one of the original readings were all within 2% (probably due to a
pipetting error or contamination of one of the original samples) the mean of these
three was used, otherwise the sample was excluded.
Further explanation of pyrosequencing and the factors involved in sequence







Table 5.2: Pyrosequencing primers for RPS6KA2 [Btn]: 5′ biotinylation,










Table 5.3: qPCR primers for RPS6KA2, colours correspond to figure 5.1
(page 209)
5.2.2 qPCR
Patients with CD were recruited from gastroenterology clinics and endoscopy
lists (Western General Hospital, Edinburgh, UK), and compared with healthy
volunteers. Written informed consent was obtained prior to sample collection6.
Blood was collected in a 9ml K3 EDTA Vacuette tube (Greiner) with PBMCs
and granulocytes isolated within 1 hour of venepuncture. PBMCs were obtained
by density centrifugation with Ficoll-Paque PLUS (GE Healthcare) as per man-
ufacturers instructions. After the PBMC layer had been removed, the remaining
Ficoll was discarded and the pellet was lysed with red cell lysis buffer to extract
granulocytes. RNA from whole blood was obtained using ‘QIAamp RNA Blood
Mini’ kits during the Ficoll centrifugation, RNA from granulocytes and PBMCs
was extracted immediately after separation using ‘miRNeasy Mini’ kits (Qiagen).
RNA was stored at -80°C until cDNA conversion with SuperScript Vilo cDNA
Synthesis Kit (Invitrogen). Primers were ordered from Sigma-Aldrich (table 4.8)
and qPCR was performed with a Rotor-Gene 6000 (Corbett life science) and
DyNAmo Flash SYBR Green (ThermoFisher). Primers are shown in table 5.3,
and control primers in table 4.8, 193. Normalisation was performed as described
by Vandesompele et al. [657], with sequential exclusion of reference genes. Final
normalisation was performed against TBP.
5.2.3 Western blot
HEK293 cells expressing LC3-GFP were plated at 2×105 cells per well in 6 well
plates and after 24 hours treated with RPS6KA2 siRNA (Dharmacon J-004663-
06) or control siRNA as per manufacturers instructions for 60 hours. Cells were
then either returned to DMEM + 10% FCS (fed) or treated with HBSS for 3
6LREC 06/S1101/16, LREC 2000/4/192
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or 6 hours (starvation). One well for each combination of RPS6KA2 siRNA
and starvation condition was treated with 200nm bafilomycin, and another was
untreated.
Cells were then scraped, protein extracted and RPS6KA2 and LC3 assayed
by western blot, and slides for each condition prepared for microscopy.
Probing for RPS6KA2 used polyclonal rabbit IgG from R&D systems (AF893)
against phosphorylated serine 218 at 1:1000 dilution.
Confirmation of reduced RPS6KA2 expression was confirmed by western blot
and qPCR. Cells were plated and after 24 hours incubated with RPS6KA2 siRNA
as above without subsequent starvation. Cells were harvested at 0, 36, 60, and
72 hours incubation, with four replicates per time point. RPS6KA2 protein and
mRNA expression was assayed as above.
5.2.4 Microarray expression data from Noble et al.
Reanalysis of raw microarray data previously generated by our group, and pub-
lished by Noble et al. [461, 462], was used to examine expression of RPS6kA2 and
other RSK family members in inflamed and non-inflamed biopsies from controls
(56 vs. 17), Crohn’s disease (48 vs. 51), and ulcerative colitis (65 vs. 64). see





As shown in figure 3.41 (page 118), initial replication was performed in a cohort of
20 adults with CD and 20 healthy controls, on seven significant results including
RPS6KA2 which replicated with p=4.4×10−5.
As with VMP1 (section 4.3.1, table 4.3), pyrosequencing of the same assay was
performed in the 20 vs 20 cohort extended to n=172 (“cohort 1”), a second adult
cohort (“cohort 2”)7 largely overlapping with the Illumina 450k study undertaken
by NTV [663], and a third adult cohort (“cohort 3”)8. The 2nd and 3rd cohorts
contained both Crohn’s disease and ulcerative colitis patients, and both healthy
volunteers and symptomatic (IBS) controls.
Significant methylation differences were found between Crohn’s disease and
controls across the three CpGs measured in all three cohorts (see figure 5.3, page
216). In cohorts 2 and 3 there were no discernible differences between healthy
controls and IBS despite appreciable differences in age, gender and smoking, with
IBS being younger, more female, and more likely to smoke (see table 4.5, page
190). These two groups were therefore combined into a single control group in
each cohort. Results were not significantly different between cohorts, and so a
combined analysis is also shown in figure 5.4 (page 217).
CpG2 is the nominal target of the Illumina 450k probe, CpG3 is also contained
within the probe, and CpG1 is just adjacent. Figure 5.11 (page 227) shows the
location of the CpGs in relation to the probe and nearby SNPs and CpGs.
1 2 3 Total Coordinate
CD 84 83 97 264 CpG 1 166970255
HC 76 116 76 268 CpG 2 166970252
UC - 77 97 174 CpG 3 166970248
Total 160 276 270 606
Table 5.4: Cohort sizes and CpG coordinates for RPS6KA2 replications
by pyrosequencing
7Assay design: ATA, Patient selection: ATA, Experimental work: ATA
8Assay design: ATA, Patient selection: NTV, Experimental work: WTCRF
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Figure 5.3: Box and whisker plots showing pyrosequencing results for all
three adult cohorts at three CpGs (see table 5.3.1, page 215 for cohort
and CpG details). Whiskers extend up to 1.5 × IQR from the 1st and
3rd quartiles, with any remaining results plotted as points. P values for




1.9×10−35 2.4×10−16 1.6×10−31 2.6×10−13 1.9×10−32 1.9×10−13











CD (264) HC (268) UC (174)
Figure 5.4: Box and whisker plots showing the combined adult pyrose-
quencing replication for RPS6KA2. Whiskers extend up to 1.5 × IQR
from the 1st and 3rd quartiles, with any remaining results plotted as
points. Individual cohort and CpG details given in table 5.4, page 215,
combined numbers by diagnosis shown below figure.
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5.3.2 Illumina 450k replication
Genome-wide methylation was assessed using the Illumina 450k platform in an
adult cohort (largely overlapping with pyrosequencing cohort 2 in figure 5.3 and
table 5.4) by work within our group undertaken by Ventham et al. [663]9 as part of
the IBD-BIOM project. In this dataset the same RPS6KA2 probe (cg17501210)
was the most significant individual finding for Crohn’s disease (p=8.52×10−25)
and IBD (p=6.85×10−19), and ninth strongest for ulcerative colitis (p=4.78×10−12).
Analysis of the IBD Character Illumina 450k whole blood results (see ap-
pendix A.1) found the same RPS6KA2 probe cg17501210 to have significant
hypomethylation for CD, UC, and IBD overall, remaining significant if samples
from Edinburgh were excluded. The β values are shown in figure 5.5 (page 219)







Table 5.5: IBD Character Illumina 450k results for RPS6KA2 probe
cg17501210
5.3.3 Biopsy microarray expression data
Analysis of microarray data10 from inflamed and non-inflamed biopsies from pa-
tients with Crohn’s disease or ulcerative colitis and controls shows an increase in
RPS6KA2 expression in inflamed Crohn’s disease biopsies, not seen in inflamed
biopsies from ulcerative colitis patients or controls, and no variation in baseline
expression.
Expression levels of other RSK family members and closely related genes
(listed in table 5.1, page 208), as well as ERK1/2 and p38 were also assessed.
The only other transcript to show significant11 disease- or inflammation-related
expression changes was RPS6KA6 (RSK4). Both significant sets of results are
shown in figure 5.6 (page 220).
9Personal communication, results awaiting publication
10Experimental work: CLN
11corrected for multiple testing m=11
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Figure 5.5: Box and whisker plots showing IBD Character RPS6KA2
Illumina 450k methylation results for all centres except Edinburgh (left),
Edinburgh alone (centre), and all centres combined (right). Group sizes
indicated below. Whiskers extend up to 1.5 × IQR from the 1st and
3rd quartiles, with any remaining results plotted as points. P values for
limma analysis of IBD vs control for the two subgroup analyses and the
overall analysis shown within each facet.
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Figure 5.6: Box and whisker plots showing microarray data for RSK3
(top) and RSK4 (bottom) expression in non-inflamed and inflamed biop-
sies from controls (56 vs. 17), Crohn’s disease (48 vs. 51), and ulcerative
colitis (65 vs. 64). Whiskers extend up to 1.5 × IQR from the 1st and 3rd
quartiles, with any remaining results plotted as points. P values for in-
flamed vs non-inflamed Wilcoxon rank sum test shown within each facet.
Reanalysis of data from two papers by Noble et al. [461, 462], see section




No clear picture emerges from qPCR analysis of RPS6KA2 mRNA expression
levels (figure 5.7). There is a non-significant trend towards increased expression
in whole blood, a non-significant trend towards decreased expression in PBMCs
and no significant difference in expression between Crohn’s disease and ulcerative
colitis in granulocytes. No significant difference in the ratio of short and long









































































Figure 5.7: Box and whisker plots showing qPCR results for RPS6KA2.
Whiskers extend up to 1.5 × IQR from the 1st and 3rd quartiles, with
any remaining results plotted as points. Transcripts (top right) shows
the relative expression of short and long transcripts in Crohn’s disease
normalised to median control expression. P values for all the shown





Knockdown of RPS6KA2 was demonstrated by the first qPCR assay in table
5.3 (84% reduction) and by western blot. However, no significant difference in
RPS6KA2 expression in response to stimulation of autophagy, and no significant
difference in autophagy measured by LC3 western blot in response to RPS6KA2
knockdown were demonstrated.
Figure 5.8: Expression of RPS6KA2 measured by qPCR after incubation
with RPS6KA2 siRNA for 36–72 hours.
Figure 5.9: Western blot showing no significant effect of RPS6KA2
knockdown (shown as hours exposure to RPS6KA2 siRNA) on autophagy
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Figure 5.10: Western blot showing RPS6KA2 expression does not




Methylation Highly significant hypomethylation of the Illumina 450k probe
cg17501210 in RPS6KA2 has been shown in 1 paediatric cohort, and two large
adult cohorts. In the IBD Character cohort the finding remained significant when
all samples from Edinburgh were excluded, for a partially independent replica-
tion. Pyrosequencing of the same local region has also found highly significant
hypomethylation in 3 adult cohorts (combined n=606, p=1.9×10−35).
This finding has not been reported in other IBD EWAS studies (table 2.4, page
33), though a weakly significant DMR was reported in an EWAS of treatment-
naive paediatric UC biopsies [249]. However, as discussed in sections 2.5 and 4.4
comparisons between EWAS studies are complicated by differences in platforms
and analytical techniques used, and tissues studied.
Al Muftah et al. found an association between probe cg17501210 and BMI
(p=4.90×10−7)12 in an EWAS for type 2 diabetes and BMI in a Qatari pop-
ulation [6]. This study showed other interesting overlaps with the paediatric
Illumina 450k results; among their 8 replicated findings were also hypomethyla-
tion of SOCS3 probe cg18181703 (the same probe showing Bonferroni significant
hypomethylation in paediatric Crohn’s disease), and hypomethylation of SBNO2
probe cg07573872. Unfortunately this probe was not present in the paediatric
Crohn’s results, after failing QC, however the two closest probes (cg18608055
and cg12170787, 4.5 and 4.6kb distance) were both significantly hypomethylated
after Bonferroni correction.
Expression Despite these highly replicable and significant methylation find-
ings, little progress has been made in establishing any biological impact of the
methylation change. While the microarray data (figure 5.6) showed increased
expression in inflammation in CD, but not UC or controls, this was not repli-
cated in the qPCR data (figure 5.7), and pre-publication data from a microarray
study by NTV for two probes in RPS6KA2 show weak changes in expression,
with opposite directions13.
The microarray probe presented here would measure all RPS6KA2 transcripts
5.1, but qPCR primers designed to distinguish between the transcripts did not
find any difference in the transcript ratio between CD and controls. Finally, no
relationship between autophagy induced by starvation and RPS6KA2 expression




was found with an antibody targeted to one of the regulatory phosphorylation
sites in RPS6KA2.
There clearly is not a straightforward relationship between the methylation of
this small intronic region of RPS6KA2 and baseline expression. The nearby re-
ported smoking-associated hypomethylation was also not found to correlate with
expression [636]. The duration and timing of expression may be more impor-
tant than baseline expression levels for RSK1-3 [449, 28] and further work should
investigate this.
Genetics RPS6KA2 lies within a GWAS risk locus for IBD [297] and genetic
risk variants for colorectal cancer [580] and dental caries [729, 682] have also been
described. As a solitary significant methylation probe, with no other nearby
probes reaching even FDR significance, the possibility of a SNP must be con-
sidered. There are no SNPs within the probe as recognized by Illumina, though
there are several of very low MAF, including the target base (figure 5.11, 227).
There is only one probe with an appreciable MAF in the local region (global 0.34,
European 0.156, British 0.165, table 5.6, page 228). Further work should include
sequencing this region in a suitable number of patients and controls to establish
if there is a SNP associated with IBD and whether it correlates with methylation
of cg17501210.
Biological relevance Ribosomal protein S6 phosphorylation has been exten-
sively studied, and multiple kinases have been shown phosphorylate the five con-
served serine residues in the carboxy tail [62, 526]. Additionally drugs, pathologi-
cal and physiological stimuli have been observed to have effects on RPS6 phospho-
rylation [62]. Despite this, the effects of RPS6 phosphorylation are incompletely
understood, and while the p90 RSKs (including RPS6KA2) have shown RPS6
phosphorylation activity in vitro this may be mostly performed by the 70kDa
S6 kinases in vivo [526], and other RPS6KA2 targets may be of much greater
importance to IBD pathogenesis.
The MAPK/p38 pathway is important in signalling by TLRs [727], NOD1
[684], and NOD2 [254, 684]. Disruptions to p38 and ERK1/2 activity have been
demonstrated in IBD and blockade has been shown to reduce the production of
inflammatory cytokines including TNFα and IL-1β [673].
As discussed previously, RPS6KA2 is in a GWAS risk locus for IBD [297] as
are RPS6KB1 [297], which shares a risk locus with the other strongest methyl-
ation finding VMP1/MIR21, ERK2 [297], p38α and ERk1 [673].
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ACAGGAAGAGAAAACGTGTTTGGCGAGGCGGGATGTGATGAGTCAGCCCCGGCTAATGCCCCGTGGTCTGGTTGCTGGCATGCAGGTTTCTTGGCACTTG
6 7 8 9 ab c
CCTGAGAACTCGTGGACTTGGCCAGAACACTGGACACCAGCTACACACTGAGTCCACGCCCAGCATACCAGCCTCTAGCGGGCTTCTAAATCTGCCTGGG
d e f g
TGAAACAATAGAAAATGTTCATTAGGGGATTGTACTTTTACAAAGACTGCCCTGACAAGTTTTTTTTGTTGTGTTTTGTTTGGGTTTCTGGTGGAGCTTA
h i j k l m n
CTGGAAGGCTGTGGGTGGCCTACCTAGAATAACGACGCCCGATTCAGACAGCTGGACTCAGAGGGATTCTGCTCCACAGAGAAACAGTAACATTACATTC
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TCTTTGGGGTTTTATTATTGTGGTGGGAAAGGAAGGTTTGTATTATGTCCTGTGTTCCTTTGGGTGTGCCAGTTGCCCACCTCTGTACTCTTGAGTCTAT




Figure 5.11: RPS6KA2 Illumina 450k probe cg17501210 with nearby




Key SNP Base MAF MAFEUR MAFGBR MAFTOP
0 rs533103818 Y -
1 rs115081741 R 0.009 0 0 AFR 0.03, AMR 0.004
2 rs187153184 R 0.0002 0.01 0 CEU 0.05
3 rs552407586 Y -
4 rs182863394 R 0.0004 0 0 AFR 0.001, SAS 0.001
5 rs111294608 Y 0.014 0.001 0 AFR 0.05
6 rs190694832 M 0.003 0.001 0 AFR 0.007, AMR 0.07
7 rs536432002 R 0.001 0 0 AMR 0.007 (PUR 0.024)
8 rs762757999 R -
9 r767406436 R -
a r73257221 K 0.058 0.002 0 AFR 0.21
b r773795942 Y -
c r553427214 W 0.0002 0 0 AFR 0.001
d rs369745394 Y -
e rs534709798 S 0.0004 0 0 AFR 0.002
f rs768304238 R -
g rs570783277 Y 0.0002 0 0 AFR 0.001
h rs552609338 Y 0.001 0 0 EAS 0.007
i rs748967106 Y -
j rs537319626 Y 0.0004 0 0 AFR 0.002
k rs569992380 R 0.0002 0 0 SAS 0.001
l rs377062324 R -
m rs748609690 TC/- -
n rs771304997 Y -
o rs77427546 Y 0.004 0 0 AFR 0.014
p rs186180596 W 0.004 0.006 0.016 AMR 0.016
q rs565685989 Y 0.0004 0 0 AFR 0.002
r rs547424440 S 0.0002 0 0 AMR 0.001
s rs182512563 R 0.0004 0 0 AFR 0.001
t rs141041007 R 0.0001 0.001 0 CEU 0.005
u rs9356490 K -
v rs536851265 S -
w rs575370430 TG/- -
x rs758915478 K -
y rs770201407 S -
z rs971152 B 0.34 0.156 0.165 All
Table 5.6: SNPs near RPS6KA2 probe cg17501210 as shown in figure 5.11 by
key. MAF: minor allele frequency overall, for Europeans (EUR), British in Eng-
land and Scotland (GBR), and where most prevalent. Other population codes:
African (AFR), Columbian, Mexican, Peruvian and Puerto Rican (AMR), east
Asian (EAS), south Asian (SAS), Utah residents with northern and western Euro-





Diagnosis of IBD may be delayed in children, especially those without colonic
involvement, and in those with non-specific symptoms [255]. If prolonged this
can have profound effects on growth and education as discussed in section 2.6.
Endoscopic investigation is the gold-standard investigation for the diagnosis of
IBD, however a blood test would allow for a lower threshold for investigation
which could reduce delayed diagnosis. A blood test would also be easier to repeat
for monitoring purposes, would be cheaper, would not require access to endoscopy
facilities and could therefore be carried out in general practice.
Epigenetic biomarkers are discussed in section 2.5.2 (page 36). DNA methy-
lation can vary with disease, expression, genetic factors, and environmental ex-
posure, making it a promising avenue for the discovery of biomarkers reflecting a
combination of these factors.
The final paediatric methylation results presented in chapter 3 were the result
of combining two paediatric datasets as discussed in section 3.3.1 (page 59). Pri-
mary analysis of the paediatric discovery cohort provided a small list of probes
which later could be tested independently in the paediatric replication cohort.
The makeup of the paediatric discovery cohort is ideal for the development of
diagnostic biomarkers. Both cases and controls had been referred for endoscopic
investigation of symptoms suggestive of IBD, with DNA sampling and diagnosis
occurring concurrently.
The work in this chapter was the basis for patent applications in the USA
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[5]1 and internationally [3]2. As part of these applications, biomarkers were also
tested based on the top results in the combined paediatric dataset. Considering
the performance of these in the paediatric patients is less scientifically rigorous, as
they are constructed and tested against the same data; however, for comparisons
against further datasets such as the adult IBD Character cohort is valid as there
are once again independent learning and testing groups.
1Inventors: Adams, AT; Kennedy, NA; Nimmo, ER & Satsangi, J. 2014: 61/941847




6.2 Materials & methods
Linear discriminant analysis of methylation beta values in the paediatric discovery
cohort was used to create biomarkers for the presence of CD, using the LDA
function in the R package ‘MASS’ [662]. All probes with FDR adjusted P values
<0.05 in the initial analysis of the discovery cohort were used as covariates,
regardless of performance in the replication cohort, with each model including 2
probes. Models were tested using the paediatric replication cohort methylation
beta values.
For the patents applications, all 2080 combinations of two probes with Bon-
ferroni significant methylation change in the combined paediatric analysis were
tested. These models were built using the paediatric discovery cohort as a learn-
ing set and the paediatric replication cohort as a testing set.
Methylation results from the adult IBD Character cohort were used for a sec-
ond replication of the paediatric models. For these analyses the entire paediatric
cohort was used as a learning set. The IBD Character results were also used to
test the 2080 models generated for the patent (excluding one probe which failed
QC, leaving a total of 2016 combinations).
True and false, positive and negative results were determined from LDA, and
sensitivity, specificity and accuracy calculated as shown below. Area under the
curve (AUC) was calculated with the R package ‘ROC’ [96].
Sens =
∑TP∑TP + FN Spec =
∑TN∑TN + FP Acc =




6.3.1 Model generation & testing in children
Models were generated using the results of the 9 top probes in the discovery co-
hort (table 6.2, page 233). No single probe performed adequately as a biomarker,
combining two probes was highly effective, but additional probes did not lead to
significant improvements. Linear discriminant analysis of the 36 unique combina-
tions of two significant probes in the paediatric discovery cohort (figure 6.1, page
234) was used to create models to predict diagnosis in the paediatric replication
cohort. The equivalent methylation results in the replication cohort are shown
in figure 6.2 (page 235), and the separation achieved in the replication cohort by
these models, and the ROC curves are shown in figure 6.3 (page 236). The same
models were constructed also including the age and sex as covariates, the results
of which are shown in figure 6.4 (page 237).
The discovery cohort top results (table 6.2) include two VMP1 probes, and
each of these performed very similarly (as shown in figure 6.3), and VMP1 is
clearly involved in many of the better performing models. Therefore only one
combination of each probe with a VMP1 probe is included from this point to avoid
overstating the overall accuracy of the models. The results of the application of
each model to the paediatric replication cohort, including and excluding age and
sex, are listed in table 6.3 (page 238), and table 6.4 (page 239) shows summary
statistics for each group of models.
Overall, the inclusion of age and sex as covariates in the model improved
sensitivity at the cost of reduced specificity; however, the differences are very
small and a much larger cohort would be required to establish if inclusion of
age and sex made a statistical difference to model performance. There was no
advantage to adding further probes into models; the results of a model consisting
of all 9 probes is shown in table 6.1.
Model TP FN TN FP Sens Spec Acc AUC
VMP1+MYO1E 14 3 18 0 0.82 1.00 0.91 0.98
9 Probes 13 4 17 1 0.76 0.94 0.86 0.95
VMP1+MYO1E+Age+Sex 15 2 18 0 0.88 0.89 0.94 0.96
9 Probes+Age+Sex 13 4 17 1 0.76 0.94 0.86 0.95
Table 6.1: The better two-probe models performed as well as using all
9 probes. T/F/P/N - true, false, positive, negative. Sens - sensitivity,




Probe Chr Coord Gene P value P value Rank P value Bonferroni
cg12054453 17 57915717 VMP1 2.19×10−10 1.55×10−5 1 1.97×10−15 8.86×10−10
cg16936953 17 57915665 VMP1 9.11×10−10 9.25×10−5 4 2.65×10−13 1.19×10−7
cg12992827 3 101901234 3.82×10−9 5.14×10−5 3 1.59×10−13 7.13×10−8
cg17501210 6 166970252 RPS6KA2 1.17×10−8 3.73×10−6 2 4.47×10−15 2.01×10−9
cg04389058 3 57041402 ARHGEF3 3.32×10−8 4.69×10−5 5 1.44×10−12 6.48×10−7
cg09349128 22 50327986 1.71×10−7 3.46×10−3 20 3.00×10−9 1.35×10−3
cg25114611 6 35696870 4.72×10−7 0.021 102 3.05×10−7 0.137
cg08423142 15 59588622 MYO1E 4.86×10−7 0.017 25 4.07×10−9 1.83×10−3
cg22628873 17 4464400 GGT6 7.55×10−7 0.101 136 6.90×10−7 0.310
Table 6.2: Probes selected for use in biomarkers, based on their significance in the discovery cohort regardless of





Figure 6.1: Results in the paediatric discovery cohort for all two-probe combinations used for training diagnostic
biomarkers; lower-left - individual β values for each two-probe combination; upper-right - 2D probability density
by diagnosis; diagonal - 1D probability density. Red: CD, blue: control.
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Figure 6.2: Results in the paediatric replication cohort for top probes in the paediatric discovery cohort used to
train models; lower-left - individual β values for each two-probe combination; upper-right - 2D probability density




Figure 6.3: Upper-right - box and whisker plots showing separation in the replication cohort by the linear
discriminant function derived from the testing cohort. Whiskers extend up to 1.5 × IQR from the 1st and 3rd
quartiles, with any remaining results plotted as points; lower-left - ROC plots and AUC for the performance of
these models in the replication cohort. Red: CD, blue: control.
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Figure 6.4: Upper-right - box and whisker plots showing separation in the replication cohort by the linear
discriminant function derived from the testing cohort, including age and sex as covariates. Whiskers extend up to
1.5 × IQR from the 1st and 3rd quartiles, with any remaining results plotted as points; lower-left - ROC plots and
AUC for the performance in the replication cohort of models previously shown, or including subject age and sex.




Methylation Methylation, age & sex
Probes TP FN TN FP Sens Spec Acc AUC TP FN TN FP Sens Spec Acc AUC
VMP1 MYO1E 14 3 18 0 0.82 1.00 0.91 0.98 15 2 18 0 0.88 1.00 0.94 0.96
VMP1 RPS6KA2 13 4 18 0 0.76 1.00 0.89 0.98 14 3 16 2 0.82 0.89 0.86 0.96
RPS6KA2 ARHGEF3 13 4 18 0 0.76 1.00 0.89 0.98 14 3 17 1 0.82 0.94 0.89 0.98
VMP1 ARHGEF3 13 4 18 0 0.76 1.00 0.89 0.97 13 4 18 0 0.76 1.00 0.89 0.96
VMP1 cg12992827 13 4 18 0 0.76 1.00 0.89 0.96 14 3 17 1 0.82 0.94 0.89 0.96
RPS6KA2 cg12992827 12 5 17 1 0.71 0.94 0.83 0.96 11 6 17 1 0.65 0.94 0.80 0.93
VMP1 VMP1 13 4 16 2 0.76 0.89 0.83 0.95 13 4 17 1 0.76 0.94 0.86 0.93
ARHGEF3 cg25114611 13 4 17 1 0.76 0.94 0.86 0.95 13 4 17 1 0.76 0.94 0.86 0.95
VMP1 cg25114611 13 4 17 1 0.76 0.94 0.86 0.94 14 3 17 1 0.82 0.94 0.89 0.94
RPS6KA2 cg09349128 12 5 17 1 0.71 0.94 0.83 0.94 12 5 16 2 0.71 0.89 0.80 0.91
RPS6KA2 cg25114611 11 6 17 1 0.65 0.94 0.80 0.94 11 6 15 3 0.65 0.83 0.74 0.92
ARHGEF3 MYO1E 12 5 16 2 0.71 0.89 0.80 0.94 13 4 17 1 0.76 0.94 0.86 0.92
RPS6KA2 MYO1E 11 6 17 1 0.65 0.94 0.80 0.93 13 4 16 2 0.76 0.89 0.83 0.91
cg12992827 ARHGEF3 12 5 17 1 0.71 0.94 0.83 0.93 13 4 17 1 0.76 0.94 0.86 0.93
VMP1 cg09349128 13 4 17 1 0.76 0.94 0.86 0.92 14 3 16 2 0.82 0.89 0.86 0.93
VMP1 GGT6 14 3 18 0 0.82 1.00 0.91 0.92 13 4 16 2 0.76 0.89 0.83 0.91
ARHGEF3 cg09349128 12 5 17 1 0.71 0.94 0.83 0.92 12 5 16 2 0.71 0.89 0.80 0.92
cg12992827 MYO1E 13 4 14 4 0.76 0.78 0.77 0.91 12 5 16 2 0.71 0.89 0.80 0.90
cg12992827 cg09349128 12 5 16 2 0.71 0.89 0.80 0.90 12 5 15 3 0.71 0.83 0.77 0.88
cg12992827 cg25114611 12 5 16 2 0.71 0.89 0.80 0.89 12 5 16 2 0.71 0.89 0.80 0.91
cg09349128 MYO1E 14 3 15 3 0.82 0.83 0.83 0.89 13 4 16 2 0.76 0.89 0.83 0.87
RPS6KA2 GGT6 11 6 16 2 0.65 0.89 0.77 0.88 11 6 15 3 0.65 0.83 0.74 0.88
ARHGEF3 GGT6 11 6 16 2 0.65 0.89 0.77 0.87 12 5 16 2 0.71 0.89 0.80 0.87
MYO1E cg25114611 10 7 15 3 0.59 0.83 0.71 0.87 10 7 15 3 0.59 0.83 0.71 0.88
cg12992827 GGT6 12 5 14 4 0.71 0.78 0.74 0.85 12 5 15 3 0.71 0.83 0.77 0.85
cg09349128 cg25114611 13 4 15 3 0.76 0.83 0.80 0.84 13 4 15 3 0.76 0.83 0.80 0.83
cg09349128 GGT6 12 5 14 4 0.71 0.78 0.74 0.82 12 5 15 3 0.71 0.83 0.77 0.80
cg25114611 GGT6 11 6 13 5 0.65 0.72 0.69 0.80 10 7 13 5 0.59 0.72 0.66 0.79
MYO1E GGT6 9 8 14 4 0.53 0.78 0.66 0.79 11 6 14 4 0.65 0.78 0.71 0.79
Table 6.3: Two-probe biomarkers, as shown in figures 6.3 (left) & 6.4 (right), excluding the similar results from
substituting between the two VMP1 probes). T/F/P/N - true, false, positive, negative. Sens - sensitivity, Spec -
specificity, Acc - accuracy, AUC - area under the curve.
238
6.3
Methylation Meth, age & sex
Min Median Max Min Median Max
Sensitivity 0.53 0.71 0.82 0.59 0.76 0.88
Specificity 0.72 0.94 1.00 0.72 0.89 1.00
Accuracy 0.66 0.83 0.91 0.66 0.80 0.94
AUC 0.79 0.92 0.98 0.79 0.91 0.98
Table 6.4: Summary results for paediatric biomarkers
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6.3.2 Testing of paediatric models in adults
Many of the probes used in the previous section were also highly significantly dif-
ferentially methylated in the adult IBD Character cohort (see table 6.5). Overall
there was a greater overlap between the methylation values in Crohn’s and control
in adults compared to children (see figure 6.5, page 241). Additionally, in probes
which were highly significant in both the children and adults, with the same di-
rection and magnitude of change in methylation, the absolute methylation values
did not always match between children and adults (see figure 6.6, page 242). The
combined effect of these factors is a reduced accuracy of the models when tested
in adults, as shown in figure 6.7 (page 243), and table 6.6 (page 244).
Probe Chr Coord Gene P value
cg04389058 3 57041402 ARHGEF3 7.14×10−8
cg08423142 15 59588622 MYO1E 1.49×10−3
cg09349128 22 50327986 CRELD2 8.41×10−21
cg12054453 17 57915717 VMP1 3.66×10−20
cg12992827 3 101901234 ZPLD1 2.60×10−11
cg16936953 17 57915665 VMP1 4.05×10−18
cg17501210 6 166970252 RPS6KA2 1.08×10−19
cg22628873 17 4464400 GGT6 1.28×10−3
cg25114611 6 35696870 LOC285847 1.27×10−8




Figure 6.5: Results in the adult IBD Character dataset for top probes in the paediatric discovery cohort used to
train models; lower-left - individual β values for each two-probe combination; upper-right - 2D probability density
by diagnosis; diagonal - 1D probability density. Red: CD, blue: control.
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Figure 6.6: Box and whisker plots showing methylation results in adults
and children, for probes which were highly significant in both analyses.
Whiskers extend up to 1.5 × IQR from the 1st and 3rd quartiles, with any
remaining results plotted as points.
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Figure 6.7: Upper-right - box and whisker plots showing separation in the adult cohort by the linear discriminant
function derived from the paediatric testing cohort. Whiskers extend up to 1.5 × IQR from the 1st and 3rd
quartiles, with any remaining results plotted as points; lower-left - ROC plots and AUC for the performance in the




Methylation Methylation, age & sex
Probes TP FN TN FP Sens Spec Acc AUC TP FN TN FP Sens Spec Acc AUC
cg12992827 ARHGEF3 71 79 269 33 0.47 0.89 0.75 0.79 41 109 293 9 0.27 0.97 0.74 0.79
ARHGEF3 cg09349128 113 37 188 114 0.75 0.62 0.67 0.79 86 64 275 27 0.57 0.91 0.80 0.79
cg09349128 MYO1E 128 22 163 139 0.85 0.54 0.64 0.80 90 60 256 46 0.60 0.85 0.77 0.78
VMP1 cg25114611 146 4 52 250 0.97 0.17 0.44 0.78 130 20 110 192 0.87 0.36 0.53 0.78
ARHGEF3 cg25114611 128 22 110 192 0.85 0.36 0.53 0.77 113 37 198 104 0.75 0.66 0.69 0.79
VMP1 RPS6KA2 140 10 91 211 0.93 0.30 0.51 0.79 95 55 241 61 0.63 0.80 0.74 0.76
VMP1 cg12992827 109 41 215 87 0.73 0.71 0.72 0.78 86 64 269 33 0.57 0.89 0.79 0.77
VMP1 cg09349128 134 16 101 201 0.89 0.33 0.52 0.78 118 32 180 122 0.79 0.60 0.66 0.77
RPS6KA2 cg12992827 104 46 237 65 0.69 0.78 0.75 0.81 48 102 294 8 0.32 0.97 0.76 0.74
RPS6KA2 ARHGEF3 125 25 168 134 0.83 0.56 0.65 0.78 63 87 286 16 0.42 0.95 0.77 0.77
cg12992827 cg09349128 79 71 265 37 0.53 0.88 0.76 0.80 43 107 291 11 0.29 0.96 0.74 0.75
VMP1 ARHGEF3 126 24 141 161 0.84 0.47 0.59 0.77 121 29 172 130 0.81 0.57 0.65 0.77
VMP1 GGT6 88 62 261 41 0.59 0.86 0.77 0.77 62 88 280 22 0.41 0.93 0.76 0.77
RPS6KA2 cg09349128 141 9 97 205 0.94 0.32 0.53 0.81 74 76 275 27 0.49 0.91 0.77 0.73
cg12992827 MYO1E 70 80 269 33 0.47 0.89 0.75 0.78 43 107 290 12 0.29 0.96 0.74 0.76
cg09349128 cg25114611 142 8 44 258 0.95 0.15 0.41 0.79 100 50 207 95 0.67 0.69 0.68 0.75
VMP1 MYO1E 125 25 131 171 0.83 0.43 0.57 0.76 122 28 157 145 0.81 0.52 0.62 0.77
RPS6KA2 cg25114611 146 4 21 281 0.97 0.07 0.37 0.79 86 64 239 63 0.57 0.79 0.72 0.74
ARHGEF3 GGT6 34 116 296 6 0.23 0.98 0.73 0.76 22 128 300 2 0.15 0.99 0.71 0.77
cg09349128 GGT6 52 98 289 13 0.35 0.96 0.75 0.79 28 122 300 2 0.19 0.99 0.73 0.74
RPS6KA2 MYO1E 133 17 138 164 0.89 0.46 0.60 0.79 63 87 280 22 0.42 0.93 0.76 0.73
RPS6KA2 GGT6 63 87 275 27 0.42 0.91 0.75 0.79 19 131 300 2 0.13 0.99 0.71 0.73
cg12992827 VMP1 74 76 267 35 0.49 0.88 0.75 0.77 49 101 289 13 0.33 0.96 0.75 0.75
cg12992827 cg25114611 74 76 266 36 0.49 0.88 0.75 0.78 37 113 292 10 0.25 0.97 0.73 0.74
cg12992827 GGT6 32 118 295 7 0.21 0.98 0.72 0.78 14 136 299 3 0.09 0.99 0.69 0.74
MYO1E cg25114611 142 8 58 244 0.95 0.19 0.44 0.76 126 24 137 165 0.84 0.45 0.58 0.76
VMP1 cg09349128 116 34 167 135 0.77 0.55 0.63 0.77 80 70 267 35 0.53 0.88 0.77 0.74
ARHGEF3 MYO1E 95 55 227 75 0.63 0.75 0.71 0.75 82 68 249 53 0.55 0.82 0.73 0.76
RPS6KA2 VMP1 127 23 152 150 0.85 0.50 0.62 0.77 72 78 278 24 0.48 0.92 0.77 0.73
VMP1 ARHGEF3 92 58 214 88 0.61 0.71 0.68 0.74 74 76 262 40 0.49 0.87 0.74 0.76
VMP1 cg25114611 134 16 98 204 0.89 0.32 0.51 0.75 98 52 207 95 0.65 0.69 0.67 0.74
VMP1 GGT6 39 111 291 11 0.26 0.96 0.73 0.75 23 127 299 3 0.15 0.99 0.71 0.74
VMP1 VMP1 124 26 121 181 0.83 0.40 0.54 0.74 114 36 165 137 0.76 0.55 0.62 0.74
MYO1E GGT6 27 123 295 7 0.18 0.98 0.71 0.74 17 133 300 2 0.11 0.99 0.70 0.74
cg25114611 GGT6 60 90 275 27 0.40 0.91 0.74 0.75 31 119 300 2 0.21 0.99 0.73 0.73
VMP1 MYO1E 102 48 199 103 0.68 0.66 0.67 0.73 78 72 249 53 0.52 0.82 0.72 0.73
Table 6.6: Paediatric models tested in the IBD Character adult cohort. T/F/P/N - true, false, positive, negative.
Sens - sensitivity, Spec - specificity, Acc - accuracy, AUC - area under the curve.
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6.3.3 Further paediatric modelling
For the patent applications, all 2080 combinations of the 65 Bonferroni significant
probes were tested. The top results in children using the discovery cohort as the
learning set and the replication cohort as the testing set are shown in table 6.7
(page 246).
As with the previously discussed probes (figure 6.6, page 242) there were fre-
quently substantial shifts in the methylation patterns seen between children and
adults, even when the probe was highly significant in both cohorts, with a similar
magnitude of disease-associated change in the same direction. This is shown in
figure 6.8 (page 247), showing a generally symmetrical shift in methylation for
Crohn’s and controls, and a preponderance of hypomethylation in adults relative
to children. One of the 65 Bonferroni significant paediatric results was filtered
during the adult data QC, leaving 64 probes and 2016 two-probe combinations.
As with the previous models, these models, constructed in children, performed
less well in adults than children. The best performing of these models in adults,
using the entire paediatric cohort as a learning set, are shown in table 6.8 (page




Methylation Methylation, age & sex
Probes TP FN TN FP Sens Spec Acc AUC TP FN TN FP Sens Spec Acc AUC
RPS6KA2 HK2 16 1 18 0 0.94 1.00 0.97 1.00 16 1 18 0 0.94 1.00 0.97 1.00
RPS6KA2 cg01726890 15 2 18 0 0.88 1.00 0.94 1.00 15 2 18 0 0.88 1.00 0.94 1.00
RPS6KA2 ZBTB16 17 0 18 0 1.00 1.00 1.00 1.00 17 0 18 0 1.00 1.00 1.00 1.00
RPS6KA2 ZEB2 12 5 18 0 0.71 1.00 0.86 1.00 12 5 18 0 0.71 1.00 0.86 1.00
RPS6KA2 CDC42BPB 12 5 18 0 0.71 1.00 0.86 1.00 12 5 18 0 0.71 1.00 0.86 1.00
RPS6KA2 SLC15A4 17 0 18 0 1.00 1.00 1.00 1.00 17 0 18 0 1.00 1.00 1.00 1.00
HK2 TNFSF10 15 2 18 0 0.88 1.00 0.94 1.00 15 2 18 0 0.88 1.00 0.94 1.00
HK2 FKBP5 16 1 18 0 0.94 1.00 0.97 1.00 16 1 18 0 0.94 1.00 0.97 1.00
TNFSF10 IL18RAP 17 0 17 1 1.00 0.94 0.97 1.00 17 0 17 1 1.00 0.94 0.97 1.00
SOCS3 IL18RAP 17 0 17 1 1.00 0.94 0.97 1.00 17 0 17 1 1.00 0.94 0.97 1.00
cg01726890 SBNO2 17 0 17 1 1.00 0.94 0.97 1.00 17 0 17 1 1.00 0.94 0.97 1.00
cg01726890 FKBP5 17 0 17 1 1.00 0.94 0.97 1.00 17 0 17 1 1.00 0.94 0.97 1.00
ZBTB16 SBNO2 17 0 18 0 1.00 1.00 1.00 1.00 17 0 18 0 1.00 1.00 1.00 1.00
ZBTB16 FKBP5 17 0 18 0 1.00 1.00 1.00 1.00 17 0 18 0 1.00 1.00 1.00 1.00
SBNO2 SLC15A4 16 1 18 0 0.94 1.00 0.97 1.00 16 1 18 0 0.94 1.00 0.97 1.00
IL18RAP SBNO2 17 0 18 0 1.00 1.00 1.00 1.00 17 0 18 0 1.00 1.00 1.00 1.00
IL18RAP MIR21 16 1 18 0 0.94 1.00 0.97 1.00 16 1 18 0 0.94 1.00 0.97 1.00
IL18RAP FKBP5 17 0 16 2 1.00 0.89 0.94 1.00 17 0 16 2 1.00 0.89 0.94 1.00
VMP1 SLC15A4 14 3 18 0 0.82 1.00 0.91 1.00 14 3 18 0 0.82 1.00 0.91 1.00
RPS6KA2 IL18RAP 16 1 18 0 0.94 1.00 0.97 1.00 16 1 18 0 0.94 1.00 0.97 1.00
HK2 SOCS3 16 1 17 1 0.94 0.94 0.94 1.00 16 1 17 1 0.94 0.94 0.94 1.00
SOCS3 ZBTB16 17 0 17 1 1.00 0.94 0.97 1.00 17 0 17 1 1.00 0.94 0.97 1.00
VMP1 ZBTB16 16 1 18 0 0.94 1.00 0.97 1.00 16 1 18 0 0.94 1.00 0.97 1.00
SBNO2 CBFA2T2 15 2 18 0 0.88 1.00 0.94 1.00 15 2 18 0 0.88 1.00 0.94 1.00
VMP1 IL18RAP 15 2 18 0 0.88 1.00 0.94 0.99 15 2 18 0 0.88 1.00 0.94 0.99
RPS6KA2 cg02560388 13 4 18 0 0.76 1.00 0.89 0.99 13 4 18 0 0.76 1.00 0.89 0.99
TNFSF10 cg01726890 13 4 18 0 0.76 1.00 0.89 0.99 13 4 18 0 0.76 1.00 0.89 0.99
TNFSF10 SLC25A13 13 4 18 0 0.76 1.00 0.89 0.99 13 4 18 0 0.76 1.00 0.89 0.99
SOCS3 LOXL2 15 2 18 0 0.88 1.00 0.94 0.99 15 2 18 0 0.88 1.00 0.94 0.99
Table 6.7: Top performing models from all 65 Bonferroni significant probes. T/F/P/N - true, false, positive,
negative. Sens - sensitivity, Spec - specificity, Acc - accuracy, AUC - area under the curve.
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Figure 6.8: Delta - absolute difference in median between adults and
children for controls (blue) and Crohn’s disease (red). Darker colours
indicate relative hypermethylation in adults compared to children, and




Methylation Methylation, age & sex
Probes TP FN TN FP Sens Spec Acc AUC TP FN TN FP Sens Spec Acc AUC
RPS6KA2 cg09349128 142 8 94 208 0.95 0.31 0.52 0.81 128 22 172 130 0.85 0.57 0.66 0.82
RPS6KA2 NMRAL1 126 24 188 114 0.84 0.62 0.69 0.81 89 61 263 39 0.59 0.87 0.78 0.81
RPS6KA2 cg12992827 107 43 233 69 0.71 0.77 0.75 0.81 72 78 279 23 0.48 0.92 0.78 0.81
RPS6KA2 TNF 108 42 242 60 0.72 0.80 0.77 0.81 66 84 289 13 0.44 0.96 0.79 0.81
CLU SBNO2 121 29 199 103 0.81 0.66 0.71 0.81 125 25 179 123 0.83 0.59 0.67 0.81
RPS6KA2 cg04345034 130 20 166 136 0.87 0.55 0.65 0.81 95 55 245 57 0.63 0.81 0.75 0.81
RPS6KA2 PTDSS2 136 14 127 175 0.91 0.42 0.58 0.80 101 49 232 70 0.67 0.77 0.74 0.81
RPS6KA2 ZEB2 128 22 162 140 0.85 0.54 0.64 0.80 104 46 232 70 0.69 0.77 0.74 0.81
RPS6KA2 RFTN1 130 20 138 164 0.87 0.46 0.59 0.80 101 49 238 64 0.67 0.79 0.75 0.81
RPS6KA2 CFI 139 11 103 199 0.93 0.34 0.54 0.80 117 33 188 114 0.78 0.62 0.67 0.81
RPS6KA2 HK2 118 32 210 92 0.79 0.70 0.73 0.79 95 55 256 46 0.63 0.85 0.78 0.81
CLU SBNO2 132 18 137 165 0.88 0.45 0.60 0.80 124 26 167 135 0.83 0.55 0.64 0.80
RPS6KA2 cg19821297 137 13 123 179 0.91 0.41 0.58 0.80 98 52 240 62 0.65 0.79 0.75 0.80
cg09349128 TNF 112 38 234 68 0.75 0.77 0.77 0.81 127 23 155 147 0.85 0.51 0.62 0.80
cg09349128 MPRIP 140 10 80 222 0.93 0.26 0.49 0.80 142 8 65 237 0.95 0.22 0.46 0.80
RPS6KA2 PTGER4 134 16 133 169 0.89 0.44 0.59 0.80 99 51 235 67 0.66 0.78 0.74 0.80
cg09349128 CLU 131 19 125 177 0.87 0.41 0.57 0.80 132 18 113 189 0.88 0.37 0.54 0.80
RPS6KA2 SLC10A6 141 9 97 205 0.94 0.32 0.53 0.80 107 43 217 85 0.71 0.72 0.72 0.81
RPS6KA2 cg21328643 137 13 125 177 0.91 0.41 0.58 0.80 105 45 223 79 0.70 0.74 0.73 0.80
cg09349128 CDC42BPB 121 29 200 102 0.81 0.66 0.71 0.80 107 43 243 59 0.71 0.80 0.77 0.80
RPS6KA2 ZBTB16 147 3 24 278 0.98 0.08 0.38 0.79 141 9 68 234 0.94 0.23 0.46 0.80
RPS6KA2 cg07398517 134 16 125 177 0.89 0.41 0.57 0.79 98 52 240 62 0.65 0.79 0.75 0.80
RPS6KA2 CLU 139 11 107 195 0.93 0.35 0.54 0.80 94 56 251 51 0.63 0.83 0.76 0.80
RPS6KA2 MPRIP 143 7 71 231 0.95 0.24 0.47 0.79 107 43 209 93 0.71 0.69 0.70 0.80
cg12992827 CFI 97 53 247 55 0.65 0.82 0.76 0.80 86 64 260 42 0.57 0.86 0.77 0.80
RPS6KA2 PRKCE 143 7 88 214 0.95 0.29 0.51 0.80 112 38 205 97 0.75 0.68 0.70 0.80
RPS6KA2 ARHGEF3 130 20 162 140 0.87 0.54 0.65 0.78 99 51 251 51 0.66 0.83 0.77 0.81
cg09349128 NMRAL1 117 33 208 94 0.78 0.69 0.72 0.80 133 17 144 158 0.89 0.48 0.61 0.79
RPS6KA2 RUNX3 131 19 155 147 0.87 0.51 0.63 0.79 84 66 267 35 0.56 0.88 0.78 0.80
Table 6.8: Top performing models built from the combined paediatric dataset, tested in the IBD Character adult




Figure 6.9: Area under the curve for adult replication of paediatric
biomarkers with and without age and sex as covariates, based on the com-
plete paediatric dataset. Point colour shows the AUC of the biomarker
in the paediatric replication cohort when constructed with the paediatric




Paediatric results No single methylation result could distinguish between CD
and symptomatic controls with enough accuracy for clinical use. However, a
combination of two methylation results was highly accurate — up to 94% using
only the probes which were significant in the initial analysis of the paediatric
replication cohort, or up to 100% using the probes which were significant from
the combined analysis, though this is less rigorous.
These findings were not restricted to particular probes and although some
models performed better than others, any possible combination of two significant
probes proved effective, with median results as shown in table 6.4 (page 239).
Differences in the absolute methylation values were observed between adults
and children, in spite of similar relative methylation changes associated with
disease (figure 6.8, page 247) which resulted in a substantial reduction in the
accuracy of the models . This may be due to differences in the proportions
of cellular populations between adults and children, or an independent effect of
ageing.
The quoted significance of results are adjusted for cell type. This entails
measuring or predicting the proportions of various cell types within each sample,
and including these proportions as covariates when estimating the association
between disease and methylation.
When correcting for cell type in the paediatric dataset, we found that the pub-
licly available reference dataset of Illumina 450k from separated cells functioned
poorly to predict whole blood makeup in children3. We therefore used the full
blood count data we had for the majority of patients, to find probes which did
not vary by disease but accurately predicted the differential cell counts in these
patients, and then applied this model to predict the cell counts in the minority
of patients in whom we lacked data. This strengthens the indication that there
are fundamental age-related differences, which would make these biomarkers of
less use in adults. However, the individual probes which exhibited methylation
changes, the direction, and magnitude of those changes do correlate well between
children and adults, and so for a future study which aimed to develop biomarkers
applicable to children and adults, a learning dataset covering both children and




Figure 6.10: Results in all paediatric samples for top probes in the paediatric discovery cohort used to train
models; lower-left - individual β values for each two-probe combination; upper-right - 2D probability density;




Figure 6.11: Results in all paediatric samples for top probes in the paediatric discovery cohort used to train
models; lower-left - individual β values for each two-probe combination; upper-right - 2D probability density by





The Inflammatory Bowel Disease characterisation by a multi-modal integrated
biomarker study consortium (“IBD Character”) is an ongoing multi-centre study
funded by the European Commission’s seventh framework programme for re-
search and technological development (FP7). The consortium will be performing
multi-omics analysis, including genotyping, RNA and protein expression, DNA
methylation and microbiome analysis in a variety of tissues and sample types.
The aim is to analyse these data to develop new biomarkers for the diagnosis
and management of IBD, and to identify novel therapeutic targets. The patients
recruited into IBD Character are recently diagnosed and treatment naive.
The IBD Character project has not yet finished, with final phenotype data
expected in April 2016. Some preliminary results from the Illumina 450k analysis
of whole blood methylation have been reported in this thesis as a replication of the
paediatric results. An abstract detailing preliminary methylation findings from
analysis of the IBD Character cohort has been accepted for presentation at the
United European Gastroenterology Week conference in October 2016 (Appendix
B.3, page 293) and publication thereafter.
The centres contributing samples and sample numbers are shown in table A.1.
This appendix contains preliminary data from Illumina 450k analysis of the
IBD-Character project, and demonstrates several aspects of Illumina 450k QC
and analysis, provides an independent replication of the paediatric Illumina 450k
results presented in chapter 3, and shows that similar results are obtained from
IBD patients and controls from outwith the UK.
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A.2 Materials & methods
Methylation was assayed using the Illumina 450k platform. Samples containing
>1% probes with detection p values >0.05 were removed. Probes with bead
counts <3 in 5% of samples, or detection p values >0.05 in 1% of samples were
also removed.
Normalisation was performed using the ‘dasen’ method as implemented in
the ‘wateRmelon’ R package, which involves equalisation of type I and II probe
backgrounds, followed by inter-array quantile normalisation of type I and type II
probes separately [493].
Sex mismatches were identified by analysis of median intensities of sex chro-
mosome probes, and removed from further analysis.
Proportions for CD8 T cells, CD4 T cells, B-cells, monocytes, granulocytes
and NK cells were estimated using the R package Minfi [25] based on the work
of Houseman et al. [270].
Probes containing SNPs were identified by the manufacturer1, but annotated
rather than filtered.
Disease associated methylation changes were identified by constructing linear
models with the R package ‘limma’ [582] using cell proportions as covariates.
Differentially methylated regions were defined using the ‘lasso’ function in the
R package ‘ChAMP’ [443].
Genotyping was performed using the Illumina HumanOmniExpressExome-8
platform. Methylation eQTLs were found using the ‘MatrixEQTL’ R package




Centre CD Control IBDU UC Unknown Total
Edinburgh 47 87 11 58 3 206
Linkoping 9 39 0 3 0 51
Maastricht 4 0 0 1 0 5
Orebro 24 64 8 25 5 126
Oslo 52 68 5 70 1 196
Zaragoza 14 40 2 10 0 66
Total 150 298 26 167 9 650
Table A.1: IBD Character samples by centre and diagnosis, after removal





Three samples (0.4% of total) with low signal intensities were removed having
>1% of probes with detection p values >0.05, and 3040 probes (0.6%) were
removed due to low signal.
Five clear sex mismatches (0.7%) were identified, as shown in figure A.1, and
removed. Two additional male samples with low Y chromosome signal intensity
are also evident (sample IDs 2113 and 4114).




A.3.2 Replication between Edinburgh and non-Edinburgh
samples
Edinburgh was the largest individual centre, with 32% of all samples. As the
character results have been used to replicate findings in chapters 4–6 it was im-
portant to ensure that these results were not due to the Edinburgh cohort alone.
Results were therefore compared between Edinburgh and and other centres, which
revealed a very strong correlation as shown in figure A.2 (Spearman’s ρ=0.94,
p<2.2×10−308, top 1000 probes).




The number of Bonferroni significant findings for each analysis are shown in table
A.2, followed by the top 20 results for each on pages 259–260. Probes containing
SNPs are indicated, and MAF shown. The complete results are shown in section
A.4 (from page 271).
Comparison Significant probes
IBD vs control 193
CD vs control 81
UC vs control 261
CD vs UC 1




Probe Chr Coord Gene P value SNP MAF
cg09349128 22 50327986 CRELD2 8.4×10−21 0.027
cg12054453 17 57915717 VMP1 3.7×10−20
cg17501210 6 166970252 RPS6KA2 1.1×10−19
cg12170787 19 1130965 SBNO2 2.7×10−19
cg18608055 19 1130866 SBNO2 2.8×10−19
cg07573872 19 1126342 SBNO2 2.2×10−18
cg16936953 17 57915665 VMP1 4.1×10−18
cg27469606 19 1154485 SBNO2 2.7×10−17
cg01059398 3 172235808 TNFSF10 1.1×10−15
cg02650017 17 47301614 PHOSPHO1 1.3×10−15
cg18513344 3 195531298 MUC4 5.5×10−15
cg03156547 14 23525003 CDH24 1.7×10−14
cg24002003 15 101668143 CHSY1 1.8×10−14
cg02716826 9 33447032 AQP3 1.9×10−14
cg06164260 3 187454439 BCL6 2.9×10−14
cg13781414 9 138951648 NACC2 8.5×10−14
cg10636246 1 159046973 AIM2 1.7×10−13
cg18942579 17 57915773 VMP1 1.8×10−13
cg01983725 1 227161799 ADCK3 4.2×10−13
cg19821297 19 12890029 HOOK2 5.7×10−13
Table A.3: IBD Character: IBD vs control - top 20
Probe Chr Coord Gene P value SNP MAF
cg12170787 19 1130965 SBNO2 1.4×10−22
cg18608055 19 1130866 SBNO2 5.5×10−21
cg09349128 22 50327986 CRELD2 1.1×10−18 0.027
cg12054453 17 57915717 VMP1 1.6×10−17
cg17501210 6 166970252 RPS6KA2 4.3×10−17
cg07573872 19 1126342 SBNO2 9.5×10−17
cg16936953 17 57915665 VMP1 1.7×10−14
cg27469606 19 1154485 SBNO2 2.2×10−14
cg01059398 3 172235808 TNFSF10 3.1×10−12
cg10967866 10 134362164 INPP5A 3.2×10−12
cg18513344 3 195531298 MUC4 4.3×10−12
cg15551881 9 123688715 TRAF1 8.3×10−12
cg20141108 1 165907859 UCK2 9.6×10−12
cg19821297 19 12890029 HOOK2 1.0×10−11
cg13781414 9 138951648 NACC2 1.2×10−11
cg18181703 17 76354621 SOCS3 1.3×10−11
cg02650017 17 47301614 PHOSPHO1 2.1×10−11
cg16292768 8 27467783 CLU 3.5×10−11
cg18942579 17 57915773 VMP1 6.7×10−11
cg03940776 6 158490013 SYNJ2 1.1×10−10
Table A.4: IBD Character: CD vs control - top 20
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Probe Chr Coord Gene P value SNP MAF
cg09349128 22 50327986 CRELD2 1.3×10−17 0.027
cg16936953 17 57915665 VMP1 1.5×10−15
cg12054453 17 57915717 VMP1 4.0×10−15
cg17501210 6 166970252 RPS6KA2 6.7×10−15
cg07573872 19 1126342 SBNO2 8.5×10−15
cg24002003 15 101668143 CHSY1 1.2×10−14
cg18608055 19 1130866 SBNO2 7.0×10−14
cg08449144 11 1857919 SYT8 9.2×10−14
cg06164260 3 187454439 BCL6 1.1×10−13
cg02650017 17 47301614 PHOSPHO1 1.6×10−13
cg27469606 19 1154485 SBNO2 2.0×10−13
cg01059398 3 172235808 TNFSF10 2.7×10−13
cg02716826 9 33447032 AQP3 7.3×10−13
cg10636246 1 159046973 AIM2 1.6×10−12
cg01983725 1 227161799 ADCK3 1.8×10−12
cg03156547 14 23525003 CDH24 2.4×10−12
cg20995564 2 145172035 ZEB2 3.5×10−12
cg03039243 1 2782699 TTC34 5.9×10−12
cg02734358 4 90227074 GPRIN3 6.3×10−12
cg12170787 19 1130965 SBNO2 6.7×10−12
Table A.5: IBD Character: UC vs control - top 20
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A.3.4 Comparison with paediatric results
In the paediatric analysis there were 65 probes with significant disease-associated
methylation differences, one of these probes was not analysed in the IBD Char-
acter cohort as it failed QC. Of the remaining 64 probes which were significant in
children, 22 also achieved Bonferroni significance in adults representing a modest
proportion (34.4%) but a massive enrichment compared to chance (2376 times
enrichment, p=5.38×10−7586). For the very strongest results the concordance was
higher; the top five paediatric results were all significant in the adults, and the
top 6 adult results were all significant in the children. Figure A.3 shows the Log2
fold-change in the paediatric results and IBD Character results.
Figure A.3: Log2 fold-change in paediatric and IBD Character samples.
Small points were significant in neither cohort, medium open circles in
one cohort, and large filled circles in both cohorts. Coloured by the sum
of the -Log10 p values
261
A: IBD Character
A.3.5 Differentially methylated regions
Using the ‘Lasso’ function in the R package ‘ChAMP’ [443] 1709 differentially
methylated regions of consecutive FDR significant probes were defined. Figure
A.4 shows the variability in probe density in different genomic environments as
found in the IBD Character dataset, and figures A.5 and A.6 (pages 263–264)
show the resulting lasso radii. Table A.6 (267) show the 100 most significant
DMRs as calculated by Stouffler’s method of p value aggregation. These in-
clude VMP1, RUNX3, ITGB2 and DIABLO, replicating findings in the paediatric



























































































































































































































































Figure A.4: Distance to the nearest probe by location (from left to right:
TSS1500, TSS200, 5′UTR, 1st exon, gene body, 3′UTR, and intergenic
region. Colour key in figure A.4), and by CpG density (island, shore,







































Figure A.5: The lasso radii needed for each region type to include a
given proportion of probes. The chosen quantile of 0.44 is indicated.
263
A: IBD Character





























































































































TSS1500 TSS200 5'UTR 1stExon Body 3'UTR IGR
Figure A.6: The range of lasso radii for each region type and CpG density
at the chosen quantile of 0.44
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A.3
Chr Coordinate Gene Size βCD-βHC P value
6 31539945 LTA 1218 0.040 1.19×10−198
5 148808075 MIR143 2164 -0.036 4.66×10−123
1 25291387 RUNX3 804 0.034 1.22×10−122
10 49892711 WDFY4 1095 -0.031 1.74×10−116
14 22974119 DAD1 5443 0.027 1.59×10−99
3 52528946 STAB1 991 -0.036 1.91×10−94
11 118213074 CD3D 1890 0.037 6.88×10−93
12 122711832 DIABLO 313 0.039 2.87×10−91
20 57582789 CTSZ 288 -0.054 3.95×10−90
13 40761318 LINC00332 1984 0.036 5.23×10−85
1 32715264 LCK 4054 0.026 5.68×10−78
21 43823691 UBASH3A 984 0.040 1.50×10−76
2 33358786 LTBP1 983 -0.054 5.13×10−72
1 11795830 AGTRAP 175 -0.048 1.02×10−71
18 21452612 LAMA3 237 0.035 3.78×10−69
20 45179072 C20orf123 460 -0.053 1.45×10−67
10 63808661 ARID5B 922 0.029 6.95×10−67
16 66400202 CDH5 624 -0.045 3.02×10−66
13 34184100 RFC3 2044 0.033 1.93×10−65
11 843830 TSPAN4 3923 -0.028 6.43×10−65
17 62083949 ICAM2 667 -0.035 2.07×10−64
12 111618513 CUX2 1355 -0.024 5.02×10−64
7 81399052 HGF 747 -0.037 7.02×10−64
22 44568219 PARVG 585 -0.040 8.05×10−64
22 45072199 PRR5 1223 -0.030 1.04×10−63
1 154941603 SHC1 4027 -0.034 1.60×10−62
18 21572492 TTC39C 513 0.032 3.34×10−62
11 69259077 CCND1 6413 -0.033 6.57×10−62
11 94278366 FUT4 285 -0.032 3.56×10−61
13 114829084 RASA3 2042 -0.028 1.37×10−59
9 35649015 SIT1 2438 0.034 8.58×10−59
1 153330143 S100A9 1046 -0.040 8.74×10−59
16 3115015 IL32 949 0.026 8.74×10−59
19 13052828 CALR 2498 -0.045 8.74×10−59
7 105319025 ATXN7L1 1207 -0.041 2.38×10−58
4 48135978 TXK 513 0.047 2.97×10−57
1 203734147 LAX1 825 0.039 4.14×10−57
Table A.6: DMRs: Continued overleaf
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A: IBD Character
Chr Coordinate Gene Size βCD-βHC P value
17 79128027 AATK 1943 -0.071 2.40×10−56
17 33775914 SLFN13 69 -0.043 4.38×10−56
7 98738107 SMURF1 1832 0.025 9.87×10−55
17 57915253 VMP1 4338 -0.011 1.12×10−54
12 56414324 IKZF4 237 -0.051 1.51×10−54
12 2733738 CACNA1C 1266 -0.040 2.93×10−54
7 128579095 IRF5 3395 -0.037 3.15×10−54
8 141598729 EIF2C2 1120 0.033 1.01×10−53
15 29213508 APBA2 609 0.023 2.44×10−53
22 42827713 NFAM1 825 -0.024 2.44×10−53
7 5564516 ACTB 3591 0.024 4.28×10−53
17 76129246 TMC8 2142 0.024 1.03×10−52
6 30719248 IER3 2076 -0.041 1.71×10−51
6 31543455 TNF 3454 0.004 1.98×10−51
8 144543156 ZC3H3 1208 0.038 1.98×10−51
8 145024977 PLEC1 284 -0.039 3.20×10−51
17 75314825 SEPT9 1912 -0.026 3.23×10−51
10 72362667 PRF1 245 0.032 1.62×10−50
8 28917989 KIF13B 2078 0.038 1.64×10−50
11 118754309 CXCR5 541 0.021 3.26×10−50
11 67204916 PTPRCAP 2410 0.025 3.72×10−50
17 19289941 MFAP4 940 -0.028 4.36×10−50
12 122443618 BCL7A 1836 0.042 4.74×10−50
1 9788526 PIK3CD 433 0.049 1.16×10−49
2 242801997 PDCD1 205 0.046 2.13×10−49
3 128779558 GP9 72 -0.058 8.52×10−49
22 38714253 CSNK1E 281 -0.030 1.22×10−48
21 46346609 ITGB2 3780 0.025 1.84×10−48
1 167486883 CD247 1163 0.050 2.04×10−48
1 24861795 RCAN3 155 0.048 7.11×10−48
11 818834 PNPLA2 153 -0.048 1.55×10−47
17 78753344 RPTOR 2673 -0.032 2.27×10−47
11 57528999 CTNND1 872 -0.047 2.55×10−47
19 827758 AZU1 825 -0.040 5.01×10−47
17 9939592 GAS7 942 -0.066 8.05×10−47
17 2907266 RAP1GAP2 1516 -0.027 1.37×10−46
17 46622473 HOXB2 4655 -0.029 1.81×10−46
Table A.6: DMRs: Continued overleaf
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Chr Coordinate Gene Size βCD-βHC P value
11 36422121 PRR5L 751 -0.030 3.78×10−46
7 23386953 IGF2BP3 856 -0.061 1.11×10−45
14 101908582 DIO3OS 341 0.033 2.78×10−45
12 53612485 RARG 313 0.024 2.82×10−45
7 139319934 HIPK2 986 0.036 3.76×10−45
19 847924 PRTN3 225 -0.042 5.57×10−45
7 2772854 GNA12 1180 -0.040 6.42×10−45
2 68592260 PLEK 890 -0.033 9.39×10−45
17 27044957 RAB34 376 -0.038 1.10×10−44
2 241642371 KIF1A 3665 0.038 1.11×10−44
5 963398 LOC100506688 2089 0.037 1.95×10−44
12 124864116 NCOR2 978 -0.047 3.13×10−44
11 1951787 TNNT3 1861 -0.032 3.37×10−44
11 64635316 EHD1 943 0.033 6.80×10−44
16 85981140 IRF8 404 0.038 1.02×10−43
17 56355217 MPO 228 -0.051 1.77×10−43
6 158066197 ZDHHC14 1116 -0.054 2.01×10−43
1 211501522 TRAF5 3395 0.026 2.19×10−43
16 4713668 MGRN1 1560 -0.031 6.30×10−43
21 34771577 IFNGR2 3591 -0.039 6.80×10−43
5 154229885 C5orf4 545 -0.049 1.49×10−42
3 15310609 SH3BP5 1073 -0.034 1.67×10−42
1 6526464 TNFRSF25 135 0.033 2.86×10−42
10 97515254 ENTPD1 263 -0.066 3.49×10−42
17 3704386 ITGAE 245 -0.040 6.00×10−42
11 113933403 ZBTB16 1937 0.018 6.01×10−42
Table A.6: Top 100 DMRs between IBD and control in the IBD Char-
acter cohort. Coordinates as per Hg19, coordinate refers to the smallest
coordinate of the DMR bounds, size denotes the width of the DMR in bp.
βCD-βHC shows the difference in mean βvalues by diagnosis. P values as




A.3.6 Methylation quantitative trait loci
After FDR correction, there were 2327 cis-meQTLs. The 100 most significant of
these are shown in table A.7.
SNP Probe Gene P value
rs1932819 cg03990033 CD34 2.06×10−108
rs1109278 cg10460946 LOC100996291 1.47×10−97
rs1109279 cg10460946 LOC100996291 3.37×10−89
rs7567627 cg18991601 FZD5 5.93×10−84
rs1567237 cg10460946 LOC100996291 2.21×10−79
rs886926 cg12582317 MSI2 5.29×10−72
rs9893344 cg12582317 MSI2 2.70×10−71
rs6755821 cg18991601 FZD5 3.54×10−67
rs9657682 cg21240736 LINC00963 5.22×10−66
rs2663879 cg18991601 FZD5 6.46×10−65
rs2663864 cg18991601 FZD5 1.04×10−62
rs3754171 cg03990033 CD34 5.29×10−59
rs2267894 cg03990033 CD34 1.21×10−58
rs11666543 cg08363114 RPS9 1.54×10−50
rs907605 cg08449144 SYT8 9.01×10−50
rs2663887 cg18991601 FZD5 4.61×10−46
rs9500284 cg07967630 GUSBP4 6.01×10−46
rs1891818 cg07967630 GUSBP4 7.52×10−43
rs2070946 cg18663307 ITGB2 3.14×10−42
rs2070946 cg04321224 ITGB2 5.69×10−42
rs3741231 cg08449144 SYT8 7.00×10−40
rs3900115 cg12105450 CASP10 8.01×10−39
rs9892194 cg12582317 MSI2 1.20×10−38
rs415890 cg24160243 RPS6KA2 1.03×10−37
rs12693932 cg12105450 CASP10 2.25×10−37
rs394522 cg24160243 RPS6KA2 3.74×10−37
rs3834129 cg12105450 CASP10 1.16×10−35
rs12693931 cg12105450 CASP10 1.39×10−35
rs1147332 cg21240736 LINC00963 1.58×10−35
rs7576306 cg12105450 CASP10 3.84×10−35
rs10188598 cg12105450 CASP10 1.16×10−34
rs4793573 cg12582317 MSI2 1.37×10−34
rs3769827 cg12105450 CASP10 1.26×10−32
Table A.7: MeQTLs: Continued overleaf
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SNP Probe Gene P value
rs1594 cg12105450 CASP10 2.30×10−32
rs12029239 cg03990033 CD34 8.22×10−32
rs2298803 cg17515347 AIM2 6.79×10−31
rs2236313 cg24160243 RPS6KA2 4.64×10−29
rs2236313 cg24160243 RPS6KA2 4.64×10−29
rs9459836 cg24160243 RPS6KA2 2.98×10−27
rs9306118 cg04321224 ITGB2 5.59×10−27
rs11672654 cg08363114 RPS9 6.20×10−27
rs144494015 cg16932065 LIMK2 1.74×10−26
rs9306118 cg18663307 ITGB2 1.92×10−26
rs4506048 cg07967630 GUSBP4 2.40×10−26
rs7818871 cg14722693 CSGALNACT1 3.99×10−26
rs1014482 cg14722693 CSGALNACT1 1.70×10−25
rs10107533 cg14722693 CSGALNACT1 4.22×10−25
rs8078424 cg12054453 VMP1 4.44×10−25
rs2849030 cg12616487 EML3 4.96×10−25
rs11231155 cg12616487 EML3 5.25×10−25
rs2301436 cg24160243 RPS6KA2 5.92×10−25
rs2301436 cg24160243 RPS6KA2 1.25×10−24
rs11231156 cg12616487 EML3 1.57×10−24
rs17009223 cg03990033 CD34 1.70×10−24
rs11231154 cg12616487 EML3 2.43×10−24
rs2273843 cg03875678 GZMB 5.39×10−24
rs2509982 cg12616487 EML3 7.76×10−24
rs3903046 cg07967630 GUSBP4 7.91×10−24
rs2256964 cg15082870 SEPT7 8.10×10−24
rs7749278 cg24160243 RPS6KA2 9.26×10−24
rs7124057 cg12616487 EML3 1.02×10−23
rs11142402 cg00049440 KLF9 1.58×10−23
rs2302479 cg07698196 TMEM176B 2.43×10−23
rs962927 cg15429134 BORCS5 2.70×10−23
rs9645752 cg15429134 BORCS5 5.39×10−23
rs1056448 cg00049440 KLF9 5.70×10−23
rs8078424 cg16936953 VMP1 8.91×10−23
rs10868824 cg00049440 KLF9 1.08×10−22
rs11553576 cg12616487 EML3 1.22×10−22
rs3769825 cg12105450 CASP10 2.81×10−22
Table A.7: MeQTLs: Continued overleaf
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SNP Probe Gene P value
rs9650314 cg02508743 LYN 7.44×10−22
rs10845552 cg15429134 BORCS5 1.27×10−21
rs4921659 cg14722693 CSGALNACT1 1.38×10−21
rs2070946 cg24707889 ITGB2 1.52×10−21
rs933575 cg15429134 BORCS5 2.07×10−21
rs2838738 cg18663307 ITGB2 3.20×10−21
rs79885699 cg10460946 LOC100996291 3.39×10−21
rs10051822 cg25368647 MXD3 5.93×10−21
rs7818368 cg14722693 CSGALNACT1 6.50×10−21
rs1147331 cg21240736 LINC00963 6.86×10−21
rs10853015 cg12054453 VMP1 7.45×10−21
rs2667978 cg02508743 LYN 7.49×10−21
rs3018561 cg12616487 EML3 1.06×10−20
rs10281675 cg07698196 TMEM176B 1.76×10−20
rs2256964 cg16805291 SEPT7 1.84×10−20
rs2516633 cg12616487 EML3 2.85×10−20
rs2333562 cg12054453 VMP1 2.97×10−20
rs2777891 cg12054453 VMP1 2.97×10−20
rs9355610 cg24160243 RPS6KA2 6.77×10−20
rs933243 cg24160243 RPS6KA2 7.44×10−20
rs11869228 cg12054453 VMP1 7.64×10−20
rs2838738 cg04321224 ITGB2 1.00×10−19
rs3782287 cg14849578 SCARB1 1.88×10−19
rs9909324 cg12054453 VMP1 2.02×10−19
rs9789054 cg12582317 MSI2 2.21×10−19
rs989892 cg14849578 SCARB1 3.29×10−19
rs7221815 cg12054453 VMP1 3.85×10−19
rs10853015 cg16936953 VMP1 4.14×10−19
rs3173833 cg07698196 TMEM176B 4.75×10−19
rs3173833 cg07698196 TMEM176B 4.75×10−19





The complete tables of significant results for IBD, CD, UC, and CD vs UC from
the preliminary analysis of the IBD Character dataset are shown below.
MAF Probe Chr Coord Gene LogFC P Value
0.027 cg09349128 22 50327986 * CRELD2 -0.25 8.41 ×10−21
cg12054453 17 57915717 VMP1 -0.55 3.66 ×10−20
cg17501210 6 166970252 RPS6KA2 -0.13 1.08 ×10−19
cg12170787 19 1130965 SBNO2 -0.13 2.70 ×10−19
cg18608055 19 1130866 SBNO2 -0.16 2.85 ×10−19
cg07573872 19 1126342 SBNO2 -0.15 2.22 ×10−18
cg16936953 17 57915665 VMP1 -0.32 4.05 ×10−18
cg27469606 19 1154485 SBNO2 -0.06 2.73 ×10−17
cg01059398 3 172235808 TNFSF10 -0.15 1.15 ×10−15
cg02650017 17 47301614 PHOSPHO1 -0.31 1.32 ×10−15
cg18513344 3 195531298 MUC4 -0.14 5.45 ×10−15
cg03156547 14 23525003 CDH24 -0.05 1.68 ×10−14
cg24002003 15 101668143 † CHSY1 -0.14 1.76 ×10−14
cg02716826 9 33447032 AQP3 -0.17 1.95 ×10−14
cg06164260 3 187454439 BCL6 -0.08 2.91 ×10−14
cg13781414 9 138951648 NACC2 -0.06 8.55 ×10−14
cg10636246 1 159046973 * AIM2 -0.21 1.74 ×10−13
cg18942579 17 57915773 VMP1 -0.22 1.75 ×10−13
cg01983725 1 227161799 ADCK3 -0.04 4.23 ×10−13
cg19821297 19 12890029 * HOOK2 -0.16 5.70 ×10−13
cg16292768 8 27467783 CLU -0.14 5.73 ×10−13
cg00159243 12 109023799 SELPLG -0.18 6.96 ×10−13
cg02734358 4 90227074 GPRIN3 -0.20 7.27 ×10−13
cg13447080 8 131054408 * ASAP1 -0.08 1.18 ×10−12
cg11393173 1 116369577 * NHLH2 -0.10 1.29 ×10−12
cg15551881 9 123688715 TRAF1 0.26 1.68 ×10−12
cg01409343 17 57915740 VMP1 -0.16 1.77 ×10−12
cg03029755 17 76265444 LOC100996291 -0.07 3.21 ×10−12
cg24129923 17 7814251 CHD3 0.06 3.36 ×10−12
cg03998636 13 111210121 RAB20 -0.08 7.83 ×10−12
cg20995564 2 145172035 ZEB2 -0.25 1.05 ×10−11
0.159 cg13028635 11 1871244 * LSP1 0.05 1.06 ×10−11
Table A.8: IBD Results: Continued overleaf
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MAF Probe Chr Coord Gene LogFC P Value
cg12269535 6 43142014 SRF -0.09 1.26 ×10−11
cg10967866 10 134362164 INPP5A 0.09 2.22 ×10−11
cg12992827 3 101901234 ZPLD1 -0.17 2.60 ×10−11
cg19281794 3 112218761 * BTLA 0.22 2.81 ×10−11
0.012 cg13789303 6 108886681 FOXO3 0.12 3.02 ×10−11
cg21190595 11 3071167 CARS -0.07 3.73 ×10−11
cg20962215 19 54713514 * RPS9 -0.07 3.84 ×10−11
cg13165240 17 3715743 NCBP3 0.09 5.28 ×10−11
cg13442606 11 3071269 CARS -0.05 6.29 ×10−11
cg02341197 21 34185927 C21orf62 0.13 6.94 ×10−11
0.015 cg19283354 17 41851905 DUSP3 -0.06 7.06 ×10−11
cg12582317 17 55822272 † MSI2 0.09 1.01 ×10−10
cg07793033 16 85256423 † LINC00311 0.07 1.08 ×10−10
cg08449144 11 1857919 SYT8 -0.05 1.40 ×10−10
0.500 cg02782634 17 57916643 VMP1 -0.14 1.44 ×10−10
cg13585930 10 72027357 NPFFR1 -0.15 1.45 ×10−10
cg23556574 10 13981154 FRMD4A 0.07 1.55 ×10−10
cg03940776 6 158490013 SYNJ2 -0.08 1.88 ×10−10
cg14849578 12 125282480 SCARB1 0.06 1.97 ×10−10
cg12680205 10 80303482 LINC00856 -0.07 2.23 ×10−10
cg18860310 4 87752504 SLC10A6 -0.10 3.00 ×10−10
cg08159663 16 57022486 * NLRC5 -0.05 3.17 ×10−10
cg10515048 14 50697283 SOS2 0.19 3.45 ×10−10
cg15772366 6 111926749 TRAF3IP2 0.24 3.61 ×10−10
cg19137806 10 134362170 INPP5A 0.07 4.49 ×10−10
cg20692268 1 25358981 † RUNX3 -0.13 4.80 ×10−10
cg22488164 12 14716910 PLBD1 0.08 4.94 ×10−10
cg04848343 19 4544095 SEMA6B 0.08 5.10 ×10−10
cg10472711 7 797592 DNAAF5 -0.08 5.29 ×10−10
cg13590277 5 150019496 SYNPO -0.05 5.80 ×10−10
cg17260706 11 118782879 * BCL9L -0.09 6.41 ×10−10
cg04321224 21 46341380 ITGB2 0.15 7.83 ×10−10
cg18734877 8 27297419 PTK2B -0.07 8.02 ×10−10
cg18663307 21 46341389 ITGB2 0.16 8.87 ×10−10
cg12370935 17 16976475 MPRIP -0.06 9.53 ×10−10
cg09018739 16 57180107 CPNE2 0.07 1.06 ×10−9
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cg11859594 17 76755745 CYTH1 0.15 1.09 ×10−9
cg25739715 22 30663881 * OSM -0.17 1.09 ×10−9
cg26804423 7 8201134 ICA1 0.07 1.20 ×10−9
cg15981982 2 8685837 ‡ ID2 -0.08 1.22 ×10−9
cg04324276 17 17817462 TOM1L2 -0.07 1.25 ×10−9
cg20748397 17 18062972 MYO15A -0.04 1.33 ×10−9
cg05279866 8 37378355 ‡ ZNF703 0.07 1.36 ×10−9
cg01145119 8 144441955 TOP1MT 0.06 1.45 ×10−9
cg15321908 3 53187213 * PRKCD -0.05 1.46 ×10−9
cg10460946 17 76247467 * LOC100996291 -0.28 1.46 ×10−9
cg02464912 14 64319543 * SYNE2 -0.22 1.50 ×10−9
cg13997435 1 153538406 * S100A2 -0.05 1.58 ×10−9
cg00049440 9 73026643 KLF9 -0.19 1.70 ×10−9
cg05968822 1 226071684 * TMEM63A 0.06 1.85 ×10−9
cg06946543 13 76377366 LMO7 0.17 2.03 ×10−9
cg17901584 1 55353706 * DHCR24 -0.12 2.16 ×10−9
cg08289839 13 111318640 CARS2 0.05 2.35 ×10−9
cg00053916 8 37457329 † ZNF703 0.04 2.59 ×10−9
cg23172671 1 203482523 * OPTC 0.18 2.65 ×10−9
cg22356061 1 227954102 SNAP47 -0.10 2.89 ×10−9
cg04987734 14 103415873 CDC42BPB 0.11 2.96 ×10−9
cg14722693 8 19436451 CSGALNACT1 -0.08 3.05 ×10−9
cg12594635 12 54129457 * CALCOCO1 -0.04 3.07 ×10−9
cg12669088 12 25541364 † LMNTD1 -0.06 3.45 ×10−9
cg21773162 2 98330087 ZAP70 -0.05 3.65 ×10−9
cg20701457 17 62084342 ICAM2 -0.05 3.72 ×10−9
cg16755067 17 72259202 * TTYH2 -0.04 3.88 ×10−9
cg18181703 17 76354621 SOCS3 -0.11 3.96 ×10−9
cg02538891 9 139549426 * EGFL7 -0.05 3.96 ×10−9
cg26227957 1 19547285 EMC1 0.08 4.10 ×10−9
cg20141108 1 165907859 † UCK2 0.09 4.25 ×10−9
cg16736826 1 41951512 * EDN2 -0.06 4.43 ×10−9
0.023 cg11415156 2 20779199 † HS1BP3 -0.06 4.61 ×10−9
cg26470501 19 45252955 BCL3 -0.08 4.91 ×10−9
cg00490406 1 159046773 * AIM2 -0.25 5.26 ×10−9
cg25368647 5 176736591 MXD3 -0.09 5.35 ×10−9
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cg15429134 12 12619103 BORCS5 0.15 5.71 ×10−9
cg20775254 2 95940705 PROM2 -0.04 5.78 ×10−9
0.233 cg18991601 2 208635549 * FZD5 0.19 5.82 ×10−9
cg05318454 19 46117805 EML2 -0.06 5.84 ×10−9
cg17803993 3 71276214 FOXP1 -0.14 6.43 ×10−9
cg03147185 2 97008030 NCAPH -0.05 7.01 ×10−9
cg18363008 17 4675114 * TM4SF5 -0.05 7.04 ×10−9
cg07698196 7 150485638 * TMEM176B -0.08 7.75 ×10−9
cg14989316 10 80757927 ZMIZ1-AS1 -0.06 8.24 ×10−9
cg24437104 1 227951794 SNAP47 -0.05 8.39 ×10−9
cg24215776 11 65152051 * SLC25A45 -0.09 8.54 ×10−9
cg24536818 12 55371892 TESPA1 0.22 8.72 ×10−9
cg26158270 11 12309622 MICALCL -0.06 8.80 ×10−9
cg23902264 1 241815413 * WDR64 0.09 8.89 ×10−9
cg06383241 12 116997022 * MAP1LC3B2 -0.20 9.01 ×10−9
cg20408175 12 53693169 PFDN5 -0.05 9.06 ×10−9
cg07267600 12 2750053 CACNA1C -0.11 9.28 ×10−9
cg26663590 16 28959310 * NFATC2IP 0.10 9.53 ×10−9
cg04310331 11 2012332 * MRPL23-AS1 -0.08 9.74 ×10−9
cg25132241 14 92396859 FBLN5 0.04 1.05 ×10−8
cg21727145 15 101458127 * ALDH1A3 0.07 1.05 ×10−8
cg08539067 3 49395985 * GPX1 -0.18 1.07 ×10−8
cg02508743 8 56903623 LYN 0.14 1.13 ×10−8
cg15082870 7 36022841 † SEPT7 0.08 1.19 ×10−8
cg25114611 6 35696870 LOC285847 -0.12 1.27 ×10−8
cg07120889 1 150535935 * ADAMTSL4 -0.11 1.29 ×10−8
cg14303526 10 101609768 ABCC2 0.07 1.39 ×10−8
cg26680989 16 85560739 † GSE1 0.06 1.47 ×10−8
cg25112191 1 151804260 RORC -0.08 1.49 ×10−8
cg16809457 6 90399677 MDN1 0.08 1.53 ×10−8
cg04496906 8 145101182 SPATC1 -0.05 1.55 ×10−8
cg16505704 13 80378331 ‡ NDFIP2 0.05 1.65 ×10−8
cg01209199 6 43274833 CRIP3 -0.03 1.67 ×10−8
cg11313780 8 103817950 † AZIN1 -0.06 1.77 ×10−8
cg07683636 2 219940977 NHEJ1 0.04 1.81 ×10−8
cg18637901 4 3247372 * HTT -0.04 1.99 ×10−8
Table A.8: IBD Results: Continued overleaf
274
A.4
MAF Probe Chr Coord Gene LogFC P Value
cg10330371 7 122527499 * CADPS2 0.15 2.05 ×10−8
cg10773266 10 43895225 HNRNPF -0.07 2.17 ×10−8
cg12053291 12 125282342 SCARB1 0.04 2.42 ×10−8
cg12308965 11 67291387 * CABP2 -0.04 2.43 ×10−8
cg01026383 6 32905012 HLA-DMB 0.03 2.48 ×10−8
cg07035242 1 11336263 UBIAD1 0.05 2.50 ×10−8
cg14114377 19 45756845 MARK4 -0.05 2.56 ×10−8
cg03875678 14 25103546 * GZMB -0.10 2.61 ×10−8
cg22562591 8 82002977 PAG1 0.15 2.70 ×10−8
cg02003183 14 103415882 CDC42BPB 0.23 2.71 ×10−8
cg07967630 6 58149317 † GUSBP4 0.22 2.73 ×10−8
cg04095776 6 31106941 PSORS1C1 -0.04 2.77 ×10−8
cg14355374 10 3850160 † KLF6 -0.05 2.82 ×10−8
cg08913523 8 126649807 ‡ TRIB1 -0.16 2.86 ×10−8
cg26748477 17 38516415 RARA -0.05 2.86 ×10−8
cg06724236 14 67853825 PLEK2 0.09 3.06 ×10−8
cg14269477 7 142630597 TRPV5 -0.02 3.30 ×10−8
cg17602444 7 644819 PRKAR1B -0.08 3.42 ×10−8
cg20271330 1 204338515 LINC00628 -0.05 3.52 ×10−8
cg16757384 12 125030150 NCOR2 -0.08 3.56 ×10−8
cg12459502 18 60904237 BCL2 0.08 3.93 ×10−8
cg21518947 11 67222648 CABP4 -0.03 3.97 ×10−8
cg24073994 17 38511770 RARA -0.03 3.99 ×10−8
cg20691205 13 36919674 SPG20 0.11 4.06 ×10−8
cg05820066 16 75145843 LDHD -0.08 4.14 ×10−8
cg03845363 17 17753516 TOM1L2 -0.10 4.54 ×10−8
cg05316065 8 130799007 GSDMC -0.07 4.62 ×10−8
cg18143317 11 2037124 † H19 -0.04 4.74 ×10−8
0.017 cg13150925 12 124529439 FAM101A 0.09 4.75 ×10−8
cg03432225 1 228294401 MRPL55 -0.03 4.90 ×10−8
cg15614653 2 129104464 † HS6ST1 -0.04 4.93 ×10−8
cg05246110 11 68238943 PPP6R3 -0.04 4.94 ×10−8
cg17332198 12 58209913 * AVIL -0.07 4.98 ×10−8
cg25840433 6 167104903 RPS6KA2 -0.04 5.16 ×10−8
cg15050111 1 24645850 GRHL3 0.16 5.47 ×10−8
cg00705600 4 185820660 * LINC01093 -0.05 5.82 ×10−8
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cg18131689 11 22214333 * ANO5 0.10 5.83 ×10−8
cg23866916 19 1155738 SBNO2 -0.06 6.01 ×10−8
cg05937055 1 181128764 † IER5 -0.10 6.46 ×10−8
cg05946309 16 85926085 * IRF8 0.03 6.82 ×10−8
cg18396675 17 56605391 SEPT4 -0.03 6.82 ×10−8
0.017 cg04389058 3 57041402 ARHGEF3 -0.06 7.14 ×10−8
cg21337881 17 5138645 LOC100130950 0.06 7.27 ×10−8
cg00009293 7 44151172 AEBP1 -0.03 7.31 ×10−8
cg12616487 11 62379063 EML3 -0.04 7.86 ×10−8
cg14965639 2 48795994 STON1-GTF2A1L -0.17 8.71 ×10−8
cg00908292 17 38699009 † CCR7 -0.07 8.81 ×10−8
cg02345399 11 65195039 NEAT1 -0.07 8.88 ×10−8
0.01 cg07539709 17 80545454 FOXK2 0.10 8.89 ×10−8
cg00107490 22 19509318 * CDC45 -0.02 9.56 ×10−8
cg24637035 12 120445227 CCDC64 0.11 9.58 ×10−8
cg11267810 20 19867026 * RIN2 0.03 9.75 ×10−8
cg12687767 20 19870109 RIN2 -0.05 1.01 ×10−7
Table A.8: Illumina 450k probes with Bonferroni significant IBD-
associated methylation changes in the IBD Character cohort. Where
the probe is not in a gene the nearest gene is given with an indication of
distance: *<10kb, †<100kb, ‡>100kb. Where the is a SNP within 10bp
the MAF (or highest if there are multiple) is shown on the left.
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cg12170787 19 1130965 SBNO2 -0.16 1.45 ×10−22
cg18608055 19 1130866 SBNO2 -0.20 5.52 ×10−21
0.027 cg09349128 22 50327986 * CRELD2 -0.28 1.13 ×10−18
cg12054453 17 57915717 VMP1 -0.63 1.58 ×10−17
cg17501210 6 166970252 RPS6KA2 -0.14 4.26 ×10−17
cg07573872 19 1126342 SBNO2 -0.16 9.54 ×10−17
cg16936953 17 57915665 VMP1 -0.32 1.72 ×10−14
cg27469606 19 1154485 SBNO2 -0.06 2.21 ×10−14
cg01059398 3 172235808 TNFSF10 -0.16 3.12 ×10−12
cg10967866 10 134362164 INPP5A 0.11 3.18 ×10−12
cg18513344 3 195531298 MUC4 -0.14 4.29 ×10−12
cg15551881 9 123688715 TRAF1 0.31 8.30 ×10−12
cg20141108 1 165907859 † UCK2 0.12 9.63 ×10−12
cg19821297 19 12890029 * HOOK2 -0.17 1.04 ×10−11
cg13781414 9 138951648 NACC2 -0.06 1.23 ×10−11
cg18181703 17 76354621 SOCS3 -0.14 1.35 ×10−11
cg02650017 17 47301614 PHOSPHO1 -0.32 2.14 ×10−11
cg16292768 8 27467783 CLU -0.15 3.51 ×10−11
cg18942579 17 57915773 VMP1 -0.23 6.68 ×10−11
cg03940776 6 158490013 SYNJ2 -0.09 1.07 ×10−10
cg26804423 7 8201134 ICA1 0.08 1.31 ×10−10
cg19137806 10 134362170 INPP5A 0.09 1.54 ×10−10
0.027 cg19281794 3 112218761 * BTLA 0.25 2.25 ×10−10
cg01409343 17 57915740 VMP1 -0.17 2.49 ×10−10
cg20995564 2 145172035 ZEB2 -0.25 2.93 ×10−10
cg20701457 17 62084342 ICAM2 -0.07 4.93 ×10−10
cg01145119 8 144441955 TOP1MT 0.07 5.00 ×10−10
cg00159243 12 109023799 SELPLG -0.19 5.63 ×10−10
cg23172671 1 203482523 * OPTC 0.23 1.19 ×10−9
cg25112191 1 151804260 RORC -0.10 1.49 ×10−9
cg12269535 6 43142014 SRF -0.09 2.98 ×10−9
cg13573513 12 14996143 ART4 0.11 3.19 ×10−9
cg15082870 7 36022841 † SEPT7 0.10 3.53 ×10−9
cg06164260 3 187454439 BCL6 -0.07 3.90 ×10−9
cg24002003 15 101668143 † CHSY1 -0.13 4.74 ×10−9
cg26340740 11 58980377 MPEG1 0.18 5.16 ×10−9
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cg12535090 11 20071677 NAV2 0.05 6.13 ×10−9
cg01983725 1 227161799 ADCK3 -0.04 7.78 ×10−9
cg21727145 15 101458127 * ALDH1A3 0.08 7.82 ×10−9
cg09018739 16 57180107 CPNE2 0.08 7.87 ×10−9
0.500 cg02782634 17 57916643 VMP1 -0.14 8.70 ×10−9
cg26227957 1 19547285 EMC1 0.09 1.06 ×10−8
cg19695507 10 13526193 BEND7 0.20 1.07 ×10−8
cg03029755 17 76265444 LOC100996291 -0.07 1.08 ×10−8
cg08363114 19 54711292 RPS9 -0.14 1.19 ×10−8
0.159 cg13028635 11 1871244 * LSP1 0.06 1.25 ×10−8
cg03998636 13 111210121 RAB20 -0.07 1.40 ×10−8
cg19769147 14 105860954 PACS2 0.06 1.40 ×10−8
cg16395997 1 3562798 WRAP73 0.11 1.47 ×10−8
cg12992827 3 101901234 ZPLD1 -0.15 1.96 ×10−8
cg05272827 17 79380706 BAHCC1 0.13 2.07 ×10−8
cg00705600 4 185820660 * LINC01093 -0.05 2.20 ×10−8
cg16809457 6 90399677 MDN1 0.09 2.23 ×10−8
cg01026383 6 32905012 HLA-DMB 0.04 2.64 ×10−8
0.012 cg11551560 15 70528789 ‡ TLE3 0.08 2.92 ×10−8
cg08289839 13 111318640 CARS2 0.06 2.96 ×10−8
0.196 cg15599437 5 40676198 * PTGER4 0.29 3.06 ×10−8
cg22488164 12 14716910 PLBD1 0.09 3.76 ×10−8
cg02716826 9 33447032 AQP3 -0.15 4.03 ×10−8
cg14989316 10 80757927 ZMIZ1-AS1 -0.07 4.12 ×10−8
cg13139542 2 8242815 LINC00299 0.09 4.77 ×10−8
cg06724236 14 67853825 PLEK2 0.11 5.90 ×10−8
cg02341197 21 34185927 C21orf62 0.13 6.44 ×10−8
cg10508317 17 76355146 SOCS3 -0.26 6.66 ×10−8
cg07793033 16 85256423 † LINC00311 0.07 6.73 ×10−8
cg17901584 1 55353706 * DHCR24 -0.13 6.77 ×10−8
cg10460946 17 76247467 * LOC100996291 -0.30 6.78 ×10−8
cg05279866 8 37378355 ‡ ZNF703 0.08 7.25 ×10−8
cg17953136 2 20232577 LAPTM4A 0.12 7.30 ×10−8
cg07298772 2 176306492 ‡ ATP5G3 0.22 7.45 ×10−8
cg10472711 7 797592 DNAAF5 -0.08 7.74 ×10−8
cg23866916 19 1155738 SBNO2 -0.07 7.90 ×10−8
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cg23556574 10 13981154 FRMD4A 0.08 8.43 ×10−8
cg04321224 21 46341380 ITGB2 0.16 8.48 ×10−8
cg09287328 10 134231487 * PWWP2B 0.12 8.56 ×10−8
cg26663590 16 28959310 * NFATC2IP 0.11 8.74 ×10−8
cg18663307 21 46341389 ITGB2 0.18 8.78 ×10−8
cg15614653 2 129104464 † HS6ST1 -0.05 9.07 ×10−8
cg10636246 1 159046973 * AIM2 -0.19 9.75 ×10−8
cg17330097 1 206316676 * CTSE 0.08 9.03 ×10−8
cg18860310 4 87752504 SLC10A6 -0.10 1.02 ×10−7
Table A.9: Illumina 450k probes with Bonferroni significant CD-
associated methylation changes in the IBD Character cohort. Where
the probe is not in a gene the nearest gene is given with an indication of
distance: *<10kb, †<100kb, ‡>100kb. Where the is a SNP within 10bp
the MAF (or highest if there are multiple) is shown on the left.
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0.027 cg09349128 22 50327986 * CRELD2 -0.26 1.32 ×10−17
cg16936953 17 57915665 VMP1 -0.34 1.50 ×10−15
cg12054453 17 57915717 VMP1 -0.55 4.01 ×10−15
cg17501210 6 166970252 RPS6KA2 -0.13 6.74 ×10−15
cg07573872 19 1126342 SBNO2 -0.16 8.53 ×10−15
cg24002003 15 101668143 † CHSY1 -0.17 1.16 ×10−14
cg18608055 19 1130866 SBNO2 -0.15 7.02 ×10−14
cg08449144 11 1857919 SYT8 -0.07 9.23 ×10−14
cg06164260 3 187454439 BCL6 -0.09 1.09 ×10−13
cg02650017 17 47301614 PHOSPHO1 -0.34 1.59 ×10−13
cg27469606 19 1154485 SBNO2 -0.06 2.02 ×10−13
cg01059398 3 172235808 TNFSF10 -0.17 2.68 ×10−13
cg02716826 9 33447032 AQP3 -0.19 7.34 ×10−13
cg10636246 1 159046973 * AIM2 -0.25 1.56 ×10−12
cg01983725 1 227161799 ADCK3 -0.04 1.77 ×10−12
cg03156547 14 23525003 CDH24 -0.05 2.38 ×10−12
cg20995564 2 145172035 ZEB2 -0.29 3.54 ×10−12
cg03039243 1 2782699 † TTC34 -0.07 5.87 ×10−12
cg02734358 4 90227074 GPRIN3 -0.24 6.26 ×10−12
cg12170787 19 1130965 SBNO2 -0.11 6.69 ×10−12
cg18513344 3 195531298 MUC4 -0.14 6.81 ×10−11
cg11393173 1 116369577 * NHLH2 -0.11 7.56 ×10−12
cg18942579 17 57915773 VMP1 -0.24 9.39 ×10−12
cg13442606 11 3071269 CARS -0.07 1.04 ×10−11
cg24129923 17 7814251 CHD3 0.07 1.45 ×10−11
cg19821297 19 12890029 * HOOK2 -0.17 1.59 ×10−11
cg13447080 8 131054408 * ASAP1 -0.09 1.68 ×10−11
cg12680205 10 80303482 LINC00856 -0.08 1.73 ×10−11
cg12992827 3 101901234 ZPLD1 -0.20 1.75 ×10−11
cg14849578 12 125282480 SCARB1 0.08 1.84 ×10−11
cg15981982 2 8685837 ‡ ID2 -0.10 2.07 ×10−11
cg15321908 3 53187213 * PRKCD -0.07 2.23 ×10−11
cg25840433 6 167104903 RPS6KA2 -0.07 2.33 ×10−11
cg03998636 13 111210121 RAB20 -0.09 2.72 ×10−11
cg21190595 11 3071167 CARS -0.08 3.25 ×10−11
cg00159243 12 109023799 SELPLG -0.20 3.87 ×10−11
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cg04436528 8 143554875 ADGRB1 -0.05 4.22 ×10−11
cg18860310 4 87752504 SLC10A6 -0.13 4.69 ×10−11
0.015 cg19283354 17 41851905 DUSP3 -0.08 4.79 ×10−11
cg13781414 9 138951648 NACC2 -0.06 1.72 ×10−10
cg22488164 12 14716910 PLBD1 0.10 7.29 ×10−10
cg16292768 8 27467783 CLU -0.14 6.17 ×10−10
cg13165240 17 3715743 NCBP3 0.11 1.10 ×10−10
cg03029755 17 76265444 LOC100996291 -0.08 5.50 ×10−10
cg10472711 7 797592 DNAAF5 -0.10 2.30 ×10−10
cg13028635 11 1871244 * LSP1 0.06 4.06 ×10−10
cg02341197 21 34185927 C21orf62 0.14 3.53 ×10−10
cg20962215 19 54713514 * RPS9 -0.07 2.87 ×10−10
cg12669088 12 25541364 † LMNTD1 -0.08 6.50 ×10−10
cg26227957 1 19547285 EMC1 0.10 5.60 ×10−10
cg05318454 19 46117805 EML2 -0.07 2.56 ×10−10
cg03147185 2 97008030 NCAPH -0.07 2.61 ×10−10
cg18363008 17 4675114 * TM4SF5 -0.07 1.64 ×10−10
cg06383241 12 116997022 * MAP1LC3B2 -0.26 2.92 ×10−10
cg20408175 12 53693169 PFDN5 -0.07 2.24 ×10−10
cg08913523 8 126649807 ‡ TRIB1 -0.21 9.96 ×10−10
cg15050111 1 24645850 GRHL3 0.23 1.55 ×10−10
cg15557758 1 13828828 LRRC38 -0.04 5.20 ×10−10
cg18396675 17 56605391 SEPT4 -0.05 6.31 ×10−10
cg09803002 11 119039103 * NLRX1 -0.04 2.68 ×10−10
cg04782146 16 85112370 KIAA0513 0.07 5.56 ×10−10
cg07168939 8 143763412 PSCA -0.08 6.01 ×10−10
cg08463231 15 78103228 ‡ LOC645752 -0.05 1.01 ×10−9
cg11986385 11 19628828 NAV2 -0.05 1.11 ×10−9
cg05007163 22 39266069 CBX6 -0.05 1.11 ×10−9
cg04299274 17 25798741 * KSR1 -0.05 1.13 ×10−9
cg10330371 7 122527499 * CADPS2 0.20 1.16 ×10−9
cg09419102 11 65550444 * AP5B1 -0.05 1.24 ×10−9
cg10773266 10 43895225 HNRNPF -0.10 1.25 ×10−9
cg20692268 1 25358981 † RUNX3 -0.15 1.32 ×10−9
cg18583702 2 3700907 * ALLC -0.04 1.43 ×10−9
cg16736826 1 41951512 * EDN2 -0.08 1.46 ×10−9
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cg00193668 9 35814283 HINT2 -0.09 1.53 ×10−9
cg26325174 14 101360687 * MEG8 -0.05 1.57 ×10−9
cg20691205 13 36919674 SPG20 0.15 1.79 ×10−9
cg01409343 17 57915740 VMP1 -0.16 1.81 ×10−9
cg24926042 12 52799999 KRT82 -0.04 1.87 ×10−9
cg26748477 17 38516415 RARA -0.07 1.97 ×10−9
cg03179542 7 2647333 IQCE -0.07 2.75 ×10−9
cg27115863 22 37921640 * CARD10 -0.16 2.79 ×10−9
cg26501007 8 126614261 ‡ TRIB1 -0.09 2.88 ×10−9
cg20748397 17 18062972 MYO15A -0.05 2.94 ×10−9
cg12594635 12 54129457 * CALCOCO1 -0.05 2.95 ×10−9
cg00014260 8 10383071 PRSS55 -0.05 3.10 ×10−9
cg08539067 3 49395985 * GPX1 -0.22 3.15 ×10−9
cg15772366 6 111926749 TRAF3IP2 0.28 3.23 ×10−9
cg10967866 10 134362164 INPP5A 0.09 3.28 ×10−9
cg03241649 19 44405924 LOC100505715 0.15 3.46 ×10−9
cg05316065 8 130799007 GSDMC -0.09 3.54 ×10−9
cg04321224 21 46341380 ITGB2 0.17 3.81 ×10−9
cg12616487 11 62379063 EML3 -0.06 4.21 ×10−9
cg18663307 21 46341389 ITGB2 0.19 4.27 ×10−9
cg14722693 8 19436451 CSGALNACT1 -0.09 4.28 ×10−9
cg12682367 13 24523698 * ANKRD20A19P -0.05 4.44 ×10−9
cg04496906 8 145101182 SPATC1 -0.07 4.59 ×10−9
cg13585930 10 72027357 NPFFR1 -0.16 4.72 ×10−9
cg22788465 5 131398845 IL3 -0.07 4.84 ×10−9
cg18506744 19 1102627 * GPX4 -0.17 5.00 ×10−9
cg20711030 7 150897624 * ABCF2 -0.05 5.19 ×10−9
cg13590277 5 150019496 SYNPO -0.06 5.53 ×10−9
cg15647725 5 1091936 SLC12A7 -0.04 5.55 ×10−9
cg26325867 6 41398693 † NCR2 -0.07 5.66 ×10−9
cg21448513 8 57103638 PLAG1 -0.06 5.71 ×10−9
cg27343325 20 3649247 ADAM33 -0.04 6.25 ×10−9
cg05824755 1 120613447 * NOTCH2 -0.04 6.26 ×10−9
cg05279866 8 37378355 ‡ ZNF703 0.08 6.30 ×10−9
cg23662734 17 16386804 LRRC75A -0.04 6.40 ×10−9
cg25739715 22 30663881 * OSM -0.19 6.43 ×10−9
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cg01209199 6 43274833 CRIP3 -0.04 6.59 ×10−9
cg17433678 10 3135764 PFKP -0.15 6.86 ×10−9
cg00490406 1 159046773 * AIM2 -0.31 6.88 ×10−9
cg04563718 1 2565777 * MMEL1 -0.05 7.03 ×10−9
cg02464912 14 64319543 * SYNE2 -0.26 7.72 ×10−9
cg04742397 14 95986554 † SNHG10 -0.12 8.20 ×10−9
cg10241823 17 841205 NXN 0.09 8.67 ×10−9
cg12274082 6 32007986 CYP21A2 -0.04 8.81 ×10−9
cg07035242 1 11336263 UBIAD1 0.06 9.11 ×10−9
cg19054096 20 59868424 CDH4 -0.04 9.18 ×10−9
cg14355374 10 3850160 † KLF6 -0.06 9.18 ×10−9
cg17206420 2 27482803 SLC30A3 -0.06 9.22 ×10−9
cg00705600 4 185820660 * LINC01093 -0.06 1.00 ×10−8
cg14269477 7 142630597 TRPV5 -0.03 1.04 ×10−8
cg20116935 3 50303757 * SEMA3B -0.06 1.06 ×10−8
cg04567334 10 73408185 CDH23 -0.04 1.11 ×10−8
cg01514353 22 46259643 † ATXN10 -0.16 1.13 ×10−8
cg13256912 3 11211081 HRH1 -0.06 1.13 ×10−8
cg05304729 1 158800024 * MNDA 0.25 1.20 ×10−8
cg01668099 11 130026798 * ST14 -0.04 1.21 ×10−8
cg24157892 17 59473707 * BCAS3 0.27 1.22 ×10−8
cg07914457 1 27241853 * NR0B2 -0.05 1.23 ×10−8
cg08782002 17 61847885 CCDC47 -0.08 1.25 ×10−8
cg18143317 11 2037124 † H19 -0.05 1.26 ×10−8
cg04987734 14 103415873 CDC42BPB 0.13 1.35 ×10−8
cg16008966 1 114761794 † SYT6 -0.08 1.38 ×10−8
cg15727249 11 116693415 APOA4 -0.04 1.39 ×10−8
0.061 cg09054949 4 74735101 * CXCL1 0.27 1.40 ×10−8
cg22471129 22 30868226 * SEC14L3 -0.04 1.43 ×10−8
cg23902264 1 241815413 * WDR64 0.11 1.50 ×10−8
cg24136205 13 100624293 * ZIC5 0.22 1.50 ×10−8
cg19281794 3 112218761 * BTLA 0.23 1.52 ×10−8
cg15460584 4 8540687 † GPR78 -0.06 1.72 ×10−8
cg22356061 1 227954102 SNAP47 -0.12 1.73 ×10−8
cg05095591 3 147129184 ZIC1 0.24 1.75 ×10−8
cg07267600 12 2750053 CACNA1C -0.13 1.83 ×10−8
Table A.10: UC Results: Continued overleaf
283
A: IBD Character
MAF Probe Chr Coord Gene LogFC P Value
cg20510033 1 8960134 † ENO1-AS1 -0.12 1.83 ×10−8
cg15114651 19 47289410 SLC1A5 -0.05 1.84 ×10−8
cg17260706 11 118782879 * BCL9L -0.10 1.89 ×10−8
cg13997435 1 153538406 * S100A2 -0.05 1.96 ×10−8
cg21518947 11 67222648 CABP4 -0.04 1.96 ×10−8
cg03990033 1 208084030 CD34 0.21 2.01 ×10−8
cg21727145 15 101458127 * ALDH1A3 0.08 2.06 ×10−8
cg08035323 2 9843525 † YWHAQ -0.21 2.06 ×10−8
cg07967630 6 58149317 † GUSBP4 0.28 2.09 ×10−8
cg18734877 8 27297419 PTK2B -0.08 2.21 ×10−8
cg04913803 14 77510549 † IRF2BPL -0.07 2.25 ×10−8
cg09018739 16 57180107 CPNE2 0.07 2.39 ×10−8
cg23432368 2 47882601 MSH2 -0.04 2.46 ×10−8
cg21422361 7 1884392 MAD1L1 -0.10 2.54 ×10−8
cg12756396 1 50886969 DMRTA2 0.19 2.57 ×10−8
cg08289839 13 111318640 CARS2 0.06 2.59 ×10−8
cg24226371 15 75945038 SNX33 -0.05 2.71 ×10−8
cg06206957 7 33080615 NT5C3A 0.16 2.72 ×10−8
cg26575914 1 228397977 C1orf145 -0.04 2.73 ×10−8
cg05209330 5 131550942 P4HA2 -0.04 2.84 ×10−8
cg20631044 19 41255890 C19orf54 -0.06 2.86 ×10−8
cg05968822 1 226071684 * TMEM63A 0.07 2.87 ×10−8
cg26708319 4 111552040 PITX2 0.18 2.89 ×10−8
cg04465154 8 9045558 † PPP1R3B -0.14 2.90 ×10−8
cg06621080 1 201631166 NAV1 -0.06 2.91 ×10−8
cg05223210 11 117630397 DSCAML1 -0.05 2.95 ×10−8
cg04848343 19 4544095 SEMA6B 0.09 3.22 ×10−8
cg16298481 1 89989717 * LRRC8B -0.24 3.26 ×10−8
cg25114611 6 35696870 LOC285847 -0.13 3.27 ×10−8
cg12582317 17 55822272 † MSI2 0.09 3.31 ×10−8
cg14058848 9 130479114 PTRH1 -0.06 3.37 ×10−8
cg04070847 3 112693867 CD200R1 0.16 3.40 ×10−8
cg00795341 5 79330929 * THBS4 0.06 3.46 ×10−8
cg22320365 17 36718198 SRCIN1 0.30 3.69 ×10−8
cg03950000 1 160617327 * SLAMF1 -0.06 3.70 ×10−8
cg21691893 6 32018110 TNXB -0.05 3.70 ×10−8
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cg17290213 11 65344355 EHBP1L1 -0.08 3.75 ×10−8
cg21241889 9 123690658 TRAF1 -0.12 3.83 ×10−8
cg06422108 10 31610399 ZEB1 0.26 3.84 ×10−8
cg20695203 13 112335939 ‡ TEX29 -0.04 3.85 ×10−8
cg02325250 5 131409289 * CSF2 -0.06 3.91 ×10−8
cg23712342 10 60936794 PHYHIPL 0.26 3.95 ×10−8
0.012 cg13789303 6 108886681 FOXO3 0.11 4.11 ×10−8
cg08176258 7 1938450 MAD1L1 -0.09 4.15 ×10−8
cg08530237 12 22094563 * ABCC9 0.22 4.16 ×10−8
cg18637901 4 3247372 * HTT -0.04 4.19 ×10−8
cg03875678 14 25103546 * GZMB -0.11 4.23 ×10−8
cg03519967 1 26010346 MAN1C1 -0.05 4.25 ×10−8
0.500 cg23523668 11 65194989 NEAT1 -0.22 4.26 ×10−8
cg24882551 4 85403032 † NKX6-1 0.18 4.29 ×10−8
cg04615865 12 121678720 CAMKK2 0.29 4.38 ×10−8
cg01436487 7 1890148 MAD1L1 -0.07 4.41 ×10−8
cg08386009 6 32094845 ATF6B -0.05 4.43 ×10−8
cg27294813 2 109791599 SH3RF3 -0.05 4.45 ×10−8
cg24621042 14 94857275 * SERPINA1 -0.10 4.55 ×10−8
cg10515048 14 50697283 SOS2 0.20 4.62 ×10−8
cg18110483 5 79330959 * THBS4 0.23 4.67 ×10−8
cg09791504 1 151701849 RIIAD1 -0.07 4.96 ×10−8
cg03845363 17 17753516 TOM1L2 -0.12 5.12 ×10−8
cg04761198 8 54793733 RGS20 0.13 5.15 ×10−8
cg12483476 5 178421711 GRM6 0.46 5.18 ×10−8
cg20466954 1 84768359 SAMD13 0.11 5.31 ×10−8
cg03432225 1 228294401 MRPL55 -0.03 5.35 ×10−8
cg02743674 11 2433468 TRPM5 -0.04 5.46 ×10−8
cg04100532 2 210636560 * UNC80 0.19 5.58 ×10−8
cg14114377 19 45756845 MARK4 -0.06 5.62 ×10−8
cg03465179 14 106054474 † TMEM121 -0.05 5.71 ×10−8
cg21773162 2 98330087 ZAP70 -0.05 5.73 ×10−8
cg25368647 5 176736591 MXD3 -0.10 5.90 ×10−8
cg01165560 11 49911386 † OR4C13 -0.04 6.02 ×10−8
cg06588876 9 139009275 C9orf69 -0.04 6.18 ×10−8
cg03699074 16 88849875 PIEZO1 -0.23 6.30 ×10−8
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cg26562462 4 6929045 TBC1D14 -0.08 6.36 ×10−8
0.500 cg03850035 2 222367110 EPHA4 -0.05 6.36 ×10−8
cg02629976 2 220411924 TMEM198 -0.05 6.41 ×10−8
cg11859594 17 76755745 CYTH1 0.16 6.43 ×10−8
cg10754002 2 121276805 † LINC01101 -0.06 6.49 ×10−8
cg05937055 1 181128764 † IER5 -0.12 6.77 ×10−8
cg13823169 9 139776893 TRAF2 -0.08 6.89 ×10−8
cg25529535 10 6125715 * RBM17 -0.06 6.92 ×10−8
0.032 cg17959631 7 44189684 GCK -0.04 7.05 ×10−8
cg00084202 8 143360290 TSNARE1 -0.04 7.20 ×10−8
cg10734581 14 101520078 * MIR382 -0.04 7.36 ×10−8
cg17280514 2 242755302 NEU4 -0.07 7.37 ×10−8
cg14646983 9 34602974 * RPP25L -0.05 7.54 ×10−8
cg23363971 12 56415271 IKZF4 0.17 7.75 ×10−8
cg04095776 6 31106941 PSORS1C1 -0.04 8.01 ×10−8
cg20673075 8 99838488 STK3 -0.08 8.02 ×10−8
cg17515347 1 159047163 * AIM2 -0.29 8.06 ×10−8
cg19303305 4 8277560 HTRA3 -0.04 8.09 ×10−8
cg18346531 17 9967431 GAS7 -0.07 8.18 ×10−8
cg21895526 18 24765490 AQP4-AS1 0.23 8.23 ×10−8
0.011 cg24661168 1 210013268 DIEXF -0.07 8.32 ×10−8
cg09481056 16 2339260 ABCA3 0.05 8.37 ×10−8
cg06401614 11 44927976 TSPAN18 -0.04 8.58 ×10−8
cg07564837 8 58126962 * LINC01606 -0.05 8.78 ×10−8
cg23986143 7 76054256 ZP3 -0.03 8.86 ×10−8
cg23689615 15 74228839 LOXL1 -0.06 8.87 ×10−8
cg05004855 5 149644009 CAMK2A -0.10 9.01 ×10−8
cg07541160 6 36985879 FGD2 -0.04 9.37 ×10−8
cg02345399 11 65195039 NEAT1 -0.09 9.53 ×10−8
cg17585031 17 25798942 * KSR1 -0.04 9.53 ×10−8
cg08858220 6 36805317 CPNE5 -0.04 9.61 ×10−8
cg05915362 6 159274480 OSTCP1 -0.12 9.72 ×10−8
cg15000071 3 134889493 EPHB1 -0.05 9.72 ×10−8
cg12308965 11 67291387 * CABP2 -0.04 9.74 ×10−8
cg20964856 19 41767669 AXL -0.08 9.78 ×10−8
cg13150925 12 124529439 FAM101A 0.11 9.91 ×10−8
Table A.10: UC Results: Continued overleaf
286
A.4
MAF Probe Chr Coord Gene LogFC P Value
cg12159215 11 118826779 * UPK2 -0.06 9.92 ×10−8
cg04324276 17 17817462 TOM1L2 -0.08 1.00 ×10−7
cg05850205 8 67350187 ADHFE1 -0.04 1.00 ×10−7
cg16086570 5 141924566 † FGF1 -0.04 1.01 ×10−7
cg12569119 10 105541150 SH3PXD2A -0.04 1.02 ×10−7
cg07120889 1 150535935 * ADAMTSL4 -0.13 1.02 ×10−7
cg14699903 3 48601227 * UCN2 -0.04 1.03 ×10−7
Table A.10: Illumina 450k probes with Bonferroni significant UC-
associated methylation changes in the IBD Character cohort. Where
the probe is not in a gene the nearest gene is given with an indication of
distance: *<10kb, †<100kb, ‡>100kb. Where the is a SNP within 10bp
the MAF (or highest if there are multiple) is shown on the left.
MAF Probe Chr Coord Gene LogFC P Value
cg11986385 11 19628828 NAV2 0.05 6.82 ×10−8
Table A.11: The single Bonferroni significant difference between CD






Genome-wide epigenetic analysis in childhood-onset Crohn’s Disease implicates
MIR21 [2]
1A T Adams, 1N A Kennedy, 2R Hansen, 1N T Ventham, 1K R O’Leary, 1H E
Drummond, 1C L Noble, 2E El-Omar, 3R K Russell, 4D C Wilson, 1E R Nimmo,
2G L Hold, 1J Satsangi
1Gastrointestinal Unit, Institute of Genetics and Molecular Medicine, University of Edin-
burgh, UK. 2Gastrointestinal Research Group, Division of Applied Medicine, University of
Aberdeen, UK. 3Department of Paediatric Gastroenterology, Royal Hospital for Sick Children,
Glasgow, UK. 4Paediatric Gastroenterology and Nutrition, Child Life and Health, University
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Introduction: DNA methylation influences transcriptional activity and marks
sites of active transcription. Technological developments allow the rapid assess-
ment of methylation state at 450,000 sites across the genome. The aim of this
study was to identify genes with a possible role in Crohn’s disease pathogenesis,
and candidate genes for methylation based diagnostic biomarkers.
Methods: Using the Illumina 450k platform we analysed genome-wide DNA
methylation in symptomatic children who underwent diagnostic colonoscopy, half
of whom were diagnosed with CD and half had no pathology. Replication was
performed in children with established CD vs. symptomatic non-disease controls.
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Further targeted replication by pyrosequencing was performed in adults with CD
vs. healthy controls, with qPCR and microarray data to analyse expression.
Results: Meta-analysis of the combined paediatric datasets (n=66) identified
165 individual CpGs with epigenome-wide significance (Bonferroni correction)
and 138 differentially methylated regions (DMR). Methylation changes were sig-
nificantly enriched (p < 0.0001) in proximity to loci implicated by genome-wide
association studies (GWAS). The strongest result by each approach was Mi-
croRNA 21, within the autophagy gene VMP1 (p = 1.2 × 10−14), 48kb from
GWAS SNP rs1292053. In adults with CD we replicated MIR21 hypomethy-
lation (p = 6.6 × 10−5, n = 172), and showed increased expression in blood
(p < 0.005, n = 66). Intestinal expression increased with inflammation in CD
(p = 1.4 × 10−6, n = 99) but not controls (n = 73). Linear discriminant analy-
sis of methylation in the paediatric discovery cohort accurately predicted disease
state in the paediatric replication cohort (94% sensitivity, 100% specificity) based
on methylation at two CpG sites.
Conclusion: MIR21 emerges as a target for further investigation based on
methylation and expression, further strengthened by other positive findings -
notably dysregulation in dysplasia and colorectal cancer in IBD, an established
role in T cell differentiation, and protection from DSS-induced fatal colitis by
MIR21 knockout. These data demonstrate a novel approach for identifying bi-
ological variations associated with germ-line variants identified by GWAS, and




Epigenome-wide analysis in childhood-onset Crohn’s disease implicates MIR21
in pathogenesis and identifies multiple methylation-based diagnostic biomarkers
[313]
N.A. Kennedy1,2*, A.T. Adams1, R. Hansen3, N.T. Ventham1, K.R. O’Leary11,
H. Drummond1, C.L. Noble1,2, E. El-Omar3, R.K. Russell4, D.C. Wilson5, E.R.
Nimmo1, G.L. Hold3, J. Satsangi1,2.
1University of Edinburgh, Gastrointestinal Unit, Centre for Genomic and Experimental
Medicine, Edinburgh, United Kingdom, 2Western General Hospital, Gastrointestinal Unit, Ed-
inburgh, United Kingdom, 3University of Aberdeen, Gastrointestinal Research Group, Division
of Applied Medicine, Aberdeen, United Kingdom, 4Royal Hospital for Sick Children, Paediatric
Gastroenterology, Glasgow, United Kingdom, 5University of Edinburgh, Paediatric Gastroen-
terology and Nutrition, Child Life and Health, Edinburgh, United Kingdom
Background: DNA methylation influences transcriptional activity and marks
sites of active transcription. Technological developments allow the rapid assess-
ment of methylation state at 450,000 sites across the genome. We have performed
a three-stage retrospective case-control study with epigenome-wide analysis of
leucocyte DNA methylation in paediatric discovery and replication cohorts and
targeted replication in adults.
Methods: Using the Illumina 450k platform we performed epigenome-wide
analysis in symptomatic children presenting for diagnostic colonoscopy, half of
whom were diagnosed with Crohn’s Disease (CD) and half never developed any
pathology. Replication was performed in children with established CD vs. symp-
tomatic non-disease controls. Further targeted replication by pyrosequencing was
performed in adults with CD vs. healthy controls.
Results: Meta-analysis of the combined paediatric datasets (n = 66) with the
Bonferroni correction for multiple testing identified 165 CpGs with epigenome-
wide significance. 138 differentially methylated regions (DMR) were identified -
defined as stretches of probes where all had false discovery rate corrected p val-
ues < 0.05 and a shared direction of change in disease. Thirdly, we demonstrate
an enrichment (p < 0.0001) of significant methylation changes in proximity to
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loci implicated by genome-wide association studies (GWAS). The strongest re-
sult by each approach was MicroRNA 21, within the autophagy gene VMP1
(p = 1.2× 10−14), 48kb from GWAS SNP rs1292053 - also the strongest result in
the initial discovery/replication analysis. We have replicated methylation changes
at this region in adults (p = 6.6×10−5, n = 172), and shown altered expression in
blood (p < 0.005, n = 66) and inflamed vs. non-inflamed intestinal biopsies in CD
(p = 1.4× 10−6, n = 99) but not controls (n = 73). Alternative lines of evidence
support further study of MIR21 in IBD - e.g. dysregulation in dysplasia and col-
orectal cancer in IBD, an established role in T cell differentiation, and protection
from DSS-induced fatal colitis by MIR21 knockout. Of immediate clinical inter-
est, linear discriminant analysis of methylation at combinations of two probes
consistently predicted disease state with high accuracy (94% sensitivity, 100%
specificity) in symptomatic children presenting for diagnostic colonoscopy. This
aspect has the advantages of bypassing the complications of proving causation
and the impact of shifting subpopulations of cells on measured methylation.
Conclusion: These data demonstrate a novel approach for identifying biologi-
cal variations associated with germ-line variants identified by GWAS; and demon-




Epigenetic alterations in inflammatory bowel disease — The influence of germline
variation (meQTLs) on genome-wide methylation alterations.
Adams AT1, Kalla R1, Nimmo ER1, IBD Character Consortium, Vatn MH2,
Jahnsen J3, Ricanek P3, Halfvarson J4, Söderholm J5, Pierik M6, Gomollón F7,
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Blesa”, IIS Aragón, Zaragoza, Spain. 8CNAG-CRG, Centre for Genomic Regulation, Barcelona
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Background:
Exploring DNA methylation in Inflammatory Bowel Disease (IBD) may provide
an insight into the complex gene-environment interactions in disease pathogenesis.
Our study aims to characterise disease-associated methylation changes in newly
diagnosed IBD and define the contribution of genetic variation, by discovery of
associated quantitative trait loci (meQTL).
Methods:
Genome-wide methylation was measured in 641 DNA samples from peripheral
blood (298 controls, 150 CD, 167 UC, 26 IBDU) using the Illumina 450k plat-
form with covariates of age, sex, and cell counts, deconvoluted by the Houseman
method.
Genotyping was performed using Illumina HumanOmniExpressExome8 Bead-
Chips. Samples were obtained from new onset IBD cases in six European centres




195 probes exhibited Bonferroni significant IBD-associated methylation differ-
ences, including VMP1/MIR21 (p=3.7×10−20), RPS6KA2 (1.1×10−19), SBNO2
(2.7×10−19), and TNFSF10 (1.1×10−15); data which provide important replica-
tion and confirmation of methylation differences previously reported in paediatric
CD1 and adult IBD2. Novel findings include PHOSPHO1 (1.3×10−15), MUC4
(5.5×10−15), and CDH24 (1.7×10−14). 1709 differentially methylated regions
of consecutive FDR significant probes were defined including VMP1/MIR21,
ITGB2, TNF and throughout the HLA region.
Results were highly similar in CD and UC, and only one probe showed a
significant difference (NAV2, 6.82×10−8). Paired genetic and methylation data
showed 2327 FDR significant MeQTLs indicating a genetic influence on sev-
eral key loci — RPS6KA2 (8.6×10−34), ITGB2 (3.3×10−38), and a replication
of two SNPs previously described as correlated to VMP1/MIR21 methylation
(rs8078424, p=4.4×10−25, rs10853015, p=7.4×10−21)2.
Previously published two-probe methylation biomarkers accurately distin-
guished IBD from controls in this cohort (AUC 60.82).
Conclusions:
These data allow profiling of the IBD methylome, involving novel associations
and important unequivocal replication of recent discoveries, together with insight
into the genetic contribution to epigenetic alterations in complex disease.
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